Aop:1	Event:1	MolecularInitiatingEvent	N/A, Unknown
Aop:1	Event:2	KeyEvent	Hyperplasia, Hyperplasia
Aop:1	Event:3	KeyEvent	Proliferation, Cell proliferation in the absence of cytotoxicity
Aop:1	Event:4	AdverseOutcome	Promotion, Hepatocelluar carcinoma
Aop:2	Event:5	MolecularInitiatingEvent	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)
Aop:2	Event:6	KeyEvent	Inhibition, NADH-ubiquinone oxidoreductase (complex I)
Aop:2	Event:7	KeyEvent	Mitochondrial dysfunction
Aop:2	Event:8	KeyEvent	Impaired, Proteostasis
Aop:2	Event:9	KeyEvent	Neuroinflammation
Aop:2	Event:10	KeyEvent	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:2	Event:11	AdverseOutcome	Parkinsonian motor deficits
Aop:3	Event:12	MolecularInitiatingEvent	Increase, Ecdysone receptor agonism
Aop:3	Event:13	KeyEvent	Increase, Nuclear receptor E75b gene expression
Aop:3	Event:14	KeyEvent	Increase, Fushi tarazu factor-1 gene expression
Aop:3	Event:15	KeyEvent	Decrease, Circulating ecdysis triggering hormone
Aop:3	Event:16	KeyEvent	Decrease, Circulating crustacean cardioactive peptide
Aop:3	Event:17	KeyEvent	Decrease, Ecdysis motoneuron bursts
Aop:3	Event:18	KeyEvent	Decrease, Excitatory postsynaptic potential
Aop:3	Event:19	KeyEvent	Decrease, Abdominal muscle contraction
Aop:3	Event:20	KeyEvent	Increase, Incomplete ecdysis
Aop:3	Event:21	AdverseOutcome	Increase, Mortality
Aop:4	Event:103	MolecularInitiatingEvent	Increase, Ecdysone receptor agonism
Aop:4	Event:988	KeyEvent	Decrease, Circulating ecdysis triggering hormone
Aop:4	Event:990	KeyEvent	Increase, Incomplete ecdysis
Aop:4	Event:993	KeyEvent	Decrease, Abdominal muscle contraction
Aop:4	Event:1264	KeyEvent	Increase, Nuclear receptor E75b gene expression
Aop:4	Event:1265	KeyEvent	Increase, Fushi tarazu factor-1 gene expression
Aop:4	Event:1266	KeyEvent	Decrease, Circulating crustacean cardioactive peptide
Aop:4	Event:1267	KeyEvent	Decrease, Ecdysis motoneuron bursts
Aop:4	Event:1268	KeyEvent	Decrease, Excitatory postsynaptic potential
Aop:4	Event:350	AdverseOutcome	Increase, Mortality
Aop:5	Event:22	MolecularInitiatingEvent	Binding of antagonist, PPAR alpha
Aop:5	Event:23	KeyEvent	stabilization, PPAR alpha co-repressor
Aop:5	Event:24	KeyEvent	Decreased, PPARalpha transactivation of gene expression
Aop:5	Event:25	KeyEvent	Fatty Acid Beta Oxidation, Decreased
Aop:5	Event:26	KeyEvent	Decreased, Ketogenesis (production of ketone bodies)
Aop:5	Event:27	KeyEvent	Not Increased, Circulating Ketone Bodies
Aop:5	Event:28	KeyEvent	Increased, Catabolism of Muscle Protein
Aop:5	Event:29	AdverseOutcome	Decreased, Body Weight
Aop:6	Event:30	MolecularInitiatingEvent	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
Aop:6	Event:31	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:6	Event:32	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:6	Event:33	AdverseOutcome	decreased, Fertility
Aop:6	Event:34	AdverseOutcome	disrupted, ovarian cycle
Aop:7	Event:35	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:7	Event:36	KeyEvent	Induction, Upregulation of glucuronyltransferase activity
Aop:7	Event:37	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:7	Event:38	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:7	Event:39	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:7	Event:40	KeyEvent	Hippocampal gene expression, Altered
Aop:7	Event:41	KeyEvent	Hippocampal anatomy, Altered
Aop:7	Event:42	KeyEvent	Hippocampal Physiology, Altered
Aop:7	Event:43	AdverseOutcome	Loss, Cochlear function
Aop:8	Event:44	MolecularInitiatingEvent	Binding at picrotoxin site, iGABAR chloride channel
Aop:8	Event:45	KeyEvent	Reduction, Ionotropic GABA receptor chloride channel conductance
Aop:8	Event:46	KeyEvent	Reduction, Neuronal synaptic inhibition
Aop:8	Event:47	KeyEvent	Generation, Amplified excitatory postsynaptic potential (EPSP)
Aop:8	Event:48	KeyEvent	Occurrence, A paroxysmal depolarizing shift
Aop:8	Event:49	AdverseOutcome	Occurrence, Epileptic seizure
Aop:9	Event:50	MolecularInitiatingEvent	Activation, PXR/SXR
Aop:10	Event:51	MolecularInitiatingEvent	Binding of antagonist, NMDA receptors
Aop:10	Event:52	KeyEvent	Inhibition, NMDARs
Aop:10	Event:53	KeyEvent	Decreased, Calcium influx
Aop:10	Event:54	KeyEvent	Reduced levels of BDNF
Aop:10	Event:55	KeyEvent	Increase, Cell injury/death
Aop:10	Event:56	KeyEvent	Neuroinflammation
Aop:10	Event:57	AdverseOutcome	N/A, Neurodegeneration
Aop:10	Event:58	AdverseOutcome	Impairment, Learning and memory
Aop:11	Event:59	MolecularInitiatingEvent	Binding of antagonist, NMDA receptors
Aop:11	Event:60	KeyEvent	Decreased, Calcium influx
Aop:11	Event:61	KeyEvent	Inhibition, NMDARs
Aop:11	Event:62	KeyEvent	Reduced levels of BDNF
Aop:11	Event:63	KeyEvent	Aberrant, Dendritic morphology
Aop:11	Event:64	KeyEvent	Decrease of synaptogenesis
Aop:11	Event:65	KeyEvent	Decrease of neuronal network function
Aop:11	Event:66	KeyEvent	Reduced, Presynaptic release of glutamate
Aop:11	Event:67	KeyEvent	Increase, Cell injury/death
Aop:11	Event:68	AdverseOutcome	Impairment, Learning and memory
Aop:12	Event:69	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:12	Event:70	KeyEvent	Inhibition, Nuclear factor kappa B (NF-kB)
Aop:12	Event:71	KeyEvent	Suppression, Inflammatory cytokines
Aop:12	Event:72	KeyEvent	Decreased, Lymphocytes
Aop:12	Event:73	KeyEvent	Induction, IKB inhibitory protein
Aop:12	Event:74	KeyEvent	Suppression, Immune system
Aop:12	Event:75	AdverseOutcome	Increased, Disease susceptibility
Aop:13	Event:76	MolecularInitiatingEvent	Alkylation, DNA
Aop:13	Event:77	KeyEvent	Inadequate DNA repair
Aop:13	Event:78	KeyEvent	Increase, Mutations
Aop:13	Event:79	AdverseOutcome	Increase, Heritable mutations in offspring
Aop:14	Event:80	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:14	Event:81	KeyEvent	Acetylcholine accumulation in synapses
Aop:14	Event:82	KeyEvent	Increased Cholinergic Signaling
Aop:14	Event:83	KeyEvent	Respiratory distress/arrest
Aop:14	Event:84	KeyEvent	Dysregulation of heart rate and vascular tone
Aop:14	Event:85	AdverseOutcome	Increased Mortality
Aop:14	Event:86	AdverseOutcome	Decrease, Population growth rate
Aop:15	Event:87	MolecularInitiatingEvent	Binding, Thiol/seleno-proteins involved in protection against oxidative stress
Aop:15	Event:88	KeyEvent	Decreased protection against oxidative stress
Aop:15	Event:89	KeyEvent	Oxidative Stress
Aop:15	Event:90	KeyEvent	Glutamate dyshomeostasis
Aop:15	Event:91	KeyEvent	Increase, Cell injury/death
Aop:15	Event:92	KeyEvent	Neuroinflammation
Aop:15	Event:93	KeyEvent	Tissue resident cell activation
Aop:15	Event:94	KeyEvent	Increased Pro-inflammatory mediators
Aop:15	Event:95	KeyEvent	Decrease of neuronal network function
Aop:15	Event:96	AdverseOutcome	Impairment, Learning and memory
Aop:16	Event:97	MolecularInitiatingEvent	Activation, PPARα
Aop:16	Event:98	KeyEvent	Decrease, Steroidogenic acute regulatory protein (STAR)
Aop:16	Event:99	KeyEvent	Reduction, Cholesterol transport in mitochondria
Aop:16	Event:100	KeyEvent	Reduction, Testosterone synthesis in Leydig cells
Aop:16	Event:101	KeyEvent	Decrease, circulating testosterone levels
Aop:16	Event:102	KeyEvent	Decrease, Translocator protein (TSPO)
Aop:16	Event:103	AdverseOutcome	decreased, Fertility
Aop:16	Event:104	AdverseOutcome	Malformation, Male reproductive tract
Aop:17	Event:105	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:17	Event:106	KeyEvent	Alteration, Wnt pathway
Aop:17	Event:107	KeyEvent	Feminisation or incomplete development, Primary and accessory male sex organs
Aop:17	Event:108	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:17	Event:109	AdverseOutcome	N/A, Impairment of reproductive capacity
Aop:18	Event:110	MolecularInitiatingEvent	Activation, AhR
Aop:18	Event:111	KeyEvent	dimerization, AHR/ARNT
Aop:18	Event:112	KeyEvent	Increase, COX-2 expression
Aop:18	Event:113	KeyEvent	Altered, Cardiovascular development/function
Aop:18	Event:114	KeyEvent	Increase, Early Life Stage Mortality
Aop:19	Event:115	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:19	Event:116	KeyEvent	Reduction, Gonadotropins, circulating concentrations
Aop:19	Event:117	KeyEvent	Reduction, Testosterone synthesis by ovarian theca cells
Aop:19	Event:118	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:19	Event:119	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:19	Event:120	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:19	Event:121	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:19	Event:122	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:19	Event:123	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:19	Event:124	AdverseOutcome	Decrease, Population growth rate
Aop:20	Event:125	MolecularInitiatingEvent	Inhibition, Aromatase
Aop:20	Event:126	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:20	Event:127	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:20	Event:128	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:20	Event:129	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:20	Event:130	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:20	Event:131	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:20	Event:132	AdverseOutcome	Decrease, Population growth rate
Aop:21	Event:133	MolecularInitiatingEvent	Inhibition, Ca++ ATPase
Aop:21	Event:134	KeyEvent	Increase, Ca++ (intracellular)
Aop:21	Event:135	KeyEvent	Disruption, Mitochondrial electron transport chain
Aop:21	Event:136	KeyEvent	Decrease, Mitochondrial ATP production
Aop:21	Event:137	KeyEvent	Increase, Reactive oxygen species
Aop:21	Event:138	KeyEvent	Decreased, Nitric Oxide
Aop:21	Event:139	KeyEvent	Decreased, Long-term potentiation (LTP)
Aop:21	Event:140	AdverseOutcome	Oxidative Stress
Aop:22	Event:141	MolecularInitiatingEvent	Inhibition, Bile Salt Export Pump (ABCB11)
Aop:22	Event:142	KeyEvent	Activation of specific nuclear receptors, Transcriptional change
Aop:22	Event:143	KeyEvent	Bile accumulation, Pathological condition
Aop:22	Event:144	KeyEvent	Release, Cytokine
Aop:22	Event:145	KeyEvent	Increase, Inflammation
Aop:22	Event:146	KeyEvent	Increase, Reactive oxygen species
Aop:22	Event:147	KeyEvent	Peptide Oxidation
Aop:22	Event:148	AdverseOutcome	Cholestasis, Pathology
Aop:23	Event:149	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:23	Event:150	KeyEvent	Reduction, Prostaglandin E2 concentration
Aop:23	Event:151	KeyEvent	Reduction, Ca and HCO3 transport to shell gland
Aop:23	Event:152	KeyEvent	Reduction, Eggshell thickness
Aop:23	Event:153	KeyEvent	N/A, Gap
Aop:23	Event:154	AdverseOutcome	N/A, Reproductive failure
Aop:24	Event:155	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:24	Event:156	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:24	Event:157	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:24	Event:158	KeyEvent	Increase, Vitellogenin synthesis in liver
Aop:24	Event:159	KeyEvent	Increase, Renal pathology due to VTG deposition
Aop:24	Event:160	AdverseOutcome	Decrease, Population growth rate
Aop:24	Event:161	AdverseOutcome	Altered, Reproductive behaviour
Aop:24	Event:162	AdverseOutcome	Altered, Larval development
Aop:24	Event:163	AdverseOutcome	Impaired development of, Reproductive organs
Aop:25	Event:164	MolecularInitiatingEvent	Antagonism, Estrogen receptor
Aop:25	Event:165	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:25	Event:166	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:25	Event:167	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:25	Event:168	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:25	Event:169	AdverseOutcome	Decrease, Population growth rate
Aop:26	Event:170	MolecularInitiatingEvent	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)
Aop:26	Event:171	KeyEvent	Altered regulation, Alpha hemoglobin
Aop:26	Event:172	KeyEvent	Oxidative Stress
Aop:26	Event:173	KeyEvent	Damaging, Red blood cells; hemolysis
Aop:26	Event:174	KeyEvent	Formation, Formation of hemoglobin adducts
Aop:26	Event:175	KeyEvent	Down Regulation, Gulcose-6-phosphate dehydrogenase
Aop:26	Event:176	KeyEvent	Increase, RBC congestion in liver
Aop:26	Event:177	KeyEvent	Increase, Liver and splenic hemosiderosis
Aop:26	Event:178	KeyEvent	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
Aop:26	Event:179	AdverseOutcome	N/A, Cyanosis occurs
Aop:27	Event:180	KeyEvent	Production, Critical Metabolites (CGA 330050 and CGA 265307)
Aop:27	Event:181	KeyEvent	Induction, Liver “Dysfunctional” Changes by CGA 330050
Aop:27	Event:182	KeyEvent	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
Aop:27	Event:183	KeyEvent	Induction, Sustained Hepatotoxicity
Aop:27	Event:184	KeyEvent	Induction, Sustained Cell Proliferation
Aop:27	Event:185	KeyEvent	Formation, Liver tumor
Aop:28	Event:186	MolecularInitiatingEvent	Activation, 5HT2c
Aop:28	Event:187	KeyEvent	N/A, Unknown
Aop:28	Event:188	AdverseOutcome	Increased, Kidney Failure
Aop:29	Event:189	MolecularInitiatingEvent	Activation, LXR
Aop:29	Event:190	MolecularInitiatingEvent	peroxisome proliferator activated receptor promoter demethylation
Aop:29	Event:191	KeyEvent	Up Regulation, CD36
Aop:29	Event:192	KeyEvent	Increase, FA Influx
Aop:29	Event:193	KeyEvent	Activation, ChREBP
Aop:29	Event:194	KeyEvent	Activation, SREBP-1c
Aop:29	Event:195	KeyEvent	Activation, FAS
Aop:29	Event:196	KeyEvent	Activation, SCD-1
Aop:29	Event:197	KeyEvent	Synthesis, De Novo Fatty Acid (FA)
Aop:29	Event:198	KeyEvent	Accumulation, Triglyceride
Aop:29	Event:199	KeyEvent	Mitochondrial dysfunction
Aop:29	Event:200	AdverseOutcome	N/A, Liver Steatosis
Aop:30	Event:201	MolecularInitiatingEvent	Accumulation, Biological membranes
Aop:30	Event:202	KeyEvent	Disruption, Membrane integrity
Aop:31	Event:203	MolecularInitiatingEvent	Decreased, PPAR-alpha activation
Aop:31	Event:204	MolecularInitiatingEvent	Decreased, PPAR-beta activation
Aop:31	Event:205	MolecularInitiatingEvent	Decreased, PPAR-gamma activation
Aop:31	Event:206	KeyEvent	Accumulation, Fatty acid
Aop:31	Event:207	KeyEvent	Decreased, HSD17B10 expression
Aop:31	Event:208	KeyEvent	Decrease, Fatty acid beta-oxidation
Aop:31	Event:209	KeyEvent	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
Aop:31	Event:210	AdverseOutcome	Increased, Liver Steatosis
Aop:32	Event:211	MolecularInitiatingEvent	Activation, PPARα
Aop:32	Event:212	KeyEvent	Increase, Phenotypic enzyme activity
Aop:32	Event:213	KeyEvent	Increase, cell proliferation (hepatocytes)
Aop:32	Event:214	KeyEvent	Increase, Clonal Expansion of Altered Hepatic Foci
Aop:32	Event:215	AdverseOutcome	Increase, hepatocellular adenomas and carcinomas
Aop:33	Event:216	MolecularInitiatingEvent	Alkylation, Protein
Aop:33	Event:217	KeyEvent	Increase, Cell injury/death
Aop:33	Event:218	KeyEvent	Tissue resident cell activation
Aop:33	Event:219	KeyEvent	Increased Pro-inflammatory mediators
Aop:33	Event:220	KeyEvent	Activation, Stellate cells
Aop:33	Event:221	KeyEvent	Accumulation, Collagen
Aop:33	Event:222	AdverseOutcome	N/A, Liver fibrosis
Aop:34	Event:223	MolecularInitiatingEvent	Covalent Binding, Protein
Aop:34	Event:224	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:34	Event:225	KeyEvent	Activation, Dendritic Cells
Aop:34	Event:226	KeyEvent	Activation/Proliferation, T-cells
Aop:34	Event:227	AdverseOutcome	Increase, Allergic Respiratory Hypersensitivity Response
Aop:35	Event:228	MolecularInitiatingEvent	Covalent Binding, Protein
Aop:35	Event:229	KeyEvent	Activation, Keratinocytes
Aop:35	Event:230	KeyEvent	Activation, Dendritic Cells
Aop:35	Event:231	KeyEvent	Activation/Proliferation, T-cells
Aop:35	Event:232	AdverseOutcome	sensitisation, skin
Aop:36	Event:233	MolecularInitiatingEvent	Activation, Long term AHR receptor driven direct and indirect gene expression changes
Aop:36	Event:234	KeyEvent	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
Aop:36	Event:235	KeyEvent	Changes/Inhibition, Cellular Homeostasis and Apoptosis
Aop:36	Event:236	KeyEvent	Alterations, Cellular proliferation / hyperplasia
Aop:36	Event:237	AdverseOutcome	Formation, Hepatocellular and Bile duct tumors
Aop:37	Event:238	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:37	Event:239	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:37	Event:240	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:37	Event:241	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:37	Event:242	KeyEvent	Hippocampal gene expression, Altered
Aop:37	Event:243	KeyEvent	Hippocampal anatomy, Altered
Aop:37	Event:244	KeyEvent	Hippocampal Physiology, Altered
Aop:37	Event:245	AdverseOutcome	Cognitive function, decreased
Aop:38	Event:246	MolecularInitiatingEvent	Inhibition, VegfR2
Aop:38	Event:247	KeyEvent	Reduction, Angiogenesis
Aop:38	Event:248	KeyEvent	Impairment, Endothelial network
Aop:38	Event:249	KeyEvent	Insufficiency, Vascular
Aop:38	Event:250	AdverseOutcome	Increased, Developmental Defects
Aop:39	Event:313	AdverseOutcome	Increase, Allergic Respiratory Hypersensitivity Response
Aop:39	Event:398	KeyEvent	Activation, Dendritic Cells
Aop:39	Event:272	KeyEvent	Activation/Proliferation, T-cells
Aop:39	Event:396	MolecularInitiatingEvent	Covalent Binding, Protein
Aop:39	Event:1496	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:40	Event:396	MolecularInitiatingEvent	Covalent Binding, Protein
Aop:40	Event:827	AdverseOutcome	sensitisation, skin
Aop:40	Event:826	KeyEvent	Activation, Keratinocytes
Aop:40	Event:398	KeyEvent	Activation, Dendritic Cells
Aop:40	Event:272	KeyEvent	Activation/Proliferation, T-cells
Aop:41	Event:251	MolecularInitiatingEvent	Formation, Pro-mutagenic DNA Adducts
Aop:41	Event:252	KeyEvent	Increased, Induced Mutations in Critical Genes
Aop:41	Event:253	KeyEvent	Metabolism of AFB1, Production of Reactive Electrophiles
Aop:41	Event:254	KeyEvent	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
Aop:41	Event:255	KeyEvent	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
Aop:41	Event:256	AdverseOutcome	Tumorigenesis, Hepatocellular carcinoma
Aop:42	Event:257	MolecularInitiatingEvent	Binding of agonist, Ionotropic glutamate receptors
Aop:42	Event:258	KeyEvent	Mitochondrial dysfunction
Aop:42	Event:259	KeyEvent	Increase, Cell injury/death
Aop:42	Event:260	KeyEvent	N/A, Neurodegeneration
Aop:42	Event:261	KeyEvent	Overactivation, NMDARs
Aop:42	Event:262	KeyEvent	Increased, Intracellular Calcium overload
Aop:42	Event:263	KeyEvent	Decreased, Neuronal network function in adult brain
Aop:42	Event:264	KeyEvent	Neuroinflammation
Aop:42	Event:265	AdverseOutcome	Impairment, Learning and memory
Aop:43	Event:266	MolecularInitiatingEvent	Activation, PPARα
Aop:43	Event:267	KeyEvent	Increase, Luteinizing hormone (LH)
Aop:43	Event:268	KeyEvent	Hyperplasia, Leydig cell
Aop:43	Event:269	KeyEvent	Increase proliferation, Leydig cell
Aop:43	Event:270	KeyEvent	Decrease, circulating testosterone levels
Aop:43	Event:271	KeyEvent	Reduction, Testosterone synthesis in Leydig cells
Aop:43	Event:272	KeyEvent	Reduction, Cholesterol transport in mitochondria
Aop:43	Event:273	AdverseOutcome	decreased, Fertility
Aop:44	Event:274	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:44	Event:275	AdverseOutcome	skewed, sex ratio
Aop:45	Event:276	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:45	Event:277	KeyEvent	Increased, Vitellogenin synthesis
Aop:45	Event:278	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:45	Event:279	KeyEvent	Increased, renal vitellogenin deposition
Aop:45	Event:280	KeyEvent	Increased, glomerular rupture and renal hemorrhaging
Aop:45	Event:281	KeyEvent	Increased, nephropathy
Aop:46	Event:282	MolecularInitiatingEvent	Inhibition, Na+/I- symporter (NIS)
Aop:46	Event:283	KeyEvent	Decrease of Thyroidal iodide
Aop:46	Event:284	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:46	Event:285	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:46	Event:286	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:46	Event:287	KeyEvent	Reduced levels of BDNF
Aop:46	Event:288	KeyEvent	Decrease of GABAergic interneurons
Aop:46	Event:289	KeyEvent	Decrease of synaptogenesis
Aop:46	Event:290	KeyEvent	Decrease of neuronal network function
Aop:46	Event:291	AdverseOutcome	Impairment, Learning and memory
Aop:47	Event:292	MolecularInitiatingEvent	Activation, AhR
Aop:47	Event:293	KeyEvent	Suppression, VLDL secretion
Aop:47	Event:294	KeyEvent	Inhibition, Mitochondrial fatty acid beta-oxidation
Aop:47	Event:295	KeyEvent	Accumulation, Fatty acid
Aop:47	Event:296	KeyEvent	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
Aop:47	Event:297	KeyEvent	Accumulation, Triglyceride
Aop:47	Event:298	KeyEvent	Up Regulation, CD36
Aop:47	Event:299	KeyEvent	Increased, FA Influx
Aop:47	Event:300	KeyEvent	Up Regulation, LDLR (low density lipoprotein receptor)
Aop:47	Event:301	KeyEvent	Increased, LDL uptake
Aop:47	Event:302	KeyEvent	Up Regulation, CYP1A1
Aop:47	Event:303	KeyEvent	Up Regulation, SCD-1
Aop:47	Event:304	AdverseOutcome	Increased, Liver Steatosis
Aop:48	Event:305	MolecularInitiatingEvent	Suppression, Constitutive androstane receptor, NR1l3
Aop:48	Event:306	MolecularInitiatingEvent	Inhibition, PPAR alpha
Aop:48	Event:307	MolecularInitiatingEvent	Activation, LXR
Aop:48	Event:308	MolecularInitiatingEvent	peroxisome proliferator activated receptor promoter demethylation
Aop:48	Event:309	KeyEvent	Activation, SREBF1
Aop:48	Event:310	KeyEvent	Activation, ChREBP
Aop:48	Event:311	KeyEvent	Increased, De Novo FA synthesis
Aop:48	Event:312	KeyEvent	Increased, Triglyceride formation
Aop:48	Event:313	KeyEvent	Up Regulation, CD36
Aop:48	Event:314	KeyEvent	Up Regulation, SCD-1
Aop:48	Event:315	KeyEvent	Up Regulation, FAS
Aop:48	Event:316	KeyEvent	Inhibition, Mitochondrial fatty acid beta-oxidation
Aop:48	Event:317	KeyEvent	Accumulation, Fatty acid
Aop:48	Event:318	KeyEvent	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
Aop:48	Event:319	KeyEvent	Increased, FA Influx
Aop:48	Event:320	AdverseOutcome	Increased, Liver Steatosis
Aop:49	Event:321	MolecularInitiatingEvent	Suppression, HNF4alpha
Aop:50	Event:322	MolecularInitiatingEvent	Activation, PXR/SXR
Aop:50	Event:323	KeyEvent	Inhibition, FoxA2
Aop:50	Event:324	KeyEvent	Decrease, Fatty acid beta-oxidation
Aop:50	Event:325	KeyEvent	Down Regulation, CPT1A
Aop:50	Event:326	KeyEvent	Down Regulation, HMGCS2
Aop:50	Event:327	KeyEvent	Up Regulation, SCD-1
Aop:50	Event:328	KeyEvent	Up Regulation, CD36
Aop:50	Event:329	KeyEvent	Increased, FA Influx
Aop:50	Event:330	KeyEvent	Decreased, Ketogenesis
Aop:50	Event:331	KeyEvent	Increased, Triglyceride formation
Aop:50	Event:332	KeyEvent	Accumulation, Fatty acid
Aop:50	Event:333	AdverseOutcome	Increased, Liver Steatosis
Aop:51	Event:334	MolecularInitiatingEvent	Activation, NRF2
Aop:51	Event:335	MolecularInitiatingEvent	Activation, NR1H4
Aop:51	Event:336	KeyEvent	Activation, SHP
Aop:51	Event:337	KeyEvent	Activation, PPARα
Aop:51	Event:338	KeyEvent	Decreased, DHB4/HSD17B4
Aop:51	Event:339	KeyEvent	Inhibition, Mitochondrial fatty acid beta-oxidation
Aop:51	Event:340	KeyEvent	Activation, LXR alpha
Aop:51	Event:341	KeyEvent	Inhibition, SREBP1c
Aop:51	Event:342	KeyEvent	Activation, MTTP
Aop:51	Event:343	KeyEvent	Increased, ApoB100
Aop:51	Event:344	KeyEvent	Increased, Triglyceride
Aop:51	Event:345	KeyEvent	Increased, De Novo FA synthesis
Aop:51	Event:346	AdverseOutcome	Increased, Liver Steatosis
Aop:52	Event:347	MolecularInitiatingEvent	systemic inflammation leading to hepatic steatosis
Aop:52	Event:348	KeyEvent	Activation, AKT2
Aop:52	Event:349	KeyEvent	Activation, SREBF1
Aop:52	Event:350	AdverseOutcome	Increased, Liver Steatosis
Aop:53	Event:351	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:53	Event:352	KeyEvent	Decrease, Ovulation
Aop:53	Event:353	KeyEvent	Reduced, Prostaglandins, ovary
Aop:53	Event:354	AdverseOutcome	Reduced, Reproductive Success
Aop:53	Event:355	AdverseOutcome	Decrease, Population growth rate
Aop:54	Event:356	MolecularInitiatingEvent	Glucocorticoid Receptor Agonist, Activation
Aop:54	Event:357	KeyEvent	Repressed expression of steroidogenic enzymes
Aop:54	Event:358	KeyEvent	Increased apoptosis, decreased fetal/adult Leydig Cells
Aop:54	Event:359	KeyEvent	Reduction, Testosterone synthesis in Leydig cells
Aop:54	Event:360	KeyEvent	Decrease, circulating testosterone levels
Aop:54	Event:361	KeyEvent	Decreased sperm quantity or quality in the adult, Decreased fertility
Aop:54	Event:362	AdverseOutcome	decreased, Fertility
Aop:55	Event:363	MolecularInitiatingEvent	Inhibition, Na+/I- symporter (NIS)
Aop:55	Event:364	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:55	Event:365	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:55	Event:366	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:55	Event:367	KeyEvent	Altered, Neuroanatomy
Aop:55	Event:368	KeyEvent	Altered, Neurophysiology
Aop:55	Event:369	AdverseOutcome	Cognitive function, decreased
Aop:56	Event:370	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Increased corticosterone
Aop:56	Event:371	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists
Aop:56	Event:372	KeyEvent	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells
Aop:56	Event:373	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:56	Event:374	KeyEvent	Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells
Aop:56	Event:375	AdverseOutcome	Decreased sperm quantity / quality in the adult, Decreased fertility
Aop:57	Event:376	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Increased estradiol
Aop:57	Event:377	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists
Aop:57	Event:378	KeyEvent	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells
Aop:57	Event:379	KeyEvent	decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells
Aop:57	Event:380	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:57	Event:381	AdverseOutcome	Decreased sperm quantity / quality in the adult, Decreased fertility
Aop:58	Event:382	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome
Aop:58	Event:383	KeyEvent	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells
Aop:58	Event:384	KeyEvent	Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells
Aop:58	Event:385	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:58	Event:386	AdverseOutcome	Decreased sperm quantity / quality in the adult, Decreased fertility
Aop:59	Event:387	MolecularInitiatingEvent	Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol
Aop:59	Event:388	MolecularInitiatingEvent	Decreased Cholesterol, Decreased Uptake of Lipoproteins
Aop:59	Event:389	MolecularInitiatingEvent	Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane
Aop:59	Event:390	KeyEvent	Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells
Aop:59	Event:391	AdverseOutcome	Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis
Aop:60	Event:392	MolecularInitiatingEvent	Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell
Aop:60	Event:393	KeyEvent	Decreased, steroidogenic protein expression
Aop:60	Event:394	KeyEvent	Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells
Aop:60	Event:395	KeyEvent	Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton
Aop:60	Event:396	AdverseOutcome	Decreased sperm quantity or quality in the adult, Decreased fertility
Aop:61	Event:397	MolecularInitiatingEvent	Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid
Aop:61	Event:398	KeyEvent	Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells
Aop:61	Event:399	KeyEvent	Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells
Aop:61	Event:400	KeyEvent	Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells
Aop:61	Event:401	AdverseOutcome	Decreased sperm quantity or quality in the adult, Decreased fertility
Aop:62	Event:402	MolecularInitiatingEvent	peroxisome proliferator activated receptor promoter demethylation
Aop:62	Event:403	MolecularInitiatingEvent	chronic high fat diet
Aop:62	Event:404	KeyEvent	Activation of specific nuclear receptors, PPAR-gamma activation
Aop:62	Event:405	KeyEvent	activation of CCAAT/enhancer-binding protein alpha
Aop:62	Event:406	KeyEvent	increased adipogenesis
Aop:62	Event:407	KeyEvent	decreased dopamine
Aop:62	Event:408	KeyEvent	decreased reward
Aop:62	Event:409	KeyEvent	decreased DNA methylation of tyrosine hydroxylase
Aop:62	Event:410	KeyEvent	decreased methylation of dopamine transporter promoter
Aop:62	Event:411	AdverseOutcome	obesity
Aop:63	Event:412	MolecularInitiatingEvent	Inhibition, Inhibition of Dopamine-beta-hydroxylase
Aop:63	Event:413	KeyEvent	Decreased, Synthesis of NE
Aop:63	Event:414	KeyEvent	Decreased, GnRH cfos activity
Aop:63	Event:415	KeyEvent	Decreased, GnRH pulsatility/release
Aop:63	Event:416	KeyEvent	Decreased, LH Surge
Aop:63	Event:417	KeyEvent	Delayed, Ovulation
Aop:63	Event:418	KeyEvent	Decreased, Cortical granule release/distribution upon fertilization
Aop:63	Event:419	KeyEvent	Altered, Formation of cortical envelope
Aop:63	Event:420	KeyEvent	Abnormal, Sperm penetration (polyspermy)
Aop:63	Event:421	KeyEvent	Altered, Chromosome number (polyploid) zygote
Aop:63	Event:422	AdverseOutcome	Decreased, Decreased fecundity
Aop:64	Event:423	MolecularInitiatingEvent	Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis
Aop:64	Event:424	KeyEvent	Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells
Aop:64	Event:425	KeyEvent	Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells
Aop:64	Event:426	KeyEvent	Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells
Aop:64	Event:427	AdverseOutcome	Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis
Aop:65	Event:428	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:65	Event:429	KeyEvent	Mitochondrial dysfunction
Aop:65	Event:430	KeyEvent	Impairment, Learning and memory
Aop:65	Event:431	KeyEvent	Abnormal, Foraging activity and behavior
Aop:65	Event:432	KeyEvent	Weakened, Colony
Aop:65	Event:433	KeyEvent	Altered, Ca2+-calmodulin activated signal transduction
Aop:65	Event:434	AdverseOutcome	Death/Failure, Colony
Aop:66	Event:435	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:66	Event:436	KeyEvent	Mitochondrial dysfunction
Aop:66	Event:437	KeyEvent	Decrease of neuronal network function
Aop:66	Event:438	KeyEvent	Impairment, Learning and memory
Aop:66	Event:439	KeyEvent	Abnormal, Roll change within caste
Aop:66	Event:440	KeyEvent	Reduced, Brood care
Aop:66	Event:441	AdverseOutcome	impaired, Larval development
Aop:66	Event:442	AdverseOutcome	Death/Failure, Colony
Aop:67	Event:443	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:67	Event:444	KeyEvent	Mitochondrial dysfunction
Aop:67	Event:445	KeyEvent	impaired, Hive thermoregulation
Aop:67	Event:446	KeyEvent	Weakened, Colony
Aop:67	Event:447	AdverseOutcome	Death/Failure, Colony
Aop:68	Event:448	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:68	Event:449	KeyEvent	Mitochondrial dysfunction
Aop:68	Event:450	KeyEvent	Accumulation, Damaged mitochondrial DNA
Aop:68	Event:451	KeyEvent	Accelerated, Aging
Aop:68	Event:452	KeyEvent	Overwhelmed, Mitochondrial DNA repair mechanisms
Aop:68	Event:453	AdverseOutcome	Decrease, Number of worker bees
Aop:68	Event:454	AdverseOutcome	impaired, Hive thermoregulation
Aop:68	Event:455	AdverseOutcome	Death/Failure, Colony
Aop:69	Event:456	KeyEvent	Increase, Energetic demands and therefore metabolic stress
Aop:69	Event:457	KeyEvent	Increased, Appetite and hunger
Aop:69	Event:458	KeyEvent	Abnormal, Foraging activity and behavior
Aop:69	Event:459	AdverseOutcome	Decrease, Number of worker bees
Aop:69	Event:460	AdverseOutcome	Death/Failure, Colony
Aop:70	Event:461	KeyEvent	Abnormal, Roll change within caste
Aop:70	Event:462	KeyEvent	Reduced, Brood care
Aop:70	Event:463	AdverseOutcome	impaired, Larval development
Aop:70	Event:464	AdverseOutcome	Death/Failure, Colony
Aop:71	Event:465	KeyEvent	Suppression, Immune system
Aop:71	Event:466	KeyEvent	Increased, Viral susceptibility
Aop:71	Event:467	KeyEvent	impaired, Development
Aop:71	Event:468	AdverseOutcome	Decrease, Number of worker bees
Aop:71	Event:469	AdverseOutcome	impaired, Hive thermoregulation
Aop:71	Event:470	AdverseOutcome	Death/Failure, Colony
Aop:72	Event:471	KeyEvent	Suppression, Immune system
Aop:72	Event:472	KeyEvent	Increased, Viral susceptibility
Aop:72	Event:473	KeyEvent	Abnormal, Foraging activity and behavior
Aop:72	Event:474	AdverseOutcome	Decrease, Number of worker bees
Aop:72	Event:475	AdverseOutcome	Death/Failure, Colony
Aop:73	Event:476	KeyEvent	Decreased, Glucose oxidase enzyme activity
Aop:73	Event:477	KeyEvent	Decreased, Hydrogen peroxide production
Aop:73	Event:478	KeyEvent	Reduced, Antiseptic incorporated in food
Aop:73	Event:479	KeyEvent	Abnormal, Roll change within caste
Aop:73	Event:480	KeyEvent	Reduced, Food storage
Aop:73	Event:481	AdverseOutcome	impaired, Larval development
Aop:73	Event:482	AdverseOutcome	Death/Failure, Colony
Aop:74	Event:483	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:74	Event:484	KeyEvent	Mitochondrial dysfunction
Aop:74	Event:485	KeyEvent	Impairment, Learning and memory
Aop:74	Event:486	KeyEvent	Abnormal, Foraging activity and behavior
Aop:74	Event:487	KeyEvent	Weakened, Colony
Aop:74	Event:488	KeyEvent	Abnormal, Role change within caste
Aop:74	Event:489	KeyEvent	Altered, Ca2+-calmodulin activated signal transduction
Aop:74	Event:490	AdverseOutcome	Death/Failure, Colony
Aop:75	Event:491	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:75	Event:492	KeyEvent	Impairment, Learning and memory
Aop:75	Event:493	KeyEvent	Abnormal, Foraging activity and behavior
Aop:75	Event:494	KeyEvent	Desensitization, Nicotinic acetylcholine receptor
Aop:75	Event:495	KeyEvent	Weakened, Colony
Aop:75	Event:496	KeyEvent	Altered, Ca2+-calmodulin activated signal transduction
Aop:75	Event:497	AdverseOutcome	Death/Failure, Colony
Aop:76	Event:498	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:76	Event:499	KeyEvent	Desensitization, Nicotinic acetylcholine receptor
Aop:76	Event:500	KeyEvent	Altered, Ca2+-calmodulin activated signal transduction
Aop:76	Event:501	KeyEvent	Impairment, Learning and memory
Aop:76	Event:502	KeyEvent	Abnormal, Foraging activity and behavior
Aop:76	Event:503	KeyEvent	Weakened, Colony
Aop:76	Event:504	KeyEvent	Abnormal, Role change within caste
Aop:76	Event:505	AdverseOutcome	Death/Failure, Colony
Aop:77	Event:506	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:77	Event:507	KeyEvent	Impairment, Learning and memory
Aop:77	Event:508	KeyEvent	Abnormal, Roll change within caste
Aop:77	Event:509	KeyEvent	Reduced, Brood care
Aop:77	Event:510	KeyEvent	Desensitization, Nicotinic acetylcholine receptor
Aop:77	Event:511	KeyEvent	Decrease of neuronal network function
Aop:77	Event:512	AdverseOutcome	impaired, Larval development
Aop:77	Event:513	AdverseOutcome	Death/Failure, Colony
Aop:78	Event:514	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:78	Event:515	KeyEvent	Decreased, Sodium conductance 1
Aop:78	Event:516	KeyEvent	Reduced, swimming speed
Aop:78	Event:517	AdverseOutcome	Reduced, feeding 1
Aop:78	Event:518	AdverseOutcome	Increased, predation
Aop:78	Event:519	AdverseOutcome	Reduced, survival
Aop:79	Event:520	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:79	Event:521	KeyEvent	Decreased, Sodium conductance 1
Aop:79	Event:522	KeyEvent	Reduced, swimming speed
Aop:79	Event:523	AdverseOutcome	Increased, predation
Aop:80	Event:524	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:80	Event:525	KeyEvent	Increased, Atrioventricular block and bradycardia
Aop:80	Event:526	KeyEvent	Respiratory distress/arrest
Aop:80	Event:527	KeyEvent	N/A, hypoxia
Aop:80	Event:528	KeyEvent	Decreased, Sodium conductance 1
Aop:80	Event:529	AdverseOutcome	Increased, amputations
Aop:81	Event:530	MolecularInitiatingEvent	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel
Aop:81	Event:531	KeyEvent	Decreased, Sodium conductance 1
Aop:81	Event:532	KeyEvent	Reduced, swimming speed
Aop:81	Event:533	KeyEvent	Reduced, feeding 1
Aop:81	Event:534	KeyEvent	Increased, predation
Aop:81	Event:535	AdverseOutcome	Reduced, survival
Aop:82	Event:536	MolecularInitiatingEvent	modulation, sodium channel
Aop:82	Event:537	KeyEvent	prolonged, Depolarization of neuronal membrane
Aop:82	Event:538	KeyEvent	Overactivation, Neuronotransmitter release
Aop:82	Event:539	KeyEvent	Overactivation, muscle contraction
Aop:82	Event:540	KeyEvent	Increased, Ataxia, paralysis, or hyperactivity
Aop:82	Event:541	AdverseOutcome	Increased Mortality
Aop:83	Event:542	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:83	Event:543	KeyEvent	Increased, muscular waves in foot
Aop:83	Event:544	KeyEvent	Increased, water retention in foot
Aop:83	Event:545	KeyEvent	Increased, valve movement
Aop:83	Event:546	KeyEvent	Depletion, energy reserves
Aop:83	Event:547	KeyEvent	Increased, foot detachment
Aop:83	Event:548	KeyEvent	Increased, locomotion
Aop:83	Event:549	KeyEvent	Increased, serotonin (5-HT)
Aop:83	Event:550	AdverseOutcome	Increase, predation
Aop:83	Event:551	AdverseOutcome	Decrease, Population growth rate
Aop:84	Event:552	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:84	Event:553	KeyEvent	Increased, serotonin (5-HT)
Aop:84	Event:554	KeyEvent	Decreased, anxiety
Aop:84	Event:555	KeyEvent	Decreased, sheltering
Aop:84	Event:556	AdverseOutcome	Increased, predation
Aop:85	Event:557	MolecularInitiatingEvent	Antagonism, Histamine Receptor (H2)
Aop:85	Event:558	KeyEvent	Decrease, histaminergic neuron excitation
Aop:85	Event:559	KeyEvent	N/A, sedation
Aop:85	Event:560	KeyEvent	Decreased, locomotion
Aop:85	Event:561	KeyEvent	Impairment, Learning and memory
Aop:85	Event:562	AdverseOutcome	Decreased, survival
Aop:85	Event:563	AdverseOutcome	Increased, predation
Aop:86	Event:564	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:86	Event:565	KeyEvent	Reduced, Prostaglandin F2alpha concentration, plasma
Aop:86	Event:566	KeyEvent	Reduced, Prostaglandin F2alpha synthesis, ovary
Aop:86	Event:567	KeyEvent	Reduced, Spawning behavior
Aop:86	Event:568	KeyEvent	Reduced, Ability to attract spawning mates
Aop:86	Event:569	AdverseOutcome	Reduced, Reproductive Success
Aop:86	Event:570	AdverseOutcome	Decrease, Population growth rate
Aop:87	Event:571	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:87	Event:572	KeyEvent	Reduced, Ability to attract spawning mates
Aop:87	Event:573	KeyEvent	Reduced, Pheromone release
Aop:87	Event:574	KeyEvent	Decreased, Prostaglandin F2alpha synthesis, ovary
Aop:87	Event:575	KeyEvent	Reduced, Prostaglandin F2alpha concentration, plasma
Aop:87	Event:576	AdverseOutcome	Reduced, Reproductive Success
Aop:87	Event:577	AdverseOutcome	Decrease, Population growth rate
Aop:88	Event:578	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:88	Event:579	KeyEvent	Reduced, Prostaglandin E2 concentration, hypothalamus
Aop:88	Event:580	KeyEvent	Reduced, Gonadotropin releasing hormone, hypothalamus
Aop:88	Event:581	KeyEvent	Reduced, Luteinizing hormone (LH), plasma
Aop:88	Event:582	KeyEvent	Reduced, Maturation inducing steroid, plasma
Aop:88	Event:583	KeyEvent	Reduced, Maturation inducing steroid receptor signalling, oocyte
Aop:88	Event:584	KeyEvent	Reduced, Meiotic prophase I/metaphase I transition, oocyte
Aop:88	Event:585	KeyEvent	Increased, cyclic adenosine monophosphate
Aop:88	Event:586	AdverseOutcome	Reduced, Reproductive Success
Aop:88	Event:587	AdverseOutcome	Decrease, Population growth rate
Aop:89	Event:588	MolecularInitiatingEvent	Inhibition, Cyclooxygenase activity
Aop:89	Event:589	KeyEvent	Reduced, Prostaglandin E2 concentration, hypothalamus
Aop:89	Event:590	KeyEvent	Reduced, Gonadotropin releasing hormone, hypothalamus
Aop:89	Event:591	KeyEvent	Reduced, Luteinizing hormone (LH), plasma
Aop:89	Event:592	KeyEvent	Reduced, Maturation inducing steroid, plasma
Aop:89	Event:593	KeyEvent	Reduced, Maturation inducing steroid receptor signalling, oocyte
Aop:89	Event:594	KeyEvent	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
Aop:89	Event:595	KeyEvent	Increased, Chromosome misseggregation
Aop:89	Event:596	AdverseOutcome	Reduced, Reproductive Success
Aop:89	Event:597	AdverseOutcome	Decrease, Population growth rate
Aop:90	Event:598	MolecularInitiatingEvent	impaired, ion channels
Aop:90	Event:599	KeyEvent	Altered, Action Potential
Aop:90	Event:600	KeyEvent	Increased, cardiac arrthymia
Aop:90	Event:601	AdverseOutcome	Increased Mortality
Aop:91	Event:602	MolecularInitiatingEvent	Increased, Binding of chemicals to 2u (serum)
Aop:91	Event:603	KeyEvent	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
Aop:91	Event:604	KeyEvent	Increase, Cytotoxicity (renal tubular cell)
Aop:91	Event:605	KeyEvent	Increase, Regenerative cell proliferation (tubular epithelial cells)
Aop:91	Event:606	KeyEvent	Increase, Hyperplasia (renal tubular cells)
Aop:91	Event:607	AdverseOutcome	Increase, Adenomas/carcinomas (renal tubular)
Aop:92	Event:608	MolecularInitiatingEvent	Binding, Tubulin
Aop:92	Event:609	KeyEvent	Disruption, Microtubule dynamics
Aop:92	Event:610	KeyEvent	Disorganization, Meiotic Spindle
Aop:92	Event:611	KeyEvent	Altered, Meiotic chromosome dynamics
Aop:92	Event:612	KeyEvent	Altered, Chromosome number
Aop:92	Event:613	AdverseOutcome	Increase, Aneuploid offspring
Aop:93	Event:614	MolecularInitiatingEvent	Activation, Constitutive androstane receptor
Aop:93	Event:615	KeyEvent	Altered gene expression specific to CAR activation, Hepatocytes
Aop:93	Event:616	KeyEvent	Increase, cell proliferation (hepatocytes)
Aop:93	Event:617	KeyEvent	Increase, Preneoplastic foci (hepatocytes)
Aop:93	Event:618	AdverseOutcome	Increase, hepatocellular adenomas and carcinomas
Aop:94	Event:619	MolecularInitiatingEvent	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme
Aop:94	Event:620	KeyEvent	Increase, Cytotoxicity
Aop:94	Event:621	KeyEvent	Peptide Oxidation
Aop:94	Event:622	KeyEvent	Increased, Induction of pyruvate dehydrogenase (PDH)
Aop:94	Event:623	KeyEvent	Increase, Oxidative metabolism
Aop:94	Event:624	AdverseOutcome	Increase, hepatocellular adenomas and carcinomas
Aop:95	Event:625	MolecularInitiatingEvent	Increase, Cytotoxicity (club cells)
Aop:95	Event:626	KeyEvent	Increase, Necrosis (terminal bronchiolar cells)
Aop:95	Event:627	KeyEvent	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
Aop:95	Event:628	KeyEvent	Increase, Hyperplasia (terminal bronchiolar cells)
Aop:95	Event:629	AdverseOutcome	Increase, Adenomas/carcinomas (bronchioloalveolar)
Aop:96	Event:630	MolecularInitiatingEvent	Inhibition, Na+/I- symporter (NIS)
Aop:96	Event:631	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:96	Event:632	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:96	Event:633	KeyEvent	Increased, Thyroid-stimulating hormone (TSH)
Aop:96	Event:634	KeyEvent	Increase, Hypertrophy and proliferation (follicular cell)
Aop:96	Event:635	KeyEvent	Increase, Hyperplasia (follicular cells)
Aop:96	Event:636	AdverseOutcome	Increase, Adenomas/carcinomas (follicular cell)
Aop:97	Event:637	MolecularInitiatingEvent	Decrease, androgen receptor activation
Aop:97	Event:638	KeyEvent	Decreased, Testosterone binding to androgen receptor (hypothalamus)
Aop:97	Event:639	KeyEvent	Increase, Hyperplasia (Leydig cells)
Aop:97	Event:640	KeyEvent	Increased, Luteinizing hormone (LH)
Aop:97	Event:641	AdverseOutcome	Increase, Leydig cell tumors
Aop:98	Event:642	MolecularInitiatingEvent	Increase, Dopaminergic activity
Aop:98	Event:643	KeyEvent	Decreased, Prolactin
Aop:98	Event:644	KeyEvent	Agonism, Estrogen receptor
Aop:98	Event:645	KeyEvent	Decreased, Progesterone from corpus luteum
Aop:98	Event:646	KeyEvent	Increase, Hyperplasia (glandular epithelial cells of endometrium)
Aop:98	Event:647	AdverseOutcome	Increase, Endometrial adenocarcinomas
Aop:99	Event:648	MolecularInitiatingEvent	Activation, Glutamate-gated chloride channel
Aop:99	Event:649	KeyEvent	Increased, Chloride conductance
Aop:99	Event:650	KeyEvent	hyperpolarisation, neuron
Aop:99	Event:651	KeyEvent	N/A, Ataxia, paralysis, or hyperactivity
Aop:99	Event:652	AdverseOutcome	Increased Mortality
Aop:99	Event:653	AdverseOutcome	Decreased, population 1
Aop:100	Event:654	MolecularInitiatingEvent	Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme
Aop:100	Event:655	KeyEvent	Increased, Plasma tyrosine
Aop:100	Event:656	KeyEvent	Increase, Cytotoxicity (corneal cells)
Aop:100	Event:657	KeyEvent	Increase, Inflammation (corneal cells)
Aop:100	Event:658	KeyEvent	Increase, Regenerative cell proliferation (corneal cells)
Aop:100	Event:659	AdverseOutcome	Increase, Papillomas/carcinomas (squamous cells)
Aop:101	Event:660	MolecularInitiatingEvent	Increase, Cytotoxicity (epithelial cells)
Aop:101	Event:661	KeyEvent	Increase, Inflammation
Aop:101	Event:662	KeyEvent	Increase, Regenerative cell proliferation (forestomach epithelial cells)
Aop:101	Event:663	KeyEvent	Increase, Hyperplasia (forestomach epithelial cells)
Aop:101	Event:664	AdverseOutcome	Increase, Papillomas/carcinomas (squamous cells)
Aop:102	Event:665	MolecularInitiatingEvent	Increase, Cytotoxicity (tubular epithelial cells)
Aop:102	Event:666	KeyEvent	Increase, Regenerative cell proliferation (tubular epithelial cells)
Aop:102	Event:667	KeyEvent	Increase, Hyperplasia (tubular epithelial cells)
Aop:102	Event:668	AdverseOutcome	Increase, Adenomas/carcinomas (renal tubular)
Aop:103	Event:669	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:103	Event:670	KeyEvent	Increase, cell proliferation (hepatocytes)
Aop:103	Event:671	KeyEvent	Increase, Preneoplastic foci (hepatocytes)
Aop:103	Event:672	AdverseOutcome	Increase, hepatocellular adenomas and carcinomas
Aop:104	Event:673	MolecularInitiatingEvent	Increase, Cytotoxicity (hepatocytes)
Aop:104	Event:674	KeyEvent	Increase, Regenerative cell proliferation (hepatocytes)
Aop:104	Event:675	KeyEvent	Increase, Preneoplastic foci (hepatocytes)
Aop:104	Event:676	AdverseOutcome	Increase, hepatocellular adenomas and carcinomas
Aop:105	Event:677	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:105	Event:678	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:105	Event:679	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:105	Event:680	KeyEvent	Increased, Thyroid-stimulating hormone (TSH)
Aop:105	Event:681	KeyEvent	Increase, Hypertrophy and proliferation (follicular cell)
Aop:105	Event:682	KeyEvent	Increase, Hyperplasia (follicular cells)
Aop:105	Event:683	AdverseOutcome	Increase, Adenomas/carcinomas (follicular cell)
Aop:106	Event:684	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:106	Event:685	KeyEvent	Increased, Leutinizing hormone (LH)
Aop:106	Event:686	KeyEvent	Increase, Hyperplasia (Leydig cells)
Aop:106	Event:687	KeyEvent	Decrease, circulating testosterone levels
Aop:106	Event:688	AdverseOutcome	Increase, Leydig cell tumors
Aop:107	Event:689	MolecularInitiatingEvent	Increase, Urinary bladder calculi
Aop:107	Event:690	KeyEvent	Increase, Cytotoxicity (urothelial cells)
Aop:107	Event:691	KeyEvent	Increase, Regenerative cell proliferation (urothelial cells)
Aop:107	Event:692	KeyEvent	Increase, Hyperplasia (urothelial)
Aop:107	Event:693	AdverseOutcome	Increase, Adenomas/carcinomas (urothelial)
Aop:108	Event:694	MolecularInitiatingEvent	Inhibition, Prolyl hydroxylases
Aop:108	Event:695	KeyEvent	Increased, HIF-1 heterodimer
Aop:108	Event:696	KeyEvent	Decreased, Aromatase (Cyp19a1) mRNA
Aop:108	Event:697	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:108	Event:698	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:108	Event:699	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:108	Event:700	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:108	Event:701	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:108	Event:702	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:108	Event:703	AdverseOutcome	Decrease, Population growth rate
Aop:109	Event:704	MolecularInitiatingEvent	modulation, Unknown
Aop:109	Event:705	KeyEvent	Increased, HIF-1 heterodimer
Aop:109	Event:706	KeyEvent	Increased, HIF-1 alpha transcription
Aop:109	Event:707	KeyEvent	Decreased, Aromatase (Cyp19a1) mRNA
Aop:109	Event:708	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:109	Event:709	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:109	Event:710	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:109	Event:711	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:109	Event:712	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:109	Event:713	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:109	Event:714	AdverseOutcome	Decrease, Population growth rate
Aop:110	Event:715	MolecularInitiatingEvent	Inhibition, HMG-CoA reductase
Aop:110	Event:716	KeyEvent	Decreased, mevalonate
Aop:110	Event:717	KeyEvent	Decreased, cholesterol
Aop:110	Event:718	KeyEvent	Decrease, circulating testosterone levels
Aop:110	Event:719	KeyEvent	malformed, Male reproductive tract
Aop:110	Event:720	AdverseOutcome	Decrease, Fertility
Aop:111	Event:721	MolecularInitiatingEvent	Inhibition, Antgonism of NE receptor
Aop:111	Event:722	KeyEvent	Decreased, Binding of NE to NE receptors on GnRH neurons
Aop:111	Event:723	KeyEvent	Decreased, GnRH cfos activity
Aop:111	Event:724	KeyEvent	Decreased, GnRH pulsatility/release
Aop:111	Event:725	KeyEvent	Decreased, LH Surge
Aop:111	Event:726	KeyEvent	Delayed, Ovulation
Aop:111	Event:727	KeyEvent	Decreased, Cortical granule release/distribution upon fertilization
Aop:111	Event:728	KeyEvent	Altered, Formation of cortical envelope
Aop:111	Event:729	KeyEvent	Abnormal, Sperm penetration (polyspermy)
Aop:111	Event:730	KeyEvent	Altered, Chromosome number (polyploid) zygote
Aop:111	Event:731	AdverseOutcome	Decreased, Decreased fecundity
Aop:112	Event:732	MolecularInitiatingEvent	Thyroid hormone synthesis, Decreased
Aop:112	Event:733	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:112	Event:734	KeyEvent	Increased, Serum creatinine
Aop:112	Event:735	KeyEvent	Occurrence, Cystic dilatation (renal tubule)
Aop:112	Event:736	KeyEvent	Occurrence, Cytoplasmic vacuolization (podocyte)
Aop:112	Event:737	KeyEvent	Occurrence, Cytoplasmic vacuolization (Renal tubule)
Aop:112	Event:738	KeyEvent	Decreased, Glomerular filtration
Aop:112	Event:739	KeyEvent	Decreased, Renal plasma flow
Aop:112	Event:740	KeyEvent	Decreased, Sodium reabsorption
Aop:112	Event:741	KeyEvent	Decreased, Renal ability to dilute urine
Aop:112	Event:742	AdverseOutcome	Occurrence, Kidney toxicity
Aop:113	Event:743	MolecularInitiatingEvent	Inhibition, Phospholipase A
Aop:113	Event:744	KeyEvent	Damage, Lipid bilayer
Aop:113	Event:745	KeyEvent	Disturbance, Lysosomal function
Aop:113	Event:746	KeyEvent	Mitochondrial dysfunction
Aop:113	Event:747	KeyEvent	Occurrence, Cytoplasmic vacuolization (hepatocyte)
Aop:113	Event:748	KeyEvent	Occurrence, Ballooning degeneration (hepatocyte)
Aop:113	Event:749	KeyEvent	Occurrence, Cytoplasmic vacuolization (kupffer cell)
Aop:113	Event:750	KeyEvent	Induction, Microvesicular fat
Aop:113	Event:751	KeyEvent	Formation, Mallory body
Aop:113	Event:752	KeyEvent	Occurrence, Cytoplasmic vacuolization (Bile duct cell)
Aop:113	Event:753	AdverseOutcome	Formation, Liver fibrosis
Aop:114	Event:754	MolecularInitiatingEvent	Activation, AhR
Aop:114	Event:755	KeyEvent	Induction, CYP1A2/CYP1A5
Aop:114	Event:756	KeyEvent	Oxidation, Uroporphyrinogen
Aop:114	Event:757	KeyEvent	Inhibition, UROD
Aop:114	Event:758	KeyEvent	Accumulation, Highly carboxylated porphyrins
Aop:114	Event:759	AdverseOutcome	Uroporphyria
Aop:115	Event:760	MolecularInitiatingEvent	Inhibition, Na+/I- symporter (NIS)
Aop:115	Event:761	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:115	Event:762	KeyEvent	Decrease of Thyroidal iodide
Aop:115	Event:763	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:115	Event:764	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:115	Event:765	KeyEvent	Hippocampal gene expression, Altered
Aop:115	Event:766	KeyEvent	Hippocampal anatomy, Altered
Aop:115	Event:767	KeyEvent	Hippocampal Physiology, Altered
Aop:115	Event:768	AdverseOutcome	Cognitive function, decreased
Aop:116	Event:769	MolecularInitiatingEvent	Decrease, Intracellular pH
Aop:116	Event:770	KeyEvent	Increase, Tissue Degeneration, Necrosis & Atrophy
Aop:116	Event:771	KeyEvent	Increase, Cell Proliferation
Aop:116	Event:772	KeyEvent	Increase, Respiratory or Squamous Metaplasia
Aop:116	Event:773	KeyEvent	Increase, Cytotoxicity
Aop:116	Event:774	KeyEvent	Increase, Mutations in Critical Genes
Aop:116	Event:775	AdverseOutcome	Increase, Site of Contact Nasal Tumors
Aop:117	Event:776	MolecularInitiatingEvent	Inhibition, organic anion transporter 1 (OAT1)
Aop:117	Event:777	KeyEvent	Increased, blood uric acid concentration
Aop:117	Event:778	KeyEvent	Occurrence, renal proximal tubular necrosis
Aop:117	Event:779	KeyEvent	Increased, blood potassium concentration
Aop:117	Event:780	KeyEvent	Occurrence, tophi (urate) deposition
Aop:117	Event:781	KeyEvent	Occurrence, cardiac arrhythmia
Aop:117	Event:782	KeyEvent	Oxidative Stress
Aop:117	Event:783	AdverseOutcome	Increased Mortality
Aop:117	Event:784	AdverseOutcome	Decrease, Population growth rate
Aop:118	Event:785	MolecularInitiatingEvent	Alkylation, DNA
Aop:118	Event:786	KeyEvent	Inadequate DNA repair
Aop:118	Event:787	KeyEvent	Increase, Mutations
Aop:118	Event:788	AdverseOutcome	Increase, Cancer
Aop:119	Event:789	MolecularInitiatingEvent	Alkylation, DNA
Aop:119	Event:790	KeyEvent	Inadequate DNA repair
Aop:119	Event:791	KeyEvent	Increase, Mutations
Aop:119	Event:792	AdverseOutcome	Increase, Cancer
Aop:120	Event:793	MolecularInitiatingEvent	Endocytotic lysosomal uptake
Aop:120	Event:794	KeyEvent	Disruption, Lysosome
Aop:120	Event:795	KeyEvent	Mitochondrial dysfunction
Aop:120	Event:796	KeyEvent	Increase, Cell injury/death
Aop:120	Event:797	KeyEvent	Increased Pro-inflammatory mediators
Aop:120	Event:798	KeyEvent	Leukocyte recruitment/activation
Aop:120	Event:799	KeyEvent	Activation, Stellate cells
Aop:120	Event:800	KeyEvent	Accumulation, Collagen
Aop:120	Event:801	AdverseOutcome	N/A, Liver fibrosis
Aop:121	Event:793	MolecularInitiatingEvent	Increase, Urinary bladder calculi
Aop:121	Event:794	KeyEvent	Increase, Cytotoxicity (urothelial cells)
Aop:121	Event:795	KeyEvent	Increase, Regenerative cell proliferation (urothelial cells)
Aop:121	Event:796	KeyEvent	Increase, Hyperplasia (urothelial)
Aop:121	Event:797	AdverseOutcome	Increase, Adenomas/carcinomas (urothelial)
Aop:122	Event:802	MolecularInitiatingEvent	Activation, EGFR
Aop:122	Event:803	KeyEvent	Increase, goblet cell number
Aop:122	Event:804	KeyEvent	Increase, Mucin production
Aop:122	Event:805	AdverseOutcome	Decrease, Lung function
Aop:123	Event:806	MolecularInitiatingEvent	Peptide Oxidation
Aop:123	Event:807	KeyEvent	KE1 : S-Glutathionylation, eNOS
Aop:123	Event:808	KeyEvent	KE2 : Decrease, GTPCH-1
Aop:123	Event:809	KeyEvent	KE3 : Decrease, Tetrahydrobiopterin
Aop:123	Event:810	KeyEvent	KE4 : Uncoupling, eNOS
Aop:123	Event:811	KeyEvent	KE6 : Depletion, Nitric Oxide
Aop:123	Event:812	KeyEvent	KE7 : Impaired, Vasodilation
Aop:123	Event:813	KeyEvent	KE8 : Increase, Vascular Resistance
Aop:123	Event:814	KeyEvent	KE5 : Decrease, AKT/eNOS activity
Aop:123	Event:815	AdverseOutcome	Hypertension
Aop:124	Event:816	MolecularInitiatingEvent	Activation, AhR
Aop:124	Event:817	KeyEvent	dimerization, AHR/ARNT
Aop:124	Event:818	KeyEvent	reduced dimerization, ARNT/HIF1-alpha
Aop:124	Event:819	KeyEvent	reduced production, VEGF
Aop:124	Event:820	KeyEvent	Impairment, Endothelial network
Aop:124	Event:821	KeyEvent	Altered, Cardiovascular development/function
Aop:124	Event:822	AdverseOutcome	Increase, Early Life Stage Mortality
Aop:125	Event:823	MolecularInitiatingEvent	Activation, AhR
Aop:125	Event:824	KeyEvent	dimerization, AHR/ARNT
Aop:125	Event:825	KeyEvent	reduced dimerization, ARNT/HIF1-alpha
Aop:125	Event:826	KeyEvent	reduced production, VEGF
Aop:125	Event:827	KeyEvent	abnormal, placental vasculature morphology
Aop:125	Event:828	KeyEvent	increase, placental insufficiency
Aop:125	Event:829	AdverseOutcome	increase, Preeclampsia
Aop:126	Event:830	MolecularInitiatingEvent	Binding, Transthyretin in serum
Aop:126	Event:831	KeyEvent	Displacement, Serum thyroxine (T4) from transthyretin
Aop:126	Event:832	KeyEvent	Increased, Free serum thyroxine (T4)
Aop:126	Event:833	KeyEvent	Increased, Uptake of thyroxine into tissue
Aop:126	Event:834	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:126	Event:835	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:126	Event:836	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:126	Event:837	KeyEvent	Hippocampal gene expression, Altered
Aop:126	Event:838	KeyEvent	Hippocampal anatomy, Altered
Aop:126	Event:839	KeyEvent	Hippocampal Physiology, Altered
Aop:126	Event:840	AdverseOutcome	Cognitive function, decreased
Aop:127	Event:841	MolecularInitiatingEvent	Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol
Aop:127	Event:842	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:127	Event:843	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:127	Event:844	KeyEvent	Decrease, E2 blood concentrations at hypothalamus
Aop:127	Event:845	KeyEvent	Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response
Aop:127	Event:846	KeyEvent	Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons
Aop:127	Event:847	KeyEvent	Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs
Aop:127	Event:848	KeyEvent	Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation
Aop:127	Event:849	AdverseOutcome	Decreased fertility, Reduced number of oocytes ovulated
Aop:128	Event:850	MolecularInitiatingEvent	Inhibition, Calcineurin Activity
Aop:128	Event:851	KeyEvent	Interference, nuclear localization of NFAT
Aop:128	Event:852	KeyEvent	Reduction, NFAT/AP-1 complex formation
Aop:128	Event:853	KeyEvent	Suppression, IL-2 and IL-4 production
Aop:128	Event:854	AdverseOutcome	Impairment, T-cell dependent antibody response
Aop:129	Event:855	MolecularInitiatingEvent	Inhibition, Deiodinase 2
Aop:129	Event:856	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:129	Event:857	KeyEvent	Reduced, Posterior swim bladder inflation
Aop:129	Event:858	KeyEvent	Reduced, Swimming performance
Aop:129	Event:859	AdverseOutcome	Increased Mortality
Aop:129	Event:860	AdverseOutcome	Decrease, Population growth rate
Aop:130	Event:861	MolecularInitiatingEvent	Inhibition, Deiodinase 2
Aop:130	Event:862	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:130	Event:863	KeyEvent	Reduced, Anterior swim bladder inflation
Aop:130	Event:864	KeyEvent	Reduced, Swimming performance
Aop:130	Event:865	AdverseOutcome	Increased Mortality
Aop:130	Event:866	AdverseOutcome	Decrease, Population growth rate
Aop:131	Event:867	MolecularInitiatingEvent	Inhibition, Deiodinase 1
Aop:131	Event:868	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:131	Event:869	KeyEvent	Reduced, Posterior swim bladder inflation
Aop:131	Event:870	KeyEvent	Reduced, Swimming performance
Aop:131	Event:871	AdverseOutcome	Increased Mortality
Aop:131	Event:872	AdverseOutcome	Decrease, Population growth rate
Aop:132	Event:873	MolecularInitiatingEvent	Inhibition, Deiodinase 1
Aop:132	Event:874	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:132	Event:875	KeyEvent	Reduced, Anterior swim bladder inflation
Aop:132	Event:876	KeyEvent	Reduced, Swimming performance
Aop:132	Event:877	AdverseOutcome	Increased Mortality
Aop:132	Event:878	AdverseOutcome	Decrease, Population growth rate
Aop:133	Event:879	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:133	Event:880	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:133	Event:881	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:133	Event:882	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:133	Event:883	KeyEvent	Reduced, Anterior swim bladder inflation
Aop:133	Event:884	KeyEvent	Reduced, Swimming performance
Aop:133	Event:885	AdverseOutcome	Increased Mortality
Aop:133	Event:886	AdverseOutcome	Decrease, Population growth rate
Aop:134	Event:887	MolecularInitiatingEvent	Activation, ionotropic GABA Receptor chloride channel
Aop:134	Event:888	KeyEvent	Increased, Inhibitory postsynaptic potential
Aop:134	Event:889	KeyEvent	Induction, Somatic muscle paralysis
Aop:134	Event:890	KeyEvent	Increased, Chloride conductance
Aop:134	Event:891	KeyEvent	Increased, Neuronal synaptic inhibition
Aop:134	Event:892	KeyEvent	Inhibition, Feeding
Aop:134	Event:893	AdverseOutcome	Increased Mortality
Aop:135	Event:894	MolecularInitiatingEvent	Activation, Glutamate-gated chloride channels
Aop:135	Event:895	KeyEvent	Increased, Neuronal synaptic inhibition
Aop:135	Event:896	KeyEvent	Increased, Inhibitory postsynaptic potential
Aop:135	Event:897	KeyEvent	Inhibition, Feeding
Aop:135	Event:898	KeyEvent	Increased, Chloride conductance
Aop:135	Event:899	KeyEvent	Induction, pharyngeal muscle paralysis
Aop:135	Event:900	AdverseOutcome	Increased Mortality
Aop:136	Event:901	KeyEvent	Induction, Upregulation of glucuronyltransferase activity
Aop:136	Event:902	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:136	Event:903	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:136	Event:904	KeyEvent	Increased, Thyroid-stimulating hormone (TSH)
Aop:136	Event:905	KeyEvent	Increase, Hypertrophy and proliferation (follicular cell)
Aop:136	Event:906	KeyEvent	Increase, Hyperplasia (follicular cells)
Aop:136	Event:907	AdverseOutcome	Increase, Adenomas/carcinomas (follicular cell)
Aop:137	Event:908	MolecularInitiatingEvent	Activation of specific nuclear receptors, PPAR-gamma activation
Aop:137	Event:909	KeyEvent	Increased, adipogenesis
Aop:137	Event:910	KeyEvent	Increased, secretion of local growth factors
Aop:137	Event:911	KeyEvent	Increased, proliferation of mesenchymal cells
Aop:137	Event:912	KeyEvent	Increased, IGF-1 (mouse)
Aop:137	Event:913	KeyEvent	Increased, Firbrosarcoma
Aop:137	Event:914	KeyEvent	Increased, liposarcoma
Aop:137	Event:915	KeyEvent	Increased, hemagiosarcoma
Aop:138	Event:916	MolecularInitiatingEvent	Activation, beta-2 adrenergic receptor
Aop:138	Event:917	KeyEvent	Increased activity, beta-2 adrenergic receptor
Aop:138	Event:918	KeyEvent	relaxation, smooth muscle
Aop:138	Event:919	KeyEvent	Proliferation/Clonal Expansion, smooth muscle
Aop:138	Event:920	KeyEvent	Hypertrophy/hyperplasia, smooth muscle
Aop:138	Event:921	AdverseOutcome	Promotion, mesovarian leiomyomas
Aop:139	Event:922	KeyEvent	Decreased, Ovarian E2
Aop:139	Event:923	KeyEvent	Suppression, Estrogen receptor (ER) activity
Aop:139	Event:924	KeyEvent	Increased, secretion of GnRH from hypothalamus
Aop:139	Event:925	KeyEvent	Increased, secrection of FSH from anterior pituitary
Aop:139	Event:926	KeyEvent	Increased, secretion of LH from anterior pituitary
Aop:139	Event:927	KeyEvent	Hyperplasia, ovarian stromal cells
Aop:139	Event:928	KeyEvent	Hyperplasia, ovarian epithelium
Aop:139	Event:929	KeyEvent	Decrease, E2 blood concentrations at hypothalamus
Aop:139	Event:930	AdverseOutcome	Promotion, ovarian adenomas
Aop:139	Event:931	AdverseOutcome	Promotion, ovarian granular cell tumors
Aop:140	Event:932	KeyEvent	Increased, PPAR-alpha activation
Aop:140	Event:933	KeyEvent	Decreased, bile flow
Aop:140	Event:934	KeyEvent	Increased, cholestasis
Aop:140	Event:935	KeyEvent	Alteration, lipid metabolism
Aop:140	Event:936	KeyEvent	prolonged, elevation of serun CCK
Aop:140	Event:937	KeyEvent	Increased, Cellular proliferation / hyperplasia of acinar cells
Aop:140	Event:938	AdverseOutcome	Increased, Pancreatic acinar tumors
Aop:141	Event:939	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:141	Event:940	KeyEvent	Sine oculis homeobox 1 gene expression, increased
Aop:141	Event:941	KeyEvent	Sine oculis homeobox 1 protein expression, increased
Aop:141	Event:942	KeyEvent	Promotion, SIX-1 postive basal-type progenitor cells
Aop:141	Event:943	KeyEvent	Proliferation/Clonal Expansion, aberrant basal cells
Aop:141	Event:944	KeyEvent	squamous metaplasia, aberrant basal cells
Aop:141	Event:945	KeyEvent	Increased, Hyperplasia (glandular epithelial cells of endometrium)
Aop:141	Event:946	AdverseOutcome	Increased, adenosquamous carcinomas of endometrium
Aop:142	Event:947	KeyEvent	Decreased, GnRH pulsatility/release in hypothalamus
Aop:142	Event:948	KeyEvent	Decreased, LH Surge from anterior pituitary
Aop:142	Event:949	KeyEvent	interruption, Ovulation
Aop:142	Event:950	KeyEvent	prolonged, estrus
Aop:142	Event:951	KeyEvent	Increased, circulating estrogen levels
Aop:142	Event:952	KeyEvent	Increased, prolactin exposure
Aop:142	Event:953	KeyEvent	Hyperplasia, Mammary gland
Aop:142	Event:954	KeyEvent	Increased, latency period
Aop:142	Event:955	AdverseOutcome	Increased, Adenomas/carcinomas (mammary)
Aop:143	Event:956	KeyEvent	Decreased, GnRH pulsatility/release in hypothalamus
Aop:143	Event:957	KeyEvent	Decreased, LH Surge from anterior pituitary
Aop:143	Event:958	KeyEvent	prolonged, estrus
Aop:143	Event:959	KeyEvent	interruption, Ovulation
Aop:143	Event:960	KeyEvent	Increased, circulating estrogen levels
Aop:143	Event:961	KeyEvent	Increased, lactotroph hyperplasia and hypertrophy
Aop:143	Event:962	AdverseOutcome	Increased, adenomas (pituitary)
Aop:144	Event:963	KeyEvent	Decreased, Dopaminergic activity
Aop:144	Event:964	KeyEvent	Increased, prolactin secretion
Aop:144	Event:965	KeyEvent	Increased, hyperplasia (mammary gland)
Aop:144	Event:966	KeyEvent	Increased, latency period
Aop:144	Event:967	AdverseOutcome	Increased, Adenomas/carcinomas (mammary)
Aop:145	Event:968	KeyEvent	persistent, cytotoxicity (pleura or peritoneum)
Aop:145	Event:969	KeyEvent	Increased, inflammation
Aop:145	Event:970	KeyEvent	Oxidative Stress
Aop:145	Event:971	KeyEvent	Increased, secretion of local growth factors
Aop:145	Event:972	KeyEvent	Increased, Cell Proliferation (mesothelium)
Aop:145	Event:973	AdverseOutcome	Increased, mesotheliomas
Aop:146	Event:974	MolecularInitiatingEvent	Substance interaction with the lung resident cell membrane components
Aop:146	Event:975	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:146	Event:976	KeyEvent	Increased, recruitment of inflammatory cells
Aop:146	Event:977	KeyEvent	Loss of alveolar capillary membrane integrity
Aop:146	Event:978	KeyEvent	Increased, activation of T (T) helper (h) type 2 cells
Aop:146	Event:979	KeyEvent	Increased, fibroblast proliferation and myofibroblast differentiation
Aop:146	Event:980	KeyEvent	Accumulation, Collagen
Aop:146	Event:981	AdverseOutcome	Pulmonary fibrosis
Aop:147	Event:982	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:147	Event:983	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:147	Event:984	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:147	Event:985	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:148	Event:986	MolecularInitiatingEvent	Inhibition, Na+/I- symporter (NIS)
Aop:148	Event:987	KeyEvent	Decrease of Thyroidal iodide
Aop:148	Event:988	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:148	Event:989	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:148	Event:990	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:149	Event:991	MolecularInitiatingEvent	Inhibition, Cyclooxygenase 1 activity
Aop:149	Event:992	KeyEvent	Decreased, Prostaglandin F2alpha concentration, plasma
Aop:149	Event:993	KeyEvent	Occurrence, renal ischemia
Aop:149	Event:994	KeyEvent	Occurrence, renal proximal tubular necrosis
Aop:149	Event:995	KeyEvent	Increased, blood potassium concentration
Aop:149	Event:996	KeyEvent	Occurrence, cardiac arrhythmia
Aop:149	Event:997	KeyEvent	Oxidative Stress
Aop:149	Event:998	KeyEvent	Increased, blood uric acid concentration
Aop:149	Event:999	KeyEvent	Occurrence, tophi (urate) deposition
Aop:149	Event:1000	AdverseOutcome	Increased Mortality
Aop:149	Event:1001	AdverseOutcome	Decrease, Population growth rate
Aop:150	Event:1002	MolecularInitiatingEvent	Activation, Nicotinic acetylcholine receptor
Aop:150	Event:1003	KeyEvent	Mitochondrial dysfunction
Aop:150	Event:1004	KeyEvent	Weakened, Colony
Aop:150	Event:1005	AdverseOutcome	Death/Failure, Colony
Aop:151	Event:1006	KeyEvent	Increased, Deformed Wing Virus levels
Aop:151	Event:1007	KeyEvent	Weakened, Colony
Aop:151	Event:1008	AdverseOutcome	Death/Failure, Colony
Aop:152	Event:1009	KeyEvent	Abnormal, Foraging activity and behavior
Aop:152	Event:1010	KeyEvent	Weakened, Colony
Aop:152	Event:1011	AdverseOutcome	Death/Failure, Colony
Aop:153	Event:1012	KeyEvent	Weakened, Colony
Aop:153	Event:1013	AdverseOutcome	Death/Failure, Colony
Aop:154	Event:1014	KeyEvent	Abnormal, Foraging activity and behavior
Aop:154	Event:1015	KeyEvent	Weakened, Colony
Aop:154	Event:1016	AdverseOutcome	Death/Failure, Colony
Aop:155	Event:1017	KeyEvent	Increased, Energetic demands and therefore metabolic stress
Aop:155	Event:1018	KeyEvent	Abnormal, Foraging activity and behavior
Aop:155	Event:1019	KeyEvent	Weakened, Colony
Aop:155	Event:1020	AdverseOutcome	Death/Failure, Colony
Aop:156	Event:1021	KeyEvent	Abnormal, Role change within caste
Aop:156	Event:1022	KeyEvent	Weakened, Colony
Aop:156	Event:1023	AdverseOutcome	Death/Failure, Colony
Aop:157	Event:1024	KeyEvent	Weakened, Colony
Aop:157	Event:1025	AdverseOutcome	Death/Failure, Colony
Aop:158	Event:1026	MolecularInitiatingEvent	Unknown, MIE
Aop:158	Event:1027	KeyEvent	Increase, Reactive oxygen species
Aop:158	Event:1028	KeyEvent	Oxidative Stress
Aop:158	Event:1029	KeyEvent	Occurrence, renal proximal tubular necrosis
Aop:158	Event:1030	KeyEvent	Increased, blood potassium concentration
Aop:158	Event:1031	KeyEvent	Occurrence, cardiac arrhythmia
Aop:158	Event:1032	AdverseOutcome	Increased Mortality
Aop:159	Event:1033	MolecularInitiatingEvent	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
Aop:159	Event:1034	MolecularInitiatingEvent	Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP
Aop:159	Event:1035	MolecularInitiatingEvent	Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin
Aop:159	Event:1036	KeyEvent	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis
Aop:159	Event:1037	KeyEvent	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
Aop:159	Event:1038	KeyEvent	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
Aop:159	Event:1039	KeyEvent	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
Aop:159	Event:1040	KeyEvent	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
Aop:159	Event:1041	KeyEvent	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
Aop:159	Event:1042	KeyEvent	Osteoporosis and vascular calcification, Bone deterioration
Aop:159	Event:1043	AdverseOutcome	Impaired recruitment , Population trajectory
Aop:160	Event:1044	MolecularInitiatingEvent	Inhibition, Iodotyrosine deiodinase (IYD)
Aop:160	Event:1045	KeyEvent	Decrease of Thyroidal iodide
Aop:160	Event:1046	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:160	Event:1047	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:160	Event:1048	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:161	Event:1049	MolecularInitiatingEvent	Inhibition, Deiodinase 1
Aop:161	Event:1050	KeyEvent	Decreased, Triiodothyronine (T3) in tissues
Aop:161	Event:1051	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:161	Event:1052	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:162	Event:1053	MolecularInitiatingEvent	Inhibition, Deiodinase 2
Aop:162	Event:1054	KeyEvent	Decreased, Triiodothyronine (T3) in tissues
Aop:162	Event:1055	KeyEvent	Increased, Thyroid-stimulating hormone (TSH)
Aop:162	Event:1056	KeyEvent	Increased, Thyroxine (T4) in serum
Aop:162	Event:1057	KeyEvent	Altered, Thyroid hormone-dependent gene expression
Aop:162	Event:1058	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:163	Event:1059	MolecularInitiatingEvent	Inhibition, Deiodinase 3
Aop:163	Event:1060	KeyEvent	Increased, Triiodothyronine (T3) in tissues
Aop:163	Event:1061	KeyEvent	Altered, Thyroid hormone-dependent gene expression
Aop:163	Event:1062	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:164	Event:1063	MolecularInitiatingEvent	Inhibition, Pendrin
Aop:164	Event:1064	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:164	Event:1065	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:164	Event:1066	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:165	Event:1067	MolecularInitiatingEvent	Inhibition, Dual oxidase
Aop:165	Event:1068	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:165	Event:1069	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:165	Event:1070	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:166	Event:1071	MolecularInitiatingEvent	Activation, Hepatic nuclear receptor(s)
Aop:166	Event:1072	KeyEvent	Increased, Hepatic thyroid hormone uptake/transport
Aop:166	Event:1073	KeyEvent	Induction, Upregulation of glucuronyltransferase activity
Aop:166	Event:1074	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:166	Event:1075	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:166	Event:1076	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:167	Event:1077	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:167	Event:1078	KeyEvent	Increased, serotonin (5-HT)
Aop:167	Event:1079	KeyEvent	Increased, oocyte maturation
Aop:167	Event:1080	KeyEvent	induced spawning
Aop:167	Event:1081	KeyEvent	Increased, valve movement
Aop:167	Event:1082	KeyEvent	Increased, Reproductive Success
Aop:167	Event:1083	KeyEvent	Increase, cilia movement
Aop:167	Event:1084	AdverseOutcome	Increased, Population
Aop:168	Event:1085	MolecularInitiatingEvent	TRPA1 activation, TRPA1 Receptor
Aop:168	Event:1086	KeyEvent	Opening of calcium channel, Calcium influx
Aop:168	Event:1087	KeyEvent	Trigeminal nerve activation
Aop:168	Event:1088	KeyEvent	SP (Substance P) release, Local increase of SP
Aop:168	Event:1089	KeyEvent	Increased CGRP, neuronal release of CGRP
Aop:168	Event:1090	KeyEvent	Increased neurokinin A (NKA) by neuronal cells
Aop:168	Event:1091	AdverseOutcome	Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea
Aop:168	Event:1092	AdverseOutcome	Irritation of nasal mucosa inducing sneeze reflex
Aop:168	Event:1093	AdverseOutcome	Increased Respiratory irritability and Chronic Cough,
Aop:169	Event:1094	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:169	Event:1095	KeyEvent	Decreased, sodium conductance 2
Aop:169	Event:1096	KeyEvent	Decreased, GABA release
Aop:170	Event:1083	KeyEvent	Decreased, Dopaminergic activity
Aop:170	Event:1084	KeyEvent	Increased, prolactin secretion
Aop:170	Event:1085	KeyEvent	Increased, hyperplasia (mammary gland)
Aop:170	Event:1080	KeyEvent	Increased, latency period
Aop:170	Event:1079	AdverseOutcome	Increased, Adenomas/carcinomas (mammary)
Aop:171	Event:1097	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:171	Event:1098	KeyEvent	Increase, Cell Proliferation (Epithelial Cells)
Aop:171	Event:1099	KeyEvent	Decreased, Apoptosis (Epithelial Cells)
Aop:171	Event:1100	KeyEvent	Mitochondrial dysfunction
Aop:171	Event:1101	KeyEvent	Oxidative Stress
Aop:171	Event:1102	KeyEvent	Increased, ER binding to DNA (classical pathway)
Aop:171	Event:1103	KeyEvent	Increased, ER binding to T.F. to DNA (non-classical pathway)
Aop:171	Event:1104	KeyEvent	Increased, Proliferation (Endothelial cells)
Aop:171	Event:1105	KeyEvent	Increased, Migration (Endothelial Cells)
Aop:171	Event:1106	KeyEvent	Increased, Non-genomic signaling
Aop:171	Event:1107	KeyEvent	Increased, Ductal Hyperplasia
Aop:171	Event:1108	KeyEvent	Increase, DNA damage
Aop:171	Event:1109	KeyEvent	modulation, Extracellular Matrix Composition
Aop:171	Event:1110	KeyEvent	Increased, Invasion
Aop:171	Event:1111	KeyEvent	Activation, Fibroblasts
Aop:171	Event:1112	KeyEvent	Activation, Macrophages
Aop:171	Event:1113	KeyEvent	Increased, Angiogenesis
Aop:171	Event:1114	KeyEvent	Altered, Gene Expression
Aop:171	Event:1115	KeyEvent	Altered, Protein Production
Aop:171	Event:1116	KeyEvent	Increased, Motility
Aop:171	Event:1117	KeyEvent	Increased, Second Messenger Production
Aop:171	Event:1118	AdverseOutcome	N/A, Breast Cancer
Aop:172	Event:1119	MolecularInitiatingEvent	Activation, Juvenile hormone receptor
Aop:172	Event:1120	KeyEvent	Induction, Doublesex1 gene
Aop:172	Event:1121	KeyEvent	Induction, Male reproductive tract
Aop:172	Event:1122	AdverseOutcome	Increased, Male offspring
Aop:172	Event:1123	AdverseOutcome	Decline, Population
Aop:172	Event:1124	AdverseOutcome	Alteration, Food-web structures
Aop:173	Event:1125	MolecularInitiatingEvent	Binding to (interferes with) topoisomerase II enzyme
Aop:173	Event:1126	KeyEvent	Increase, DNA double-strand breaks
Aop:173	Event:1127	KeyEvent	MLL chromosomal translocation
Aop:173	Event:1128	AdverseOutcome	Infant leukaemia
Aop:174	Event:1129	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:174	Event:1130	KeyEvent	Increased, valve movement
Aop:174	Event:1131	KeyEvent	Increase, cilia movement
Aop:174	Event:1132	KeyEvent	increased mantel display
Aop:174	Event:1133	KeyEvent	Induced parturition
Aop:174	Event:1134	KeyEvent	Increased, serotonin (5-HT)
Aop:174	Event:1135	AdverseOutcome	Decreased, Reproductive Success
Aop:174	Event:1136	AdverseOutcome	Decrease, Population growth rate
Aop:175	Event:1137	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:175	Event:1138	KeyEvent	Increased, valve movement
Aop:175	Event:1139	KeyEvent	Increase, cilia movement
Aop:175	Event:1140	KeyEvent	Induced parturition
Aop:175	Event:1141	KeyEvent	increased mantel display
Aop:175	Event:1142	KeyEvent	Increased, serotonin (5-HT)
Aop:175	Event:1143	AdverseOutcome	Increased, Reproductive Success
Aop:175	Event:1144	AdverseOutcome	Increased, Population
Aop:176	Event:1145	MolecularInitiatingEvent	Decompartmentalization
Aop:176	Event:1146	MolecularInitiatingEvent	Direct mitochondrial inhibition
Aop:176	Event:1147	MolecularInitiatingEvent	narcosis
Aop:176	Event:1148	KeyEvent	Mitochondrial dysfunction
Aop:176	Event:1149	AdverseOutcome	Apoptosis
Aop:176	Event:1150	AdverseOutcome	Necrosis
Aop:177	Event:1151	MolecularInitiatingEvent	Inactivation of PPARγ
Aop:177	Event:1152	KeyEvent	Activation of TGF-β signaling
Aop:177	Event:1153	KeyEvent	Increase, Inflammation
Aop:177	Event:1154	KeyEvent	Collagen Deposition
Aop:177	Event:1155	KeyEvent	Epithelial Mesenchymal Transition
Aop:177	Event:1156	AdverseOutcome	Lung fibrosis
Aop:178	Event:1157	MolecularInitiatingEvent	Activation, NADPH Oxidase
Aop:178	Event:1158	KeyEvent	Increase, Reactive oxygen species
Aop:178	Event:1159	KeyEvent	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
Aop:178	Event:1160	KeyEvent	Activation, HIF-1
Aop:178	Event:1161	KeyEvent	Increased, DNA Damage-Repair
Aop:178	Event:1162	KeyEvent	Mitochondrial dysfunction
Aop:178	Event:1163	KeyEvent	Apoptosis
Aop:178	Event:1164	AdverseOutcome	Reproductive failure
Aop:179	Event:1165	KeyEvent	Activation, JAK/STAT pathway
Aop:179	Event:1166	KeyEvent	Activation, TGF-beta pathway
Aop:179	Event:1167	AdverseOutcome	Reproductive failure
Aop:180	Event:1168	KeyEvent	Up Regulation, SREBF2
Aop:180	Event:1169	KeyEvent	Up Regulation, Unsaturated fatty acid
Aop:180	Event:1170	KeyEvent	Down Regulation, GSS and GSTs gene
Aop:180	Event:1171	KeyEvent	Glutathione synthesis
Aop:180	Event:1172	KeyEvent	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
Aop:180	Event:1173	KeyEvent	Perturbation of cholesterol
Aop:180	Event:1174	KeyEvent	Glutathione homeostasis
Aop:180	Event:1175	AdverseOutcome	Hepatotoxicity
Aop:181	Event:1176	KeyEvent	Peptide Oxidation
Aop:181	Event:1177	KeyEvent	Activation, JNK
Aop:181	Event:1178	KeyEvent	Activation, FOXO
Aop:181	Event:1179	KeyEvent	Inhibition, Wnt pathway
Aop:181	Event:1180	KeyEvent	Defect of Embryogenesis
Aop:181	Event:1181	AdverseOutcome	Reproductive failure
Aop:182	Event:560	KeyEvent	Abnormal, Foraging activity and behavior
Aop:182	Event:1107	KeyEvent	Weakened, Colony
Aop:182	Event:563	AdverseOutcome	Death/Failure, Colony
Aop:183	Event:1182	MolecularInitiatingEvent	Histone deacetylase inhibition
Aop:183	Event:1183	KeyEvent	Histone acetylation, increase
Aop:183	Event:1184	KeyEvent	Cell cycle, disrupted
Aop:183	Event:1185	KeyEvent	Apoptosis
Aop:183	Event:1186	KeyEvent	Spermatocyte depletion
Aop:183	Event:1187	AdverseOutcome	Testicular atrophy
Aop:184	Event:1188	MolecularInitiatingEvent	Inhibition, Fatty Acid Beta Oxidation
Aop:184	Event:1189	KeyEvent	Increase, cytosolic fatty acid
Aop:184	Event:1190	KeyEvent	Increased, Liver Steatosis
Aop:184	Event:1191	KeyEvent	Increase, Reactive oxygen species
Aop:184	Event:1192	KeyEvent	Increased, Oncotic Necrosis
Aop:184	Event:1193	AdverseOutcome	N/A, Steatohepatisis
Aop:185	Event:1194	KeyEvent	Inhibit, serotonin transporter activity
Aop:185	Event:1195	KeyEvent	Decreased, serotonin transporter activity
Aop:185	Event:1196	KeyEvent	Decreased, extracellular sodium (Na+)
Aop:185	Event:1197	KeyEvent	Decreased, extracellular chloride (Cl-)
Aop:185	Event:1198	KeyEvent	Increased, extracellular serotonin
Aop:185	Event:1199	KeyEvent	Decreased, extracellular serotonin
Aop:185	Event:1200	KeyEvent	Increased, intracellular sodium (Na+)
Aop:185	Event:1201	KeyEvent	Increased, intracellular chloride (Cl-)
Aop:185	Event:1202	KeyEvent	Decreased, intracellular serotonin
Aop:185	Event:1203	KeyEvent	Decreased, packaged serotonin
Aop:185	Event:1204	KeyEvent	Decreased, synaptic release
Aop:185	Event:1205	KeyEvent	Increased, 5-HT3 (5-hydroxytryptamine)
Aop:185	Event:1206	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:185	Event:1207	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:185	Event:1208	KeyEvent	Decreased, neuroplasticity
Aop:185	Event:1209	KeyEvent	Increase, cortisone
Aop:185	Event:1210	KeyEvent	Activation, Glucocorticoid Receptor
Aop:185	Event:1211	KeyEvent	Reduced, BDNF (Brain-derived neurotrophic factor)
Aop:185	Event:1212	KeyEvent	Activation, 5-HT2A (Serotonin 2A)
Aop:185	Event:1213	KeyEvent	Activate, PLC (Phospholipase C)
Aop:185	Event:1214	KeyEvent	Increase, inositol triphosphate
Aop:185	Event:1215	KeyEvent	Increase, intracellular calcium
Aop:185	Event:1216	KeyEvent	Activate, calmodulin
Aop:185	Event:1217	KeyEvent	Increase, myosin light chain phosphorylation
Aop:185	Event:1218	KeyEvent	Increase, vascular smooth muscle contraction
Aop:185	Event:1219	AdverseOutcome	Increased, seizure
Aop:185	Event:1220	AdverseOutcome	Increased, agitation
Aop:185	Event:1221	AdverseOutcome	Increased, depression
Aop:185	Event:1222	AdverseOutcome	Increase, hypertension
Aop:186	Event:1223	KeyEvent	Activated, presynaptic neuron 1
Aop:186	Event:1224	KeyEvent	Increased, glutamate
Aop:186	Event:1225	KeyEvent	Activated, NMDA receptor
Aop:186	Event:1226	KeyEvent	Increased, intracellular sodium (Na+)
Aop:186	Event:1227	KeyEvent	Activated, voltage-gated sodium channel
Aop:186	Event:1228	KeyEvent	Binding to voltage-gated sodium channel
Aop:186	Event:1229	KeyEvent	Treat, carbamazepine
Aop:186	Event:1230	KeyEvent	Activated, membrane depolarization
Aop:186	Event:1231	KeyEvent	Inactive, membrane depolarization
Aop:186	Event:1232	KeyEvent	Increased, RDX dose
Aop:186	Event:1233	KeyEvent	Repress, GABA-A receptor
Aop:186	Event:1234	KeyEvent	Activate, GABA-A receptor
Aop:186	Event:1235	KeyEvent	Activate, presynaptic neuron 2
Aop:186	Event:1236	KeyEvent	Increase, GABA
Aop:186	Event:1237	KeyEvent	Increased, intracellular chloride (Cl-)
Aop:186	Event:1238	AdverseOutcome	Increase, seizure
Aop:186	Event:1239	AdverseOutcome	Increased, hippocampal hyperdepolarization
Aop:186	Event:1240	AdverseOutcome	Increased, epilepsy
Aop:187	Event:1241	MolecularInitiatingEvent	Deposition of Energy
Aop:187	Event:1242	KeyEvent	Increase, DNA strand breaks
Aop:187	Event:1243	KeyEvent	Increase, Follicular atresia
Aop:187	Event:1244	KeyEvent	Decrease, Oogenesis
Aop:187	Event:1245	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:187	Event:1246	AdverseOutcome	Decrease, Population growth rate
Aop:188	Event:1247	KeyEvent	Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1)
Aop:188	Event:1248	KeyEvent	Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)
Aop:188	Event:1249	KeyEvent	Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2)
Aop:188	Event:1250	KeyEvent	Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2)
Aop:188	Event:1251	KeyEvent	Increase, bicarbonate
Aop:188	Event:1252	KeyEvent	Increase, mucous
Aop:188	Event:1253	KeyEvent	Increase, mucosal blood flow
Aop:188	Event:1254	KeyEvent	Increase, platelet aggregation
Aop:188	Event:1255	KeyEvent	Increase, angiogenesis
Aop:188	Event:1256	KeyEvent	Decrease, leukocyte adherence
Aop:188	Event:1257	KeyEvent	Increase, leukocyte adherence
Aop:188	Event:1258	KeyEvent	Activate, leukocyte
Aop:188	Event:1259	KeyEvent	Activate, mucosal defense
Aop:188	Event:1260	KeyEvent	Increase, surfactant
Aop:188	Event:1261	KeyEvent	Decrease, surfactant
Aop:188	Event:1262	KeyEvent	Activate, phospholipase
Aop:188	Event:1263	KeyEvent	Increase, ammonium (NH4+)
Aop:188	Event:1264	AdverseOutcome	Inhibit, gastric ulcer formation
Aop:188	Event:1265	AdverseOutcome	Activated, gastric ulcer formation
Aop:189	Event:1266	MolecularInitiatingEvent	CYP7B activity, inhibition
Aop:189	Event:1267	KeyEvent	7α-hydroxypregnenolone synthesis in the brain, decreased
Aop:189	Event:1268	KeyEvent	Dopamine release in the brain, decreased
Aop:189	Event:1269	KeyEvent	Locomotor activity, decreased
Aop:189	Event:1270	KeyEvent	Decreased, Reproductive Success
Aop:189	Event:1271	AdverseOutcome	Decrease, Population growth rate
Aop:190	Event:1272	MolecularInitiatingEvent	CYP7B activity, inhibition
Aop:190	Event:1273	KeyEvent	7α-hydroxypregnenolone synthesis in the brain, decreased
Aop:190	Event:1274	KeyEvent	Dopamine release in the brain, decreased
Aop:190	Event:1275	KeyEvent	Sexual behavior, decreased
Aop:190	Event:1276	KeyEvent	Decreased, Reproductive Success
Aop:190	Event:1277	AdverseOutcome	Decrease, Population growth rate
Aop:191	Event:1278	MolecularInitiatingEvent	Activation of Cyp2E1
Aop:191	Event:1279	KeyEvent	Oxidative Stress
Aop:191	Event:1280	KeyEvent	Hepatocytotoxicity
Aop:191	Event:1281	KeyEvent	Induction, persistent proliferation/sustained proliferation
Aop:191	Event:1282	AdverseOutcome	Liver Cancer
Aop:192	Event:1283	MolecularInitiatingEvent	Increased, glucocorticoid receptor activity
Aop:192	Event:1284	KeyEvent	Reduced, BDNF (Brain-derived neurotrophic factor)
Aop:192	Event:1285	KeyEvent	Decreased, neuroplasticity
Aop:192	Event:1286	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:192	Event:1287	KeyEvent	Decreased, extracellular serotonin
Aop:192	Event:1288	KeyEvent	Decreased, synaptic release
Aop:192	Event:1289	KeyEvent	Decreased, packaged serotonin
Aop:192	Event:1290	KeyEvent	Decreased, intracellular serotonin
Aop:192	Event:1291	KeyEvent	Decreased, serotonin transporter activity
Aop:192	Event:1292	KeyEvent	Increased, extracellular serotonin
Aop:192	Event:1293	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:192	Event:1294	AdverseOutcome	Increased, depression
Aop:193	Event:1295	MolecularInitiatingEvent	Increased, glucocorticoid receptor activity
Aop:193	Event:1296	KeyEvent	Reduced, BDNF (Brain-derived neurotrophic factor)
Aop:193	Event:1297	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:193	Event:1298	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:193	Event:1299	KeyEvent	Decreased, neuroplasticity
Aop:193	Event:1300	KeyEvent	Decreased, extracellular serotonin
Aop:193	Event:1301	KeyEvent	Decreased, serotonin transporter activity
Aop:193	Event:1302	KeyEvent	Increased, extracellular serotonin
Aop:193	Event:1303	KeyEvent	Decreased, synaptic release
Aop:193	Event:1304	KeyEvent	Decreased, packaged serotonin
Aop:193	Event:1305	KeyEvent	Decreased, intracellular serotonin
Aop:193	Event:1306	AdverseOutcome	Increased, agitation
Aop:194	Event:1307	MolecularInitiatingEvent	Increased, serotonin transporter activity
Aop:194	Event:1308	KeyEvent	Increased, extracellular serotonin
Aop:194	Event:1309	KeyEvent	Decreased, extracellular serotonin
Aop:194	Event:1310	KeyEvent	Increased, intracellular serotonin
Aop:194	Event:1311	KeyEvent	Increased, packaged serotonin
Aop:194	Event:1312	KeyEvent	Increased, synaptic release
Aop:194	Event:1313	KeyEvent	Decreased, 5-HT3
Aop:194	Event:1314	AdverseOutcome	Increased, seizure
Aop:195	Event:1315	MolecularInitiatingEvent	Increased, serotonin transporter activity
Aop:195	Event:1316	KeyEvent	Increased, intracellular serotonin
Aop:195	Event:1317	KeyEvent	Increased, packaged serotonin
Aop:195	Event:1318	KeyEvent	Increased, synaptic release
Aop:195	Event:1319	KeyEvent	Increased, extracellular serotonin
Aop:195	Event:1320	KeyEvent	Decreased, extracellular serotonin
Aop:195	Event:1321	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:195	Event:1322	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:195	Event:1323	KeyEvent	Decreased, neuroplasticity
Aop:195	Event:1324	AdverseOutcome	Increased, depression
Aop:196	Event:1325	KeyEvent	Increased, serotonin transporter activity
Aop:196	Event:1326	KeyEvent	Increased, intracellular serotonin
Aop:196	Event:1327	KeyEvent	Increased, packaged serotonin
Aop:196	Event:1328	KeyEvent	Increased, extracellular serotonin
Aop:196	Event:1329	KeyEvent	Decreased, extracellular serotonin
Aop:196	Event:1330	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:196	Event:1331	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:196	Event:1332	KeyEvent	Decreased, neuroplasticity
Aop:196	Event:1333	KeyEvent	Increased, synaptic release
Aop:196	Event:1334	AdverseOutcome	Increased, agitation
Aop:197	Event:1335	MolecularInitiatingEvent	Decreased, serotonin transporter activity
Aop:197	Event:1336	KeyEvent	Decreased, intracellular serotonin
Aop:197	Event:1337	KeyEvent	Decreased, packaged serotonin
Aop:197	Event:1338	KeyEvent	Decreased, synaptic release
Aop:197	Event:1339	KeyEvent	Increased, extracellular serotonin
Aop:197	Event:1340	KeyEvent	Decreased, extracellular serotonin
Aop:197	Event:1341	KeyEvent	Activation, 5-HT2A (Serotonin 2A)
Aop:197	Event:1342	KeyEvent	Activate, PLC (Phospholipase C)
Aop:197	Event:1343	KeyEvent	Increase, inositol triphosphate
Aop:197	Event:1344	KeyEvent	Increase, intracellular calcium
Aop:197	Event:1345	KeyEvent	Activate, calmodulin
Aop:197	Event:1346	KeyEvent	Increase, myosin light chain phosphorylation
Aop:197	Event:1347	KeyEvent	Increase, vascular smooth muscle contraction
Aop:197	Event:1348	AdverseOutcome	Increase, hypertension
Aop:198	Event:1349	MolecularInitiatingEvent	Reduced, PTGS1 function
Aop:198	Event:1350	KeyEvent	Reduced, platelet aggregation
Aop:198	Event:1351	KeyEvent	Decreased, mucosal blood flow
Aop:198	Event:1352	KeyEvent	Reduced, mucosal defense
Aop:198	Event:1353	KeyEvent	Decreased, mucous
Aop:198	Event:1354	KeyEvent	Decreased, bicarbonate
Aop:198	Event:1355	AdverseOutcome	Activated, gastric ulcer formation
Aop:199	Event:1356	MolecularInitiatingEvent	Reduced, PTGS2 function
Aop:199	Event:1357	KeyEvent	Decreased, angiogenesis
Aop:199	Event:1358	KeyEvent	Increased, leukocyte adherence
Aop:199	Event:1359	KeyEvent	Increased, leukocyte activation
Aop:199	Event:1360	AdverseOutcome	Activated, gastric ulcer formation
Aop:200	Event:1361	MolecularInitiatingEvent	Helicobacter pylori infection
Aop:200	Event:1362	KeyEvent	Increase, ammonium (NH4+)
Aop:200	Event:1363	KeyEvent	Activate, phospholipase
Aop:200	Event:1364	KeyEvent	Decrease, surfactant
Aop:200	Event:1365	KeyEvent	Reduced, mucosal defense
Aop:200	Event:1366	AdverseOutcome	Activated, gastric ulcer formation
Aop:201	Event:1367	MolecularInitiatingEvent	Activated, presynaptic neuron 1
Aop:201	Event:1368	KeyEvent	Increased, glutamate
Aop:201	Event:1369	KeyEvent	Activated, NMDA receptor
Aop:201	Event:1370	KeyEvent	Increased, intracellular sodium (Na+)
Aop:201	Event:1371	KeyEvent	Activated, voltage-gated sodium channel
Aop:201	Event:1372	KeyEvent	Treat, carbamazepine
Aop:201	Event:1373	KeyEvent	Binding to voltage-gated sodium channel
Aop:201	Event:1374	KeyEvent	Activated, membrane depolarization
Aop:201	Event:1375	KeyEvent	Increased, hippocampal hyperdepolarization
Aop:201	Event:1376	KeyEvent	Increased, seizure
Aop:201	Event:1377	AdverseOutcome	Increased, epilepsy
Aop:202	Event:1378	MolecularInitiatingEvent	Reduced, presynaptic neuron 2 activity
Aop:202	Event:1379	KeyEvent	Decreased, GABA
Aop:202	Event:1380	KeyEvent	Reduced, GABA-A receptor activation
Aop:202	Event:1381	KeyEvent	Decreased, intracellular chloride
Aop:202	Event:1382	KeyEvent	Activated, membrane depolarization
Aop:202	Event:1383	KeyEvent	Increased, hippocampal hyperdepolarization
Aop:202	Event:1384	KeyEvent	Increased, seizure
Aop:202	Event:1385	KeyEvent	Increased, RDX dose
Aop:202	Event:1386	AdverseOutcome	Increased, epilepsy
Aop:203	Event:1387	MolecularInitiatingEvent	NFE2/Nrf2 repression
Aop:203	Event:1388	KeyEvent	Reduced, FXR activity
Aop:203	Event:1389	KeyEvent	Reduced, SHP activity
Aop:203	Event:1390	KeyEvent	Activated, LXR
Aop:203	Event:1391	KeyEvent	Reduced, PPARalpha
Aop:203	Event:1392	KeyEvent	Reduced, HSD17B4 activity
Aop:203	Event:1393	KeyEvent	Reduced, fatty acid beta oxidation
Aop:203	Event:1394	AdverseOutcome	Increased, Liver Steatosis
Aop:204	Event:1395	MolecularInitiatingEvent	Mu Opioid Receptor Agonism
Aop:204	Event:1396	KeyEvent	Release of G Proteins
Aop:204	Event:1397	KeyEvent	Opening of G protein gated inward rectifying K channels
Aop:204	Event:1398	KeyEvent	hyperpolarisation, neuron
Aop:204	Event:1399	AdverseOutcome	Analgesia
Aop:205	Event:1400	MolecularInitiatingEvent	Mu Opioid Receptor Agonism
Aop:205	Event:1401	KeyEvent	Release of G Proteins
Aop:205	Event:1402	KeyEvent	Inhibition of N-type Ca ion channels
Aop:205	Event:1403	KeyEvent	Inhibition of neurotransmitter vesicle release
Aop:205	Event:1404	AdverseOutcome	Analgesia
Aop:206	Event:1405	MolecularInitiatingEvent	Serotonin 1A Receptor Agonism
Aop:206	Event:1406	KeyEvent	Release of G Proteins
Aop:206	Event:1407	KeyEvent	Opening of G protein gated inward rectifying K channels
Aop:206	Event:1408	KeyEvent	hyperpolarisation, neuron
Aop:206	Event:1409	AdverseOutcome	Anti-depressant Activity
Aop:207	Event:1410	MolecularInitiatingEvent	Serotonin 1A Receptor Agonism
Aop:207	Event:1411	KeyEvent	Release of G Proteins
Aop:207	Event:1412	KeyEvent	Inhibition of N-type Ca ion channels
Aop:207	Event:1413	KeyEvent	Inhibition of neurotransmitter vesicle release
Aop:207	Event:1414	AdverseOutcome	Anti-depressant Activity
Aop:208	Event:1415	MolecularInitiatingEvent	Substance interaction with the lung resident cell membrane components
Aop:208	Event:1416	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:208	Event:1417	KeyEvent	Transcription of genes encoding acute phase proteins, Increased
Aop:208	Event:1418	KeyEvent	Systemic acute phase response
Aop:208	Event:1419	AdverseOutcome	Atherosclerosis
Aop:209	Event:1420	MolecularInitiatingEvent	Deposition of Energy
Aop:209	Event:1421	KeyEvent	Increase, DNA strand breaks
Aop:209	Event:1422	KeyEvent	Increase, Oocyte apoptosis
Aop:209	Event:1423	KeyEvent	Decrease, Oogenesis
Aop:209	Event:1424	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:209	Event:1425	AdverseOutcome	Decrease, Population growth rate
Aop:210	Event:209	KeyEvent	Peptide Oxidation
Aop:210	Event:1292	KeyEvent	Activation, JNK
Aop:210	Event:1293	KeyEvent	Activation, FOXO
Aop:210	Event:1294	KeyEvent	Inhibition, Wnt pathway
Aop:210	Event:1295	KeyEvent	Defect of Embryogenesis
Aop:210	Event:1277	AdverseOutcome	Reproductive failure
Aop:212	Event:1426	MolecularInitiatingEvent	Activation, Latent Transforming Growth Factor Beta 1
Aop:212	Event:1427	KeyEvent	Increase, Differentiation of fibroblasts
Aop:212	Event:1428	KeyEvent	Epithelial Mesenchymal Transition
Aop:212	Event:1429	KeyEvent	Accumulation, Collagen
Aop:212	Event:1430	KeyEvent	Activation, Transforming Growth Factor beta pathway
Aop:212	Event:1431	AdverseOutcome	Pulmonary fibrosis
Aop:213	Event:1432	MolecularInitiatingEvent	Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts
Aop:213	Event:1433	KeyEvent	Inhibition of lysyl oxidase
Aop:213	Event:1434	KeyEvent	Reduction of collagen crosslinking
Aop:213	Event:1435	KeyEvent	Weak collagen matrix
Aop:213	Event:1436	KeyEvent	Notochord distortion or malformations
Aop:213	Event:1437	KeyEvent	Reduced, Swimming performance
Aop:213	Event:1438	AdverseOutcome	Growth, reduction
Aop:213	Event:1439	AdverseOutcome	Decreased, survival
Aop:214	Event:1440	MolecularInitiatingEvent	Increase, Uncoupling of photophosphorylation
Aop:214	Event:1441	KeyEvent	Decrease, ATP production
Aop:214	Event:1442	KeyEvent	Decrease, Chlorophyll synthesis
Aop:214	Event:1443	KeyEvent	Decrease, Light harvest capacity
Aop:214	Event:1444	KeyEvent	Decrease, Photosynthesis
Aop:214	Event:1445	KeyEvent	Decrease, Glycolysis
Aop:214	Event:1446	KeyEvent	Decrease, Oxidative phosphorylation
Aop:214	Event:1447	KeyEvent	Decrease, Mitochondrial ATP production
Aop:214	Event:1448	KeyEvent	Decrease, Leaf cell mitosis
Aop:214	Event:1449	KeyEvent	Decrease, Leaf development
Aop:214	Event:1450	AdverseOutcome	Decrease, Growth
Aop:215	Event:1451	MolecularInitiatingEvent	Inhibition of mitochondrial DNA polymerase gamma (Pol gamma)
Aop:215	Event:1452	KeyEvent	Depletion, mtDNA
Aop:215	Event:1453	KeyEvent	Mitochondrial dysfunction
Aop:215	Event:1454	KeyEvent	Increase, Cytotoxicity (renal tubular cell)
Aop:215	Event:1455	AdverseOutcome	Occurrence, Kidney toxicity
Aop:216	Event:1456	MolecularInitiatingEvent	Binding of substrate, endocytic receptor
Aop:216	Event:1457	KeyEvent	Disturbance, Lysosomal function
Aop:216	Event:1458	KeyEvent	Disruption, Lysosome
Aop:216	Event:1459	KeyEvent	Increase, Cytotoxicity (renal tubular cell)
Aop:216	Event:1460	AdverseOutcome	Occurrence, Kidney toxicity
Aop:217	Event:1461	MolecularInitiatingEvent	Alkylation, Protein
Aop:217	Event:1462	KeyEvent	Mitochondrial dysfunction
Aop:217	Event:1463	KeyEvent	Decrease, Mitochondrial ATP production
Aop:217	Event:1464	KeyEvent	Increase, Cytotoxicity (renal tubular cell)
Aop:217	Event:1465	AdverseOutcome	Occurrence, Kidney toxicity
Aop:218	Event:1386	MolecularInitiatingEvent	CYP7B activity, inhibition
Aop:218	Event:1387	KeyEvent	7α-hydroxypregnenolone synthesis in the brain, decreased
Aop:218	Event:1388	KeyEvent	Dopamine release in the brain, decreased
Aop:218	Event:1389	KeyEvent	Locomotor activity, decreased
Aop:218	Event:1141	KeyEvent	Decreased, Reproductive Success
Aop:218	Event:360	AdverseOutcome	Decrease, Population growth rate
Aop:219	Event:1466	MolecularInitiatingEvent	CYP2E1 Activation
Aop:219	Event:1467	MolecularInitiatingEvent	Protein Adduct Formation
Aop:219	Event:1468	KeyEvent	Oxidative Stress
Aop:219	Event:1469	KeyEvent	Lipid Peroxidation
Aop:219	Event:1470	KeyEvent	Unfolded Protein Response
Aop:219	Event:1471	KeyEvent	General Apoptosis
Aop:219	Event:1472	AdverseOutcome	Neurodegeneration
Aop:220	Event:1473	MolecularInitiatingEvent	Blockade, L-Type Calcium Channels
Aop:220	Event:1474	KeyEvent	Decrease, Calcium currents
Aop:220	Event:1475	KeyEvent	Decrease, Calcium binding to Troponin C
Aop:220	Event:1476	KeyEvent	Decrease, Cardiac contractility
Aop:220	Event:1477	KeyEvent	Decrease, Cardiac ejection fraction
Aop:220	Event:1478	KeyEvent	Disruption, Intracellular calcium mobilization
Aop:220	Event:1479	KeyEvent	Disruption, Sarcomere assembly
Aop:220	Event:1480	AdverseOutcome	Heart failure
Aop:221	Event:1335	KeyEvent	Reduced, BDNF (Brain-derived neurotrophic factor)
Aop:221	Event:1330	KeyEvent	Decreased, neuroplasticity
Aop:221	Event:1328	KeyEvent	Inactivated, 5-HTR (serotonin receptors)
Aop:221	Event:1347	KeyEvent	Decreased, extracellular serotonin
Aop:221	Event:1325	KeyEvent	Decreased, synaptic release
Aop:221	Event:1324	KeyEvent	Decreased, packaged serotonin
Aop:221	Event:1323	KeyEvent	Decreased, intracellular serotonin
Aop:221	Event:1317	KeyEvent	Decreased, serotonin transporter activity
Aop:221	Event:1320	KeyEvent	Increased, extracellular serotonin
Aop:221	Event:1346	AdverseOutcome	Increased, depression
Aop:221	Event:1329	KeyEvent	Reduce expression, BDNF (Brain-derived neurotrophic factor)
Aop:221	Event:1396	MolecularInitiatingEvent	Increased, glucocorticoid receptor activity
Aop:222	Event:1481	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:222	Event:1482	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:222	Event:1483	KeyEvent	Decrease, Cell proliferation
Aop:222	Event:1484	AdverseOutcome	Decrease, Growth
Aop:223	Event:1485	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:223	Event:1486	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:223	Event:1487	KeyEvent	Increase, Cell injury/death
Aop:223	Event:1488	AdverseOutcome	Decrease, Growth
Aop:224	Event:1489	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:224	Event:1490	KeyEvent	Increase, Cytosolic calcium
Aop:224	Event:1491	KeyEvent	Increase, Cell injury/death
Aop:224	Event:1492	AdverseOutcome	Decrease, Growth
Aop:225	Event:1493	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:225	Event:1494	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:225	Event:1495	KeyEvent	Decreased Na/K ATPase activity
Aop:225	Event:1496	KeyEvent	Increase, Cell membrane depolarization
Aop:225	Event:1497	KeyEvent	Increase, Cell injury/death
Aop:225	Event:1498	AdverseOutcome	Decrease, Growth
Aop:226	Event:1499	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:226	Event:1500	KeyEvent	Increase, Glycolysis
Aop:226	Event:1501	KeyEvent	Decrease, Glucose pool
Aop:226	Event:1502	KeyEvent	Decrease, Cell proliferation
Aop:226	Event:1503	AdverseOutcome	Decrease, Growth
Aop:227	Event:1504	MolecularInitiatingEvent	Decrease, Coupling of oxidative phosphorylation
Aop:227	Event:1505	KeyEvent	Increase, Mitochondrial swelling
Aop:227	Event:1506	KeyEvent	Increase, Cell injury/death
Aop:227	Event:1507	AdverseOutcome	Decrease, Growth
Aop:228	Event:1408	MolecularInitiatingEvent	Reduced, PTGS2 function
Aop:228	Event:1385	AdverseOutcome	Activated, gastric ulcer formation
Aop:228	Event:1409	KeyEvent	Decreased, angiogenesis
Aop:228	Event:1410	KeyEvent	Increased, leukocyte adherence
Aop:228	Event:1411	KeyEvent	Increased, leukocyte activation
Aop:229	Event:1412	MolecularInitiatingEvent	Helicobacter pylori infection
Aop:229	Event:1384	KeyEvent	Increase, ammonium (NH4+)
Aop:229	Event:1383	KeyEvent	Activate, phospholipase
Aop:229	Event:1382	KeyEvent	Decrease, surfactant
Aop:229	Event:1405	KeyEvent	Reduced, mucosal defense
Aop:229	Event:1385	AdverseOutcome	Activated, gastric ulcer formation
Aop:230	Event:1508	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:230	Event:1509	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:230	Event:1510	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:230	Event:1511	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:230	Event:1512	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:231	Event:1513	MolecularInitiatingEvent	Deposition of Energy
Aop:231	Event:1514	KeyEvent	Increase, DNA strand breaks
Aop:231	Event:1515	KeyEvent	Inadequate DNA repair
Aop:231	Event:1516	KeyEvent	Increase, Mutations
Aop:231	Event:1517	KeyEvent	Increase, Chromosomal aberrations
Aop:231	Event:1518	KeyEvent	Increase, Cell Proliferation
Aop:231	Event:1519	AdverseOutcome	Increase, lung cancer
Aop:232	Event:1520	MolecularInitiatingEvent	Increase, Mitochondrial complex III antagonism
Aop:232	Event:1521	MolecularInitiatingEvent	Mitochondrial Complex IV inhibition
Aop:232	Event:1522	MolecularInitiatingEvent	Mitochondrial Complex V inhibition
Aop:232	Event:1523	MolecularInitiatingEvent	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)
Aop:232	Event:1524	MolecularInitiatingEvent	Inhibition, NADH-ubiquinone oxidoreductase (complex I)
Aop:232	Event:1525	MolecularInitiatingEvent	Binding of inhibitor to mitochondrial complex III
Aop:232	Event:1526	MolecularInitiatingEvent	Binding of inhibitor to mitochondrial complex IV
Aop:232	Event:1527	MolecularInitiatingEvent	Binding of inhibitor to mitochondrial complex V
Aop:232	Event:1528	KeyEvent	Decrease in mitochondrial oxidative phosphorylation
Aop:232	Event:1529	KeyEvent	Increase, Reactive oxygen species
Aop:232	Event:1530	KeyEvent	Mitochondrial Injury
Aop:232	Event:1531	KeyEvent	Impaired, Proteostasis
Aop:232	Event:1532	KeyEvent	Increase, Cell injury/death
Aop:232	Event:1533	KeyEvent	Mitochondrial dysfunction
Aop:232	Event:1534	AdverseOutcome	Necrotic Tissue
Aop:232	Event:1535	AdverseOutcome	Liver Injury
Aop:233	Event:1536	MolecularInitiatingEvent	Histone deacetylase inhibition
Aop:233	Event:1537	KeyEvent	Neural crest cell migration, reduced
Aop:233	Event:1538	KeyEvent	Collagen production, reduced
Aop:233	Event:1539	AdverseOutcome	Facial cartilage structures are reduced in size and morphologically distorted
Aop:234	Event:1540	MolecularInitiatingEvent	Histone deacetylase inhibition
Aop:234	Event:1541	KeyEvent	Histone acetylation, increase
Aop:234	Event:1542	KeyEvent	Altered, Gene Expression
Aop:234	Event:1543	KeyEvent	Altered differentiation
Aop:234	Event:1544	AdverseOutcome	Neural tube defects
Aop:235	Event:1545	MolecularInitiatingEvent	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)
Aop:235	Event:1546	KeyEvent	Inhibition, NADH-ubiquinone oxidoreductase (complex I)
Aop:235	Event:1547	KeyEvent	Decrease, Oxidative phosphorylation
Aop:235	Event:1548	KeyEvent	Decreased Na/K ATPase activity
Aop:235	Event:1549	KeyEvent	Decreased proximal tubular vectorial transport
Aop:235	Event:1550	AdverseOutcome	Chemical induced Fanconi syndrome
Aop:236	Event:1551	MolecularInitiatingEvent	Impaired IL-1R1 signaling in T cell
Aop:236	Event:1552	KeyEvent	Inhibition, Nuclear factor kappa B (NF-kB)
Aop:236	Event:1553	KeyEvent	Suppression of T cell activation
Aop:236	Event:1554	AdverseOutcome	Impairment, T-cell dependent antibody response
Aop:237	Event:1555	MolecularInitiatingEvent	Inhibition, IKK complex
Aop:237	Event:1556	KeyEvent	Inhibition, Nuclear factor kappa B (NF-kB)
Aop:237	Event:1557	KeyEvent	Activation, Caspase 8 pathway
Aop:237	Event:1558	KeyEvent	Increase, Cell injury/death
Aop:237	Event:1559	KeyEvent	Activation, Tissue resident cells (Kuppfer cells)
Aop:237	Event:1560	KeyEvent	Increase, proinflammatory mediators (TNFalpha)
Aop:237	Event:1561	AdverseOutcome	Necrotic Tissue
Aop:237	Event:1562	AdverseOutcome	Liver Injury
Aop:238	Event:1563	MolecularInitiatingEvent	Binding of microtubule stabilizing agents (MSA) to microtubules
Aop:238	Event:1564	KeyEvent	Disturbance in microtubule dynamic instability
Aop:238	Event:1565	KeyEvent	Impaired axonial transport
Aop:238	Event:1566	AdverseOutcome	Sensory axonal peripheral neuropathy
Aop:239	Event:1567	MolecularInitiatingEvent	Interaction of α-diketones with arginine residues
Aop:239	Event:1568	KeyEvent	Proteasomal dysfunction
Aop:239	Event:1569	KeyEvent	Airway epithelial injury
Aop:239	Event:1570	KeyEvent	Increase, Inflammation
Aop:239	Event:1571	KeyEvent	Epithelial Mesenchymal Transition
Aop:239	Event:1572	KeyEvent	Fibroproliferative airway lesions
Aop:239	Event:1573	AdverseOutcome	Bronchiolitis obliterans
Aop:240	Event:1574	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:240	Event:1575	KeyEvent	Acetylcholine accumulation in synapses
Aop:240	Event:1576	KeyEvent	Increased Muscarinic Acetylcholine Receptors
Aop:240	Event:1577	KeyEvent	Occurrence, Focal Seizure
Aop:240	Event:1578	KeyEvent	Increased, glutamate
Aop:240	Event:1579	KeyEvent	Overactivation, NMDARs
Aop:240	Event:1580	KeyEvent	Status epilepticus
Aop:240	Event:1581	KeyEvent	Increased, Intracellular Calcium overload
Aop:240	Event:1582	KeyEvent	Increase, Cell injury/death
Aop:240	Event:1583	AdverseOutcome	N/A, Neurodegeneration
Aop:241	Event:1584	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:241	Event:1585	KeyEvent	Oxidation of membrane lipids
Aop:241	Event:1586	KeyEvent	Oxidation/denatuation of membrane proteins
Aop:241	Event:1587	AdverseOutcome	Inflamatory events in light-exposed tissues
Aop:242	Event:1462	MolecularInitiatingEvent	Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts
Aop:242	Event:1463	KeyEvent	Inhibition of lysyl oxidase
Aop:242	Event:1464	KeyEvent	Reduction of collagen crosslinking
Aop:242	Event:1465	KeyEvent	Weak collagen matrix
Aop:242	Event:1466	KeyEvent	Notochord distortion or malformations
Aop:242	Event:1005	KeyEvent	Reduced, Swimming performance
Aop:242	Event:1467	AdverseOutcome	Growth, reduction
Aop:242	Event:636	AdverseOutcome	Decreased, survival
Aop:243	Event:1588	MolecularInitiatingEvent	Binding, Thiol/seleno-proteins involved in protection against oxidative stress
Aop:243	Event:1589	KeyEvent	Oxidation, Glutathione (To be considered with MIE)
Aop:243	Event:1590	KeyEvent	Decreased protection against oxidative stress
Aop:243	Event:1591	KeyEvent	Oxidative Stress
Aop:243	Event:1592	KeyEvent	Disruption, Mitochondrial electron transport chain
Aop:243	Event:1593	KeyEvent	Increase, Cytotoxicity
Aop:243	Event:1594	AdverseOutcome	Chronic kidney disease
Aop:244	Event:1595	MolecularInitiatingEvent	Inhibition of N-linked glycosylation
Aop:244	Event:1596	KeyEvent	Accumulation of misfolded proteins
Aop:244	Event:1597	KeyEvent	Unfolded Protein Response
Aop:244	Event:1598	KeyEvent	Apoptosis
Aop:244	Event:1599	KeyEvent	Activation of hepatic stellate cells
Aop:244	Event:1600	KeyEvent	Increased, Liver Steatosis
Aop:244	Event:1601	AdverseOutcome	Liver Injury
Aop:245	Event:1602	MolecularInitiatingEvent	Increase, Mitochondrial complex III antagonism
Aop:245	Event:1603	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:245	Event:1604	KeyEvent	Decrease, Cell proliferation
Aop:245	Event:1605	AdverseOutcome	Decrease, Growth
Aop:246	Event:1606	MolecularInitiatingEvent	Increase, Mitochondrial complex III antagonism
Aop:246	Event:1607	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:246	Event:1608	KeyEvent	Increase, Cell death
Aop:246	Event:1609	AdverseOutcome	Decrease, Growth
Aop:247	Event:1610	MolecularInitiatingEvent	Inhibition, Cytochrome P450 enzyme (CYP17A1) activity
Aop:247	Event:1611	KeyEvent	Reduction, dehydroepiandrosterone
Aop:247	Event:1612	KeyEvent	Reduction, androstenedione
Aop:247	Event:1613	KeyEvent	Decrease, circulating testosterone levels
Aop:247	Event:1614	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:247	Event:1615	KeyEvent	Decrease, androgen receptor activation
Aop:247	Event:1616	KeyEvent	Impaired inguinoscrotal testicular descent phase
Aop:247	Event:1617	AdverseOutcome	Malformation, cryptorchidism - maldescended testis
Aop:248	Event:1618	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:248	Event:1619	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:248	Event:1620	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:248	Event:1621	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:248	Event:1622	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:248	Event:1623	AdverseOutcome	Decrease, Population growth rate
Aop:249	Event:1624	MolecularInitiatingEvent	Increase, Mitochondrial ATP synthase antagonism
Aop:249	Event:1625	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:249	Event:1626	KeyEvent	Decrease, Cell proliferation
Aop:249	Event:1627	AdverseOutcome	Decrease, Growth
Aop:250	Event:1628	MolecularInitiatingEvent	Increase, Mitochondrial ATP synthase antagonism
Aop:250	Event:1629	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:250	Event:1630	KeyEvent	Increase, Cell death
Aop:250	Event:1631	AdverseOutcome	Decrease, Growth
Aop:251	Event:1632	MolecularInitiatingEvent	Inhibition of tyrosinase
Aop:251	Event:1633	KeyEvent	Reduction of L-Dopaquinone
Aop:251	Event:1634	KeyEvent	Reduction in melanin level
Aop:251	Event:1635	KeyEvent	Reduction of melanosome level
Aop:251	Event:1636	KeyEvent	Reduction fo Pigmentation pattern
Aop:251	Event:1637	AdverseOutcome	Decrease, Population growth rate
Aop:252	Event:1638	MolecularInitiatingEvent	Increase, DNA damage
Aop:252	Event:1639	KeyEvent	Tissue resident cell activation
Aop:252	Event:1640	KeyEvent	Increased Pro-inflammatory mediators
Aop:252	Event:1641	KeyEvent	Increase in reactive oxygen and nitrogen species (RONS)
Aop:252	Event:1642	KeyEvent	Leukocyte recruitment/activation
Aop:252	Event:1643	KeyEvent	Increase, Cell Proliferation (Epithelial Cells)
Aop:252	Event:1644	AdverseOutcome	Increase, Mutations
Aop:252	Event:1645	AdverseOutcome	Increased, Ductal Hyperplasia
Aop:252	Event:1646	AdverseOutcome	N/A, Breast Cancer
Aop:253	Event:1647	MolecularInitiatingEvent	Increase in reactive oxygen and nitrogen species (RONS)
Aop:253	Event:1648	KeyEvent	Increase, Cell Proliferation (Epithelial Cells)
Aop:253	Event:1649	KeyEvent	Tissue resident cell activation
Aop:253	Event:1650	KeyEvent	Increased Pro-inflammatory mediators
Aop:253	Event:1651	KeyEvent	Leukocyte recruitment/activation
Aop:253	Event:1652	AdverseOutcome	Increase, DNA damage
Aop:253	Event:1653	AdverseOutcome	Increase, Mutations
Aop:253	Event:1654	AdverseOutcome	Increased, Ductal Hyperplasia
Aop:253	Event:1655	AdverseOutcome	N/A, Breast Cancer
Aop:255	Event:1656	MolecularInitiatingEvent	Increase, Oxidative DNA damage
Aop:255	Event:1657	KeyEvent	Inadequate DNA repair
Aop:255	Event:1658	KeyEvent	Increase, DNA strand breaks
Aop:255	Event:1659	AdverseOutcome	Increase, Mutations
Aop:255	Event:1660	AdverseOutcome	Increase, Chromosomal aberrations
Aop:256	Event:1661	MolecularInitiatingEvent	Retinaldehyde dehydrogenase inhibition
Aop:256	Event:1662	KeyEvent	Altered, Photoreceptor patterning
Aop:256	Event:1663	KeyEvent	Decreased retinoic acid (RA) synthesis
Aop:256	Event:1664	KeyEvent	Decreased plasma RA level
Aop:256	Event:1665	KeyEvent	Altered, Visual function
Aop:256	Event:1666	AdverseOutcome	Decrease, Population growth rate
Aop:257	Event:1667	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:257	Event:1668	KeyEvent	Increase, porcupine-induced Wnt secretion and Wnt signaling activation
Aop:257	Event:1669	KeyEvent	beta-catenin activation
Aop:257	Event:1670	KeyEvent	Epithelial Mesenchymal Transition
Aop:257	Event:1671	AdverseOutcome	Treatment-resistant gastric cancer
Aop:258	Event:1672	MolecularInitiatingEvent	Deposition of Energy
Aop:258	Event:1673	KeyEvent	Increase, Oxidative DNA damage
Aop:258	Event:1674	KeyEvent	Increase, Follicular atresia
Aop:258	Event:1675	KeyEvent	Decrease, Oogenesis
Aop:258	Event:1676	KeyEvent	Increase, Reactive oxygen species
Aop:258	Event:1677	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:258	Event:1678	AdverseOutcome	Decrease, Population growth rate
Aop:259	Event:1679	MolecularInitiatingEvent	Antagonism, Thyroid Receptor
Aop:259	Event:1680	KeyEvent	Hippocampal gene expression, Altered
Aop:259	Event:1681	KeyEvent	Hippocampal anatomy, Altered
Aop:259	Event:1682	KeyEvent	Hippocampal Physiology, Altered
Aop:259	Event:1683	AdverseOutcome	Cognitive function, decreased
Aop:260	Event:1684	MolecularInitiatingEvent	Inhibition of cystathionine beta-synthase
Aop:260	Event:1685	KeyEvent	Increased Homocysteine level
Aop:260	Event:1686	KeyEvent	Increased, Plasma HCY level
Aop:260	Event:1687	KeyEvent	Induced, dysfunction of microcirculation
Aop:260	Event:1688	AdverseOutcome	Impaired,anterior-posterior axis development
Aop:261	Event:1689	MolecularInitiatingEvent	Inhibition of lung surfactant function
Aop:261	Event:1690	KeyEvent	Alveolar collapse
Aop:261	Event:1691	KeyEvent	Loss of alveolar capillary membrane integrity
Aop:261	Event:1692	KeyEvent	Reduced tidal volume
Aop:261	Event:1693	AdverseOutcome	Decrease, Lung function
Aop:262	Event:1694	MolecularInitiatingEvent	Frustrated phagocytosis
Aop:262	Event:1695	KeyEvent	Release, Cytokine
Aop:262	Event:1696	KeyEvent	Increased, recruitment of inflammatory cells
Aop:262	Event:1697	KeyEvent	Increase, Reactive oxygen species
Aop:262	Event:1698	KeyEvent	Increased, DNA damage and mutation
Aop:262	Event:1699	KeyEvent	Increase, Cell Proliferation
Aop:262	Event:1700	AdverseOutcome	Lung cancer
Aop:263	Event:1701	MolecularInitiatingEvent	Inhibition, TBX1
Aop:263	Event:1702	KeyEvent	Disruption, Neural crest cell migration
Aop:263	Event:1703	KeyEvent	Disruption, Progenitor cells of second heart field
Aop:263	Event:1704	KeyEvent	Impairment, Fourth pharyngeal arch development
Aop:263	Event:1705	KeyEvent	Abnormalities, Cardiac outflow tract formation
Aop:263	Event:1706	AdverseOutcome	Anomalies, Congenital cardiac conotruncal
Aop:264	Event:1707	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:264	Event:1708	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:264	Event:1709	KeyEvent	Decrease, androgen receptor activation
Aop:264	Event:1710	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:264	Event:1711	AdverseOutcome	anogenital distance (AGD), decreased
Aop:265	Event:1712	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:265	Event:1713	KeyEvent	Decrease, androgen receptor activation
Aop:265	Event:1714	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:265	Event:1715	AdverseOutcome	anogenital distance (AGD), decreased
Aop:266	Event:1716	KeyEvent	Decrease, circulating testosterone levels
Aop:266	Event:1717	KeyEvent	Decrease, androgen receptor activation
Aop:266	Event:1718	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:266	Event:1719	KeyEvent	Decrease, intratesticular testosterone levels
Aop:266	Event:1720	AdverseOutcome	anogenital distance (AGD), decreased
Aop:267	Event:1721	MolecularInitiatingEvent	Antagonism,LH receptor
Aop:267	Event:1722	KeyEvent	Reduction, Progesterone synthesis
Aop:267	Event:1723	KeyEvent	Decreased, Progesterone levels
Aop:267	Event:1724	KeyEvent	Reduction, progesterone uptake, decresed maturation
Aop:267	Event:1725	KeyEvent	Impaired ovulation
Aop:267	Event:1726	KeyEvent	Decrease of egg production and cummulative fecundity
Aop:267	Event:1727	AdverseOutcome	Decline, Population trajectory
Aop:268	Event:1728	MolecularInitiatingEvent	Activation, AhR
Aop:268	Event:1729	KeyEvent	dimerization, AHR/ARNT
Aop:268	Event:1730	KeyEvent	Increase, DNA methyltransferase expression
Aop:268	Event:1731	KeyEvent	Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor
Aop:268	Event:1732	KeyEvent	Decrease, expression of gonadotropin releasing hormone receptor
Aop:268	Event:1733	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:268	Event:1734	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:268	Event:1735	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:268	Event:1736	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:268	Event:1737	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:268	Event:1738	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:268	Event:1739	AdverseOutcome	Decrease, Population growth rate
Aop:269	Event:1740	MolecularInitiatingEvent	Deposition of Energy
Aop:269	Event:1741	KeyEvent	Increase, Oxidative DNA damage
Aop:269	Event:1742	KeyEvent	Increase, Oocyte apoptosis
Aop:269	Event:1743	KeyEvent	Decrease, Oogenesis
Aop:269	Event:1744	KeyEvent	Increase, Reactive oxygen species
Aop:269	Event:1745	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:269	Event:1746	AdverseOutcome	Decrease, Population growth rate
Aop:270	Event:1747	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:270	Event:1748	KeyEvent	Acetylcholine accumulation in synapses
Aop:270	Event:1749	KeyEvent	Increased Cholinergic Signaling
Aop:270	Event:1750	KeyEvent	Impaired coordination and movement
Aop:270	Event:1751	AdverseOutcome	Increased Mortality
Aop:270	Event:1752	AdverseOutcome	Decrease, Population growth rate
Aop:271	Event:1753	MolecularInitiatingEvent	Stimulation, TLR7/8
Aop:271	Event:1754	KeyEvent	Maturation of TNF/iNOS-Producing Dendritic Cells
Aop:271	Event:1755	KeyEvent	Increase, IL-23 from matured dendritic cells
Aop:271	Event:1756	KeyEvent	Th17 cell migration and inflammation induction
Aop:271	Event:1757	AdverseOutcome	Psoriatic skin disease
Aop:272	Event:1758	MolecularInitiatingEvent	Binding to estrogen receptor (ER)-α in immune cells
Aop:272	Event:1759	KeyEvent	Induction of GATA3 expression
Aop:272	Event:1760	KeyEvent	Increase of Th2 cells producing IL-4
Aop:272	Event:1761	KeyEvent	Increase of anti-DNA antibody from autoreactive B cell
Aop:272	Event:1762	AdverseOutcome	Exacerbation of systemic lupus erythematosus (SLE)
Aop:273	Event:1763	MolecularInitiatingEvent	Inhibition of JAK3
Aop:273	Event:1764	KeyEvent	Blockade of STAT5 phosphorylation
Aop:273	Event:1765	KeyEvent	Suppression of STAT5 binding to cytokine gene promoters
Aop:273	Event:1766	KeyEvent	Suppression of IL-4 production
Aop:273	Event:1767	AdverseOutcome	Impairment of T-cell dependent antibody response
Aop:274	Event:1768	MolecularInitiatingEvent	Trypsin inhibition
Aop:274	Event:1769	KeyEvent	Increased intestinal monitor peptide level
Aop:274	Event:1770	KeyEvent	Increased blood CCK level
Aop:274	Event:1771	KeyEvent	Increased exocrine secretion from pancreatic acinar cells
Aop:274	Event:1772	KeyEvent	Acinar cell proliferation
Aop:274	Event:1773	AdverseOutcome	Pancreatic acinar cell tumors
Aop:275	Event:1774	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:275	Event:1775	KeyEvent	Decrease, Acyl-CoA dehydrogenases
Aop:275	Event:1776	KeyEvent	Decreased, Mitochondrial Fatty Acid Beta Oxidation
Aop:275	Event:1777	KeyEvent	Accumulation, Triglyceride
Aop:275	Event:1778	AdverseOutcome	Increased, Liver Steatosis
Aop:276	Event:1779	MolecularInitiatingEvent	Induced dysregulation of ACE2
Aop:276	Event:1780	KeyEvent	Dysregulation, ACE2 expression and activity
Aop:276	Event:1781	KeyEvent	Increased Angiotensin II
Aop:276	Event:1782	KeyEvent	Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)
Aop:276	Event:1783	KeyEvent	Increase, Reactive oxygen species
Aop:276	Event:1784	KeyEvent	Increased activation, Nuclear factor kappa B (NF-kB)
Aop:276	Event:1785	KeyEvent	Accumulation, Collagen
Aop:276	Event:1786	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:276	Event:1787	AdverseOutcome	Lung fibrosis
Aop:277	Event:1788	MolecularInitiatingEvent	Binding to ACE2
Aop:277	Event:1789	KeyEvent	SARS-CoV-2 cell entry
Aop:277	Event:1790	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:277	Event:1791	KeyEvent	Increased SARS-CoV-2 production
Aop:277	Event:1792	KeyEvent	Toll Like Receptor (TLR) Dysregulation
Aop:277	Event:1793	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:277	Event:1794	KeyEvent	Increased inflammatory immune responses
Aop:277	Event:1795	KeyEvent	Increase, the risk of acute respiratory failure
Aop:277	Event:1796	AdverseOutcome	Increased Mortality
Aop:278	Event:1574	MolecularInitiatingEvent	Inhibition, IKK complex
Aop:278	Event:202	KeyEvent	Inhibition, Nuclear factor kappa B (NF-kB)
Aop:278	Event:1575	KeyEvent	Activation, Caspase 8 pathway
Aop:278	Event:55	KeyEvent	Increase, Cell injury/death
Aop:278	Event:1576	KeyEvent	Activation, Tissue resident cells (Kuppfer cells)
Aop:278	Event:1548	AdverseOutcome	Necrotic Tissue
Aop:278	Event:1549	AdverseOutcome	Liver Injury
Aop:278	Event:1579	KeyEvent	Increase, proinflammatory mediators (TNFalpha)
Aop:279	Event:1797	MolecularInitiatingEvent	Alkylation, DNA
Aop:279	Event:1798	KeyEvent	Inadequate DNA repair
Aop:279	Event:1799	KeyEvent	Increase, DNA strand breaks
Aop:279	Event:1800	KeyEvent	Increase, Apoptosis
Aop:279	Event:1801	AdverseOutcome	Reduce, Sperm count
Aop:280	Event:1802	MolecularInitiatingEvent	Activation, PPARα
Aop:280	Event:1803	KeyEvent	Decreased, cholesterol
Aop:280	Event:1804	KeyEvent	Decreased, plasma 11-ketotestosterone level
Aop:280	Event:1805	KeyEvent	Impaired, Spermatogenesis
Aop:280	Event:1806	AdverseOutcome	Decreased, Viable Offspring
Aop:280	Event:1807	AdverseOutcome	Decrease, Population growth rate
Aop:281	Event:1808	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:281	Event:1809	KeyEvent	Increase, Oxidative DNA damage
Aop:281	Event:1810	KeyEvent	Increase, Cell injury/death
Aop:281	Event:1811	AdverseOutcome	Decrease, Growth
Aop:282	Event:1812	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:282	Event:1813	KeyEvent	Increase, Lipid peroxidation
Aop:282	Event:1814	KeyEvent	Increase, Cell injury/death
Aop:282	Event:1815	AdverseOutcome	Decrease, Growth
Aop:283	Event:1816	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:283	Event:1817	KeyEvent	Increase, Protein oxidation
Aop:283	Event:1818	KeyEvent	Increase, Cell injury/death
Aop:283	Event:1819	AdverseOutcome	Decrease, Growth
Aop:284	Event:1820	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:284	Event:1821	KeyEvent	Increase, Protein oxidation
Aop:284	Event:1822	KeyEvent	Increase, Abnormal osmoregulation
Aop:284	Event:1823	KeyEvent	Increase, Body fluid overload
Aop:284	Event:1824	AdverseOutcome	Increase, Mortality
Aop:285	Event:1825	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:285	Event:1826	KeyEvent	Decrease, Mitochondrial membrane potential
Aop:285	Event:1827	KeyEvent	Decrease, Oxidative phosphorylation
Aop:285	Event:1828	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:285	Event:1829	AdverseOutcome	Increase, Mortality
Aop:286	Event:1830	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:286	Event:1831	KeyEvent	Increase, Lipid peroxidation
Aop:286	Event:1832	KeyEvent	Decrease, Triglyceride
Aop:286	Event:1833	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:286	Event:1834	AdverseOutcome	Increase, Mortality
Aop:287	Event:1835	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:287	Event:1836	KeyEvent	Increase, Oxidative DNA damage
Aop:287	Event:1837	KeyEvent	Increase, DNA double-strand breaks
Aop:287	Event:1838	KeyEvent	Increase, Apoptosis
Aop:287	Event:1839	AdverseOutcome	Increase, Mortality
Aop:288	Event:1840	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:288	Event:1841	KeyEvent	Increase, Oxidative DNA damage
Aop:288	Event:1842	KeyEvent	Cell cycle, disrupted
Aop:288	Event:1843	KeyEvent	Decrease, Cell proliferation
Aop:288	Event:1844	KeyEvent	Increase, DNA strand breaks
Aop:288	Event:1845	AdverseOutcome	Decrease, Growth
Aop:289	Event:1846	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:289	Event:1847	KeyEvent	Increase, Lipid peroxidation
Aop:289	Event:1848	KeyEvent	Cell cycle, disrupted
Aop:289	Event:1849	KeyEvent	Decrease, Cell proliferation
Aop:289	Event:1850	AdverseOutcome	Decrease, Growth
Aop:290	Event:1851	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:290	Event:1852	KeyEvent	Decrease, Coupling of oxidative phosphorylation
Aop:290	Event:1853	KeyEvent	Decrease, Adenosine triphosphate pool
Aop:290	Event:1854	KeyEvent	Decrease, Cell proliferation
Aop:290	Event:1855	AdverseOutcome	Decrease, Growth
Aop:291	Event:1856	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:291	Event:1857	KeyEvent	Altered Cell Differentiation Signaling
Aop:291	Event:1858	KeyEvent	Altered Bone Cell Homeostasis
Aop:291	Event:1859	KeyEvent	Inhibition, Fin regeneration
Aop:291	Event:1860	KeyEvent	Reduced, Swimming performance
Aop:291	Event:1861	AdverseOutcome	Decrease, Population growth rate
Aop:292	Event:1862	MolecularInitiatingEvent	Mitochondrial dysfunction
Aop:292	Event:1863	KeyEvent	Urothelial cell injury/death
Aop:292	Event:1864	KeyEvent	Increase, Regenerative cell proliferation (urothelial cells)
Aop:292	Event:1865	KeyEvent	Increase, Hyperplasia (urothelial)
Aop:292	Event:1866	AdverseOutcome	Urothelial Tumor
Aop:293	Event:1867	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:293	Event:1868	KeyEvent	Decrease, Global DNA methylation
Aop:293	Event:1869	KeyEvent	Increase, Caspase transcription
Aop:293	Event:1870	KeyEvent	Increase, Oocyte apoptosis
Aop:293	Event:1871	KeyEvent	Decrease, Oogenesis
Aop:293	Event:1872	AdverseOutcome	Decrease, Fecundity
Aop:293	Event:1873	AdverseOutcome	Decrease, Population growth rate
Aop:294	Event:1874	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:294	Event:1875	KeyEvent	Decrease, Global DNA methylation
Aop:294	Event:1876	KeyEvent	Increase, Caspase transcription
Aop:294	Event:1877	KeyEvent	Increase, Ovarian somatic cell apoptosis
Aop:294	Event:1878	KeyEvent	Increase, Ovarian follicle breakdown
Aop:294	Event:1879	KeyEvent	Decrease, Oogenesis
Aop:294	Event:1880	AdverseOutcome	Decrease, Fecundity
Aop:294	Event:1881	AdverseOutcome	Decrease, Population growth rate
Aop:295	Event:1882	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:295	Event:1883	KeyEvent	Increase, DNA double-strand breaks
Aop:295	Event:1884	KeyEvent	Increase, Caspase transcription
Aop:295	Event:1885	KeyEvent	Increase, Oocyte apoptosis
Aop:295	Event:1886	KeyEvent	Decrease, Oogenesis
Aop:295	Event:1887	AdverseOutcome	Decrease, Fecundity
Aop:295	Event:1888	AdverseOutcome	Decrease, Population growth rate
Aop:296	Event:1889	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:296	Event:1890	KeyEvent	Increase, DNA double-strand breaks
Aop:296	Event:1891	KeyEvent	Increase, Caspase transcription
Aop:296	Event:1892	KeyEvent	Increase, Ovarian somatic cell apoptosis
Aop:296	Event:1893	KeyEvent	Increase, Ovarian follicle breakdown
Aop:296	Event:1894	KeyEvent	Decrease, Oogenesis
Aop:296	Event:1895	AdverseOutcome	Decrease, Fecundity
Aop:296	Event:1896	AdverseOutcome	Decrease, Population growth rate
Aop:297	Event:1897	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:297	Event:1898	KeyEvent	Decrease, Global DNA methylation
Aop:297	Event:1899	KeyEvent	Decrease, Heritable DNA methylation (F3)
Aop:297	Event:1900	KeyEvent	Increase, Caspase transcription (F3)
Aop:297	Event:1901	KeyEvent	Increase, Oocyte apoptosis (F3)
Aop:297	Event:1902	KeyEvent	Decrease, Oogenesis (F3)
Aop:297	Event:1903	AdverseOutcome	Decrease, Fecundity (F3)
Aop:297	Event:1904	AdverseOutcome	Decrease, Population growth rate
Aop:298	Event:1905	MolecularInitiatingEvent	Increase, DNA methyltransferase inhibition
Aop:298	Event:1906	KeyEvent	Decrease, Global DNA methylation
Aop:298	Event:1907	KeyEvent	Decrease, Heritable DNA methylation (F3)
Aop:298	Event:1908	KeyEvent	Increase, Caspase transcription (F3)
Aop:298	Event:1909	KeyEvent	Increase, Ovarian somatic cell apoptosis (F3)
Aop:298	Event:1910	KeyEvent	Increase, Ovarian follicle breakdown (F3)
Aop:298	Event:1911	KeyEvent	Decrease, Oogenesis (F3)
Aop:298	Event:1912	AdverseOutcome	Decrease, Fecundity (F3)
Aop:298	Event:1913	AdverseOutcome	Decrease, Population growth rate
Aop:299	Event:1914	MolecularInitiatingEvent	Inhibition, Chitin synthase 1
Aop:299	Event:1915	KeyEvent	Decrease, Cuticular chitin content
Aop:299	Event:1916	KeyEvent	Increase, Premature molting
Aop:299	Event:1917	AdverseOutcome	Increase, Mortality
Aop:300	Event:1918	MolecularInitiatingEvent	Increase, Sulfonylurea receptor binding
Aop:300	Event:1919	KeyEvent	Increase, Cell membrane depolarization
Aop:300	Event:1920	KeyEvent	Increase, Opening of voltage-dependent calcium channel
Aop:300	Event:1921	KeyEvent	Decrease, Cuticular chitin content
Aop:300	Event:1922	KeyEvent	Increase, Premature molting
Aop:300	Event:1923	AdverseOutcome	Increase, Mortality
Aop:301	Event:1924	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:301	Event:1925	KeyEvent	Decrease, androgen receptor activation
Aop:301	Event:1926	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:301	Event:1927	AdverseOutcome	Nipple retention (NR), increased
Aop:302	Event:1928	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:302	Event:1929	KeyEvent	Decrease, androgen receptor activation
Aop:302	Event:1930	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:302	Event:1931	KeyEvent	Granulosa cell proliferation of gonadotropin-independent follicles, Reduced
Aop:302	Event:1932	AdverseOutcome	disrupted, ovarian cycle
Aop:302	Event:1933	AdverseOutcome	decreased, Fertility
Aop:303	Event:1934	MolecularInitiatingEvent	Inhibition, Aromatase
Aop:303	Event:1935	KeyEvent	Reduction, 17beta-estradiol synthesis by the undifferentiated gonad
Aop:303	Event:1936	KeyEvent	Increased, Differentiation to Testis
Aop:303	Event:1937	KeyEvent	Increased, Male Biased Sex Ratio
Aop:303	Event:1938	AdverseOutcome	Decrease, Population growth rate
Aop:304	Event:1939	MolecularInitiatingEvent	Toll-like receptor 4 activation
Aop:304	Event:1940	MolecularInitiatingEvent	Inactivation of PPARγ
Aop:304	Event:1941	KeyEvent	Activation, JNK
Aop:304	Event:1942	KeyEvent	Activator protein 1 activation
Aop:304	Event:1943	KeyEvent	Pin-1 activation
Aop:304	Event:1944	KeyEvent	Latent Transforming growth Factor beta expression
Aop:304	Event:1945	KeyEvent	Activation, TGF-beta pathway
Aop:304	Event:1946	KeyEvent	Epithelial Mesenchymal Transition
Aop:304	Event:1947	AdverseOutcome	Pulmonary fibrosis
Aop:305	Event:1948	MolecularInitiatingEvent	Inhibition of 11β-HSD
Aop:305	Event:1949	KeyEvent	Decreased, plasma 11-ketotestosterone level
Aop:305	Event:1950	KeyEvent	Impaired, Spermatogenesis
Aop:305	Event:1951	KeyEvent	decreased, Fertility
Aop:305	Event:1952	AdverseOutcome	Decrease, Population growth rate
Aop:306	Event:1953	MolecularInitiatingEvent	11β-hydroxylase inhibition
Aop:306	Event:1954	KeyEvent	Cortisol and 11β-(OH) testosterone decreased
Aop:306	Event:1955	KeyEvent	Decreased, plasma 11-ketotestosterone level
Aop:306	Event:1956	KeyEvent	Decreased plasma Cortisol level
Aop:306	Event:1957	KeyEvent	Decreased spermatogenesis
Aop:306	Event:1958	KeyEvent	decreased oocyte maturation
Aop:306	Event:1959	KeyEvent	decreased, Fertility
Aop:306	Event:1960	AdverseOutcome	Decrease, Population growth rate
Aop:307	Event:1961	MolecularInitiatingEvent	Inhibition, Chitinase
Aop:307	Event:1962	KeyEvent	Decrease, Digestion of old cuticle
Aop:307	Event:1963	KeyEvent	Increase, Premature molting
Aop:307	Event:1964	AdverseOutcome	Increase, Mortality
Aop:308	Event:1965	MolecularInitiatingEvent	Inhibition, Chitobiase
Aop:308	Event:1966	KeyEvent	Decrease, Digestion of old cuticle
Aop:308	Event:1967	KeyEvent	Increase, Premature molting
Aop:308	Event:1968	AdverseOutcome	Increase, Mortality
Aop:309	Event:1969	MolecularInitiatingEvent	Inhibition, Chitin synthase 1
Aop:309	Event:1970	KeyEvent	Decrease, Cuticular chitin content
Aop:309	Event:1971	KeyEvent	Increase, Premature molting
Aop:309	Event:1972	AdverseOutcome	Increase, Mortality
Aop:310	Event:1973	MolecularInitiatingEvent	Increase, Sulfonylurea receptor binding
Aop:310	Event:1974	KeyEvent	Increase, Cell membrane depolarization
Aop:310	Event:1975	KeyEvent	Increase, Opening of voltage-dependent calcium channel
Aop:310	Event:1976	KeyEvent	Decrease, Cuticular chitin content
Aop:310	Event:1977	KeyEvent	Increase, Premature molting
Aop:310	Event:1978	AdverseOutcome	Increase, Mortality
Aop:311	Event:1979	MolecularInitiatingEvent	benzoquinone imine and acylglucuronide metabolites
Aop:311	Event:1980	KeyEvent	Mitochondrial dysfunction
Aop:311	Event:1981	KeyEvent	Activation of ER stress
Aop:311	Event:1982	KeyEvent	Apoptotic cell death
Aop:311	Event:1983	KeyEvent	Immune cell activation
Aop:311	Event:1984	KeyEvent	IFNγ signaling
Aop:311	Event:1985	KeyEvent	Increase in inflammation
Aop:311	Event:1986	AdverseOutcome	Immune mediated hepatitis
Aop:312	Event:1987	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:312	Event:1988	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:312	Event:1989	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:312	Event:1990	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:312	Event:1991	KeyEvent	Altered, retinal layer structure
Aop:312	Event:1992	KeyEvent	Altered, Visual function
Aop:312	Event:1993	AdverseOutcome	Increased Mortality
Aop:312	Event:1994	AdverseOutcome	Decrease, Population growth rate
Aop:313	Event:1995	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:313	Event:1996	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:313	Event:1997	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:313	Event:1998	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:313	Event:1999	KeyEvent	Decreased, Eye size
Aop:313	Event:2000	KeyEvent	Altered, Visual function
Aop:313	Event:2001	AdverseOutcome	Increased Mortality
Aop:313	Event:2002	AdverseOutcome	Decrease, Population growth rate
Aop:314	Event:2003	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:314	Event:2004	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:314	Event:2005	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:314	Event:2006	KeyEvent	Decreased, Triiodothyronine (T3)
Aop:314	Event:2007	KeyEvent	Altered, Photoreceptor patterning
Aop:314	Event:2008	KeyEvent	Altered, Visual function
Aop:314	Event:2009	AdverseOutcome	Increased Mortality
Aop:314	Event:2010	AdverseOutcome	Decrease, Population growth rate
Aop:315	Event:2011	MolecularInitiatingEvent	Binding, Transthyretin in serum
Aop:315	Event:2012	KeyEvent	Displacement, Serum thyroxine (T4) from carrier protein
Aop:315	Event:2013	KeyEvent	Increased, Free serum thyroxine (T4)
Aop:315	Event:2014	KeyEvent	Increased, Hepatic thyroid hormone uptake/transport
Aop:315	Event:2015	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:315	Event:2016	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:315	Event:2017	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:316	Event:2018	MolecularInitiatingEvent	Binding, Thyroid binding globulin in serum
Aop:316	Event:2019	KeyEvent	Displacement, Serum thyroxine (T4) from carrier protein
Aop:316	Event:2020	KeyEvent	Increased, Free serum thyroxine (T4)
Aop:316	Event:2021	KeyEvent	Increased, Hepatic thyroid hormone uptake/transport
Aop:316	Event:2022	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:316	Event:2023	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:316	Event:2024	AdverseOutcome	Altered, Amphibian metamorphosis
Aop:317	Event:2025	MolecularInitiatingEvent	Inhibition, cytochrome oxidase
Aop:317	Event:2026	KeyEvent	Increase, Cell death
Aop:317	Event:2027	AdverseOutcome	Increased, nasal lesions
Aop:318	Event:122	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:318	Event:860	KeyEvent	Decreased, Mitochondrial Fatty Acid Beta Oxidation
Aop:318	Event:459	AdverseOutcome	Increased, Liver Steatosis
Aop:318	Event:291	KeyEvent	Accumulation, Triglyceride
Aop:318	Event:1834	KeyEvent	Decrease, Acyl-CoA dehydrogenases
Aop:319	Event:1752	KeyEvent	Increased Angiotensin II 
Aop:319	Event:1740	MolecularInitiatingEvent	Induced dysregulation of ACE2 
Aop:319	Event:68	KeyEvent	Accumulation, Collagen
Aop:319	Event:1276	AdverseOutcome	Lung fibrosis
Aop:319	Event:1851	KeyEvent	Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)
Aop:319	Event:1115	KeyEvent	Increase, Reactive oxygen species
Aop:319	Event:1172	KeyEvent	Increased activation, Nuclear factor kappa B (NF-kB)
Aop:319	Event:1496	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:319	Event:1854	KeyEvent	Dysregulation, ACE2 expression and activity
Aop:320	Event:1496	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:320	Event:1738	KeyEvent	SARS-CoV-2 cell entry 
Aop:320	Event:1739	MolecularInitiatingEvent	Binding to ACE2
Aop:320	Event:1748	KeyEvent	Increase, the risk of acute respiratory failure
Aop:320	Event:1750	KeyEvent	Increased inflammatory immune responses
Aop:320	Event:351	AdverseOutcome	Increased Mortality
Aop:320	Event:1848	KeyEvent	Toll Like Receptor (TLR) Dysregulation
Aop:320	Event:1847	KeyEvent	Increased SARS-CoV-2 production
Aop:320	Event:1901	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:321	Event:2028	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:321	Event:2029	KeyEvent	Decrease, androgen receptor activation
Aop:321	Event:2030	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:321	Event:2031	KeyEvent	Malformation, cryptorchidism - maldescended testis
Aop:321	Event:2032	AdverseOutcome	Testicular Cancer
Aop:322	Event:97	MolecularInitiatingEvent	Alkylation, DNA
Aop:322	Event:155	KeyEvent	Inadequate DNA repair
Aop:322	Event:1635	KeyEvent	Increase, DNA strand breaks
Aop:322	Event:1365	KeyEvent	Increase, Apoptosis
Aop:322	Event:1757	AdverseOutcome	Reduce, Sperm count
Aop:323	Event:2033	MolecularInitiatingEvent	Binding to ACE2
Aop:323	Event:2034	KeyEvent	Neuroinflammation
Aop:323	Event:2035	KeyEvent	N/A, Neurodegeneration
Aop:323	Event:2036	AdverseOutcome	Encephalitis
Aop:324	Event:1634	KeyEvent	Increase, Oxidative DNA damage
Aop:324	Event:55	KeyEvent	Increase, Cell injury/death
Aop:324	Event:1521	AdverseOutcome	Decrease, Growth
Aop:324	Event:1115	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:325	Event:2037	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:325	Event:2038	KeyEvent	Increased, Differentiation to Testis
Aop:325	Event:2039	KeyEvent	Increased, Male Biased Sex Ratio
Aop:325	Event:2040	AdverseOutcome	Decrease, Population growth rate
Aop:326	Event:2041	MolecularInitiatingEvent	Prolonged TLR9 activation
Aop:326	Event:2042	KeyEvent	increased MyD88 activation
Aop:326	Event:2043	KeyEvent	NLRP3 inflammasome activity, increased
Aop:326	Event:2044	KeyEvent	Increased activation, Nuclear factor kappa B (NF-kB)
Aop:326	Event:2045	KeyEvent	Release, Cytokine
Aop:326	Event:2046	KeyEvent	Increased Pro-inflammatory mediators
Aop:326	Event:2047	KeyEvent	Increased, recruitment of inflammatory cells
Aop:326	Event:2048	KeyEvent	Th17 cell migration and inflammation induction
Aop:326	Event:2049	KeyEvent	Oxidative Stress
Aop:326	Event:2050	KeyEvent	Diminished protective oxidative stress response
Aop:326	Event:2051	KeyEvent	Mitochondrial dysfunction
Aop:326	Event:2052	KeyEvent	Increase, Cell injury/death
Aop:326	Event:2053	KeyEvent	Increase, Cell death
Aop:326	Event:2054	KeyEvent	Increase, Tissue/organ damage
Aop:326	Event:2055	KeyEvent	increased release of danger/damage associated molecular patterns
Aop:326	Event:2056	KeyEvent	Toll Like Receptor (TLR) Dysregulation
Aop:326	Event:2057	KeyEvent	increased platelet surface TLR9 expression
Aop:326	Event:2058	KeyEvent	formation of neutrophil extracellular traps (NETs)
Aop:326	Event:2059	KeyEvent	Platelet-neutrophil interactions, Increased
Aop:326	Event:2060	KeyEvent	Thrombosis and Disseminated Intravascular Coagulation
Aop:326	Event:2061	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:326	Event:2062	KeyEvent	Hyperinflammation
Aop:326	Event:2063	KeyEvent	Inflammation, Liver
Aop:326	Event:2064	KeyEvent	systemic inflammatory response syndrome
Aop:326	Event:2065	KeyEvent	Increase, the risk of acute respiratory failure
Aop:326	Event:2066	KeyEvent	Heart failure
Aop:326	Event:2067	KeyEvent	Occurrence, Kidney toxicity
Aop:326	Event:2068	KeyEvent	Increased, Kidney Failure
Aop:326	Event:2069	AdverseOutcome	Multi Organ Failure involving Acute Respiratory Distress Syndrome
Aop:326	Event:2070	AdverseOutcome	Increased Mortality
Aop:327	Event:2071	MolecularInitiatingEvent	Toll Like Receptor (TLR) Dysregulation
Aop:328	Event:2072	MolecularInitiatingEvent	Binding to ACE2
Aop:328	Event:2073	KeyEvent	SARS-CoV-2 cell entry
Aop:328	Event:2074	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:328	Event:2075	KeyEvent	Increased SARS-CoV-2 production
Aop:328	Event:2076	KeyEvent	Diminished protective oxidative stress response
Aop:328	Event:2077	KeyEvent	Coagulation
Aop:328	Event:2078	AdverseOutcome	Thrombosis and Disseminated Intravascular Coagulation
Aop:329	Event:2079	MolecularInitiatingEvent	Binding to ACE2
Aop:329	Event:2080	KeyEvent	Downregulation, ACE2
Aop:329	Event:2081	KeyEvent	Increased Angiotensin II
Aop:329	Event:2082	KeyEvent	Imbalanced salty and sweet taste responses
Aop:329	Event:2083	KeyEvent	Impaired gustatory nerve
Aop:329	Event:2084	AdverseOutcome	dysgeusia
Aop:330	Event:2085	MolecularInitiatingEvent	Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)
Aop:330	Event:2086	KeyEvent	Increase, Reactive oxygen species
Aop:330	Event:2087	KeyEvent	Increased activation, Nuclear factor kappa B (NF-kB)
Aop:330	Event:2088	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:330	Event:2089	KeyEvent	Accumulation, Collagen
Aop:330	Event:2090	AdverseOutcome	Lung fibrosis
Aop:331	Event:2091	MolecularInitiatingEvent	Induced dysregulation of ACE2
Aop:331	Event:2092	KeyEvent	Increase plasma Ang II
Aop:331	Event:2093	KeyEvent	Increased Ang II type 1 receptor (AT1R)
Aop:331	Event:2094	KeyEvent	Increase, Reactive oxygen species
Aop:331	Event:2095	KeyEvent	Increased, extracellular matrix deposition
Aop:331	Event:2096	AdverseOutcome	N/A, Liver fibrosis
Aop:332	Event:2097	MolecularInitiatingEvent	Hyperactivation of ACE/Ang-II/AT1R axis
Aop:332	Event:2098	KeyEvent	Increased Angiotensin II
Aop:332	Event:2099	KeyEvent	Increased Ang II type 1 receptor (AT1R)
Aop:332	Event:2100	KeyEvent	Increase, Reactive oxygen species
Aop:332	Event:2101	KeyEvent	Increased Sodium-sensitive hypertension
Aop:332	Event:2102	AdverseOutcome	Chronic kidney disease
Aop:333	Event:2103	MolecularInitiatingEvent	Binding to ACE2
Aop:333	Event:2104	KeyEvent	Dysregulation, ACE2 expression and activity
Aop:333	Event:2105	KeyEvent	Downregulation, ACE2
Aop:333	Event:2106	KeyEvent	Increased Angiotensin II
Aop:333	Event:2107	KeyEvent	Occurrence, (Micro)vascular dysfunction
Aop:334	Event:2108	MolecularInitiatingEvent	Deposition of Energy
Aop:334	Event:2109	KeyEvent	Increase, Reactive oxygen species
Aop:334	Event:2110	KeyEvent	Increase, D1 protein deactivation
Aop:334	Event:2111	KeyEvent	Decrease, Photosystem II efficiency
Aop:334	Event:2112	KeyEvent	Decrease, Photosynthesis
Aop:334	Event:2113	KeyEvent	Decrease, ATP production
Aop:334	Event:2114	AdverseOutcome	Decrease, Reproduction
Aop:334	Event:2115	AdverseOutcome	Decrease, Population growth rate
Aop:335	Event:2116	MolecularInitiatingEvent	Deposition of Energy
Aop:335	Event:2117	KeyEvent	Increase, Reactive oxygen species
Aop:335	Event:2118	KeyEvent	Decrease, Mitochondrial membrane potential
Aop:335	Event:2119	KeyEvent	Decrease, Oxidative phosphorylation
Aop:335	Event:2120	KeyEvent	Decrease, ATP production
Aop:335	Event:2121	KeyEvent	Decrease, Mitochondrial ATP production
Aop:335	Event:2122	AdverseOutcome	Decrease, Reproduction
Aop:335	Event:2123	AdverseOutcome	Decrease, Population growth rate
Aop:336	Event:2124	MolecularInitiatingEvent	Deposition of Energy
Aop:336	Event:2125	KeyEvent	Increase, DNA damage
Aop:336	Event:2126	KeyEvent	Increase, Programmed cell death
Aop:336	Event:2127	AdverseOutcome	Decrease, Reproduction
Aop:336	Event:2128	AdverseOutcome	Decrease, Population growth rate
Aop:337	Event:2129	MolecularInitiatingEvent	Increase, Oxygen-evolving complex damage
Aop:337	Event:2130	KeyEvent	Decrease, Photosystem II efficiency
Aop:337	Event:2131	KeyEvent	Decrease, Photosynthesis
Aop:337	Event:2132	KeyEvent	Decrease, ATP production
Aop:337	Event:2133	KeyEvent	Decrease, Leaf development
Aop:337	Event:2134	AdverseOutcome	Decrease, Reproduction
Aop:337	Event:2135	AdverseOutcome	Decrease, Population growth rate
Aop:338	Event:2136	MolecularInitiatingEvent	Fibrinolysis, decreased
Aop:338	Event:2137	MolecularInitiatingEvent	Bradykinin system, hyperactivated
Aop:338	Event:2138	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:338	Event:2139	KeyEvent	Increased, recruitment of inflammatory cells
Aop:338	Event:2140	AdverseOutcome	Hyperinflammation
Aop:339	Event:2141	MolecularInitiatingEvent	Increased, Hepatic thyroid hormone uptake/transport
Aop:339	Event:2142	KeyEvent	Cell cycle, disrupted
Aop:339	Event:2143	KeyEvent	Altered, Thyroid hormone-dependent gene expression
Aop:339	Event:2144	KeyEvent	systemic inflammatory response syndrome
Aop:339	Event:2145	KeyEvent	Increase cell proliferation
Aop:339	Event:2146	KeyEvent	Apoptosis
Aop:340	Event:2147	MolecularInitiatingEvent	Binding to ACE2
Aop:340	Event:2148	KeyEvent	SARS-CoV-2 cell entry
Aop:340	Event:2149	KeyEvent	Increased SARS-CoV-2 production
Aop:340	Event:2150	KeyEvent	Sustentacular cells, decrease
Aop:340	Event:2151	KeyEvent	olfactory sensory neurons, decrease
Aop:340	Event:2152	KeyEvent	Olfactory epithelium degeneration
Aop:340	Event:2153	AdverseOutcome	impaired olfactory function (anosmia)
Aop:341	Event:2154	MolecularInitiatingEvent	Binding to ACE2
Aop:341	Event:2155	KeyEvent	SARS-CoV-2 cell entry
Aop:341	Event:2156	KeyEvent	blood brain barrier disruption
Aop:341	Event:2157	KeyEvent	Thrombosis and Disseminated Intravascular Coagulation
Aop:341	Event:2158	AdverseOutcome	Cerebrovascular disease (stroke)
Aop:342	Event:2159	MolecularInitiatingEvent	Deposition of Ionizing Energy
Aop:342	Event:2160	KeyEvent	Oxidative Stress
Aop:342	Event:2161	KeyEvent	Altered, Meiotic chromosome dynamics
Aop:342	Event:2162	KeyEvent	Increase, Oocyte apoptosis
Aop:342	Event:2163	KeyEvent	Increase, Reactive oxygen species
Aop:342	Event:2164	KeyEvent	Decreased spermatogenesis
Aop:342	Event:2165	KeyEvent	Increase, DNA damage
Aop:342	Event:2166	KeyEvent	decreased, Fertility
Aop:342	Event:2167	KeyEvent	Cell cycle, disrupted
Aop:342	Event:2168	KeyEvent	Decrease, Oogenesis
Aop:342	Event:2169	AdverseOutcome	Decrease of egg production and cummulative fecundity
Aop:342	Event:2170	AdverseOutcome	Decrease, Reproduction
Aop:342	Event:2171	AdverseOutcome	Decreased, Population size
Aop:343	Event:2172	MolecularInitiatingEvent	Bulky DNA adducts, increase
Aop:343	Event:2173	KeyEvent	Inadequate DNA repair
Aop:343	Event:2174	AdverseOutcome	Increase, Mutations
Aop:344	Event:2175	MolecularInitiatingEvent	Decreased, ALDH1A (RALDH) enzyme activity
Aop:344	Event:2176	KeyEvent	Decreased, all-trans retinoic acid (atRA) concentration
Aop:344	Event:2177	KeyEvent	Disrupted, initiation of meiosis of oogonia in the ovary
Aop:344	Event:2178	KeyEvent	Decreased, size of the ovarian reserve
Aop:344	Event:2179	KeyEvent	disrupted, ovarian cycle
Aop:344	Event:2180	AdverseOutcome	decreased, Fertility
Aop:345	Event:2181	MolecularInitiatingEvent	Inhibition of Fyna
Aop:345	Event:2182	KeyEvent	Inhibition of Plxna2
Aop:345	Event:2183	KeyEvent	Overexpression of rasl11b
Aop:345	Event:2184	KeyEvent	Decrease, Cell proliferation
Aop:345	Event:2185	KeyEvent	Decreased, Eye size
Aop:345	Event:2186	KeyEvent	Altered, Visual function
Aop:345	Event:2187	AdverseOutcome	Increased Mortality
Aop:345	Event:2188	AdverseOutcome	Decrease, Population growth rate
Aop:346	Event:2189	MolecularInitiatingEvent	Increased (ectopic) all-trans retinoic acid concentration
Aop:346	Event:2190	KeyEvent	Premature initiation of meiosis in fetal male germ cells
Aop:346	Event:2191	KeyEvent	Decrease (loss of) fetal male germ cells
Aop:346	Event:2192	AdverseOutcome	Reduce, Sperm count
Aop:347	Event:2193	MolecularInitiatingEvent	protein-coupled estrogen receptor 1 (GPER) activation
Aop:347	Event:2194	KeyEvent	Activation, PI3K
Aop:347	Event:2195	KeyEvent	Activation, AKT
Aop:347	Event:2196	KeyEvent	Activation, mTORC1
Aop:347	Event:2197	KeyEvent	Activation, PPARα
Aop:347	Event:2198	KeyEvent	Abnormal lipid metabolism
Aop:347	Event:2199	KeyEvent	Down Regulation, CPT1A
Aop:347	Event:2200	KeyEvent	Up Regulation, SREBF2
Aop:347	Event:2201	KeyEvent	Up Regulation, SCD-1
Aop:347	Event:2202	AdverseOutcome	N/A, Steatohepatisis
Aop:348	Event:2203	MolecularInitiatingEvent	Thyroperoxidase, Inhibition
Aop:348	Event:2204	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:348	Event:2205	KeyEvent	Decrease, Serum thyroid hormone (T4/T3)
Aop:348	Event:2206	KeyEvent	Brain thyroid hormone (T4/T3) decreased
Aop:348	Event:2207	KeyEvent	Altered, Thyroid hormone-dependent gene expression
Aop:348	Event:2208	KeyEvent	Abnormal, neuroblast migration
Aop:348	Event:2209	AdverseOutcome	Periventricular heterotopia formation
Aop:348	Event:2210	AdverseOutcome	Increase, seizure
Aop:349	Event:1796	MolecularInitiatingEvent	11β-hydroxylase inhibition
Aop:349	Event:1756	KeyEvent	Decreased,  plasma 11-ketotestosterone level
Aop:349	Event:1798	KeyEvent	Decreased spermatogenesis 
Aop:349	Event:1835	KeyEvent	Cortisol and 11β-(OH) testosterone decreased
Aop:349	Event:1836	KeyEvent	Decreased plasma Cortisol level
Aop:349	Event:1837	KeyEvent	decreased oocyte maturation
Aop:349	Event:360	AdverseOutcome	Decrease, Population growth rate
Aop:349	Event:406	KeyEvent	decreased, Fertility
Aop:351	Event:2211	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:351	Event:2212	KeyEvent	Acetylcholine accumulation in synapses
Aop:351	Event:2213	KeyEvent	Increased Cholinergic Signaling
Aop:351	Event:2214	KeyEvent	Decrease of neuronal network function
Aop:351	Event:2215	AdverseOutcome	Cognitive function, decreased
Aop:352	Event:2216	MolecularInitiatingEvent	Binding to ACE2
Aop:352	Event:2217	KeyEvent	SARS-CoV-2 cell entry
Aop:352	Event:2218	KeyEvent	Increased SARS-CoV-2 production
Aop:352	Event:2219	KeyEvent	Diminished protective oxidative stress response
Aop:352	Event:2220	KeyEvent	NLRP3 inflammasome activity, increased
Aop:352	Event:2221	AdverseOutcome	Hyperinflammation
Aop:353	Event:2222	MolecularInitiatingEvent	Binding to ACE2
Aop:353	Event:2223	KeyEvent	SARS-CoV-2 cell entry
Aop:353	Event:2224	KeyEvent	Increased SARS-CoV-2 production
Aop:353	Event:2225	KeyEvent	Diminished protective oxidative stress response
Aop:353	Event:2226	KeyEvent	NLRP3 inflammasome activity, increased
Aop:353	Event:2227	AdverseOutcome	Pyroptosis
Aop:355	Event:2228	MolecularInitiatingEvent	Frustrated phagocytosis
Aop:355	Event:2229	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:355	Event:2230	KeyEvent	Increased, recruitment of inflammatory cells
Aop:355	Event:2231	KeyEvent	Increase, Reactive oxygen species
Aop:355	Event:2232	KeyEvent	Increased, DNA damage and mutation
Aop:355	Event:2233	KeyEvent	Genomic instability
Aop:355	Event:2234	KeyEvent	Increase, Cell Proliferation
Aop:355	Event:2235	AdverseOutcome	Increased, mesotheliomas
Aop:356	Event:2236	MolecularInitiatingEvent	GSK3beta inactivation
Aop:356	Event:2237	KeyEvent	Repression of Gbx2 expression
Aop:356	Event:2238	KeyEvent	foxi1 expression, increased
Aop:356	Event:2239	KeyEvent	six1b expression, increased
Aop:356	Event:2240	KeyEvent	eya1 expression, inhibited
Aop:356	Event:2241	KeyEvent	Increase, Cell death
Aop:356	Event:2242	KeyEvent	altered, inner ear development
Aop:356	Event:2243	KeyEvent	Reduced, Hearing
Aop:356	Event:2244	AdverseOutcome	Increased Mortality
Aop:356	Event:2245	AdverseOutcome	Decrease, Population growth rate
Aop:357	Event:2246	MolecularInitiatingEvent	Oxidative Stress
Aop:357	Event:2247	KeyEvent	Cilia Beat Frequency, Decreased
Aop:357	Event:2248	KeyEvent	Mucociliary Clearance, Decreased
Aop:357	Event:2249	AdverseOutcome	Decrease, Lung function
Aop:358	Event:2250	KeyEvent	Endothelial cell dysfunction
Aop:358	Event:2251	KeyEvent	Release, Cytokine
Aop:358	Event:2252	KeyEvent	Platelet activation, Increased
Aop:358	Event:2253	KeyEvent	Neutrophil activation, Increased
Aop:358	Event:2254	KeyEvent	Platelet-neutrophil interactions, Increased
Aop:358	Event:2255	AdverseOutcome	Thromboinflammation, Increased
Aop:359	Event:2256	MolecularInitiatingEvent	Oxidation, Glutathione (To be considered with MIE)
Aop:359	Event:2257	KeyEvent	Increase, Reactive oxygen species
Aop:359	Event:2258	KeyEvent	Increase, Lipid peroxidation
Aop:359	Event:2259	KeyEvent	Increase, Necrosis
Aop:359	Event:2260	KeyEvent	Increased, Kidney Failure
Aop:359	Event:2261	AdverseOutcome	Increased Mortality
Aop:360	Event:2262	MolecularInitiatingEvent	Activation, AhR
Aop:360	Event:2263	KeyEvent	Altered gene expression, TGF-β dependent fibrosis pathway
Aop:360	Event:2264	KeyEvent	Epithelial Mesenchymal Transition
Aop:360	Event:2265	KeyEvent	Increased, extracellular matrix deposition
Aop:360	Event:2266	KeyEvent	Lung fibrosis
Aop:361	Event:2267	MolecularInitiatingEvent	Activation, AhR
Aop:361	Event:2268	KeyEvent	Altered gene expression, NF-kB dependent Interleukin-6 pathway
Aop:361	Event:2269	KeyEvent	Epithelial Mesenchymal Transition
Aop:361	Event:2270	KeyEvent	Increased, extracellular matrix deposition
Aop:361	Event:2271	AdverseOutcome	Lung fibrosis
Aop:362	Event:2272	MolecularInitiatingEvent	Activation, AhR
Aop:362	Event:2273	KeyEvent	Altered gene expression, NF-kB dependent Interleukin-6 pathway
Aop:362	Event:2274	KeyEvent	Increased, Interleukin-6 production
Aop:362	Event:2275	KeyEvent	Increase, Reactive oxygen species
Aop:362	Event:2276	KeyEvent	Increased, DNA damage and mutation
Aop:362	Event:2277	AdverseOutcome	Lung cancer
Aop:363	Event:2278	MolecularInitiatingEvent	Activation, AhR
Aop:363	Event:2279	KeyEvent	Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway
Aop:363	Event:2280	KeyEvent	Increased, Reactive metabolites production
Aop:363	Event:2281	KeyEvent	Increased, DNA damage and mutation
Aop:363	Event:2282	AdverseOutcome	Lung cancer
Aop:364	Event:2283	KeyEvent	Activation, AhR
Aop:364	Event:2284	KeyEvent	Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway
Aop:364	Event:2285	KeyEvent	Increase, Reactive oxygen species
Aop:364	Event:2286	KeyEvent	Increase, Cell death
Aop:364	Event:2287	KeyEvent	Decrease, Lung function
Aop:365	Event:2288	KeyEvent	Activation, AhR
Aop:365	Event:2289	KeyEvent	Altered gene expression, P53 dependent apoptosis pathway
Aop:365	Event:2290	KeyEvent	Apoptosis
Aop:365	Event:2291	AdverseOutcome	Decrease, Lung function
Aop:366	Event:2292	MolecularInitiatingEvent	Activation, AhR
Aop:366	Event:2293	KeyEvent	Altered gene expression, NRF2 dependent antioxidant pathway
Aop:366	Event:2294	KeyEvent	Increase, Cell Proliferation
Aop:366	Event:2295	KeyEvent	Lung cancer
Aop:367	Event:2296	KeyEvent	Altered gene expression, NRF2 dependent antioxidant pathway
Aop:368	Event:2297	MolecularInitiatingEvent	Binding to ACE2
Aop:368	Event:2298	KeyEvent	SARS-CoV-2 cell entry
Aop:368	Event:2299	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:368	Event:2300	KeyEvent	Increased SARS-CoV-2 production
Aop:368	Event:2301	KeyEvent	Intestinal barrier, disruption
Aop:369	Event:2302	MolecularInitiatingEvent	Activation, PARP1
Aop:369	Event:2303	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:369	Event:2304	KeyEvent	Releasing, Apoptosis-Inducing Factor (AIF)
Aop:369	Event:2305	KeyEvent	Mitochondrial dysfunction
Aop:369	Event:2306	KeyEvent	Increase, DNA damage
Aop:369	Event:2307	AdverseOutcome	Apoptotic cell death
Aop:370	Event:2308	MolecularInitiatingEvent	Oxidative Stress
Aop:370	Event:2309	KeyEvent	Cystic Fibrosis Transmembrane Regulator Function, Decreased
Aop:370	Event:2310	KeyEvent	Airway Surface Liquid Height, Decreased
Aop:370	Event:2311	KeyEvent	Cilia Beat Frequency, Decreased
Aop:370	Event:2312	KeyEvent	Mucociliary Clearance, Decreased
Aop:370	Event:2313	AdverseOutcome	Decrease, Lung function
Aop:371	Event:2314	MolecularInitiatingEvent	Oxidative Stress
Aop:371	Event:2315	KeyEvent	FOXJ1 Protein, Decreased
Aop:371	Event:2316	KeyEvent	Motile Cilia Number/Length, Decreased
Aop:371	Event:2317	KeyEvent	Cilia Beat Frequency, Decreased
Aop:371	Event:2318	KeyEvent	Mucociliary Clearance, Decreased
Aop:371	Event:2319	AdverseOutcome	Decrease, Lung function
Aop:372	Event:2320	MolecularInitiatingEvent	Binding to ACE2
Aop:372	Event:2321	KeyEvent	Heart failure
Aop:372	Event:2322	KeyEvent	SARS-CoV-2 cell entry
Aop:372	Event:2323	KeyEvent	Increased inflammatory immune responses
Aop:372	Event:2324	KeyEvent	Endothelial cell dysfunction
Aop:372	Event:2325	KeyEvent	Induced, dysfunction of microcirculation
Aop:372	Event:2326	KeyEvent	Impaired mechanotransduction of pericytes
Aop:372	Event:2327	KeyEvent	Pericyte dysfunction
Aop:372	Event:2328	KeyEvent	Increased ACE2 expression
Aop:372	Event:2329	AdverseOutcome	Myocardial Infarction
Aop:373	Event:2330	MolecularInitiatingEvent	Binding to ACE2
Aop:373	Event:2331	KeyEvent	Downregulation, ACE2
Aop:373	Event:2332	KeyEvent	Angiotensin (1-7) levels diminished
Aop:373	Event:2333	KeyEvent	Angiotensin II degradation reduced
Aop:373	Event:2334	KeyEvent	Induced, Angiotensin (Ang) II accumulation
Aop:373	Event:2335	KeyEvent	Hyperactivation of ACE/Ang-II/AT1R axis
Aop:373	Event:2336	KeyEvent	ADAM17 expression induction
Aop:373	Event:2337	KeyEvent	ACE2 increased shedding
Aop:373	Event:2338	AdverseOutcome	Heart failure
Aop:374	Event:2339	MolecularInitiatingEvent	Binding to ACE2
Aop:374	Event:2340	KeyEvent	Dysregulation, ACE2 expression and activity
Aop:374	Event:2341	KeyEvent	Gut microbiota, alteration
Aop:375	Event:2342	KeyEvent	Mitochondrial dysfunction EMPTY
Aop:375	Event:2343	KeyEvent	Oxidative Stress
Aop:375	Event:2344	KeyEvent	Hyperphosphorylation of Tau
Aop:375	Event:2345	KeyEvent	Dysfunctional Autophagy
Aop:375	Event:2346	KeyEvent	Accumulation, Cytosolic toxic Tau oligomers
Aop:375	Event:2347	KeyEvent	Synaptic dysfunction
Aop:375	Event:2348	KeyEvent	Impaired axonial transport
Aop:375	Event:2349	KeyEvent	Neuroinflammation
Aop:375	Event:2350	KeyEvent	Decrease of neuronal network function
Aop:375	Event:2351	AdverseOutcome	Memory Loss
Aop:376	Event:2352	MolecularInitiatingEvent	Binding to ACE2
Aop:376	Event:2353	KeyEvent	SARS-CoV-2 cell entry
Aop:376	Event:2354	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:376	Event:2355	KeyEvent	Increased SARS-CoV-2 production
Aop:376	Event:2356	AdverseOutcome	Viral infection and host-to-host transmission, proliferated
Aop:377	Event:2357	MolecularInitiatingEvent	Increase, TNF
Aop:377	Event:2358	KeyEvent	Decrease, GLUT4
Aop:377	Event:2359	KeyEvent	Decrease, Glucose uptake
Aop:377	Event:2360	KeyEvent	Abnormal, Glucose homeostasis
Aop:377	Event:2361	AdverseOutcome	Gestational diabetes mellitus
Aop:378	Event:2362	MolecularInitiatingEvent	Deposition of Energy
Aop:378	Event:2363	KeyEvent	Increase in reactive oxygen and nitrogen species (RONS)
Aop:378	Event:2364	KeyEvent	Increase, DNA damage
Aop:378	Event:2365	KeyEvent	Inadequate DNA repair
Aop:378	Event:2366	KeyEvent	Increase, Mutations in Critical Genes
Aop:378	Event:2367	KeyEvent	Increase, Cell Proliferation
Aop:378	Event:2368	KeyEvent	Increased Pro-inflammatory mediators
Aop:378	Event:2369	KeyEvent	Suppression, Immune system
Aop:378	Event:2370	AdverseOutcome	Acute Myeloid Leukemia
Aop:379	Event:2371	MolecularInitiatingEvent	hERG channel blockade
Aop:379	Event:2372	KeyEvent	Inhibition of rapid delayed rectifying potassium current
Aop:379	Event:2373	KeyEvent	Prolongation of Action Potential Duration
Aop:379	Event:2374	KeyEvent	Prolongation of QT interval
Aop:379	Event:2375	KeyEvent	Torsades de Pointes
Aop:379	Event:2376	AdverseOutcome	Sudden cardiac death
Aop:381	Event:2377	MolecularInitiatingEvent	Deposition of Energy
Aop:381	Event:2378	KeyEvent	Increase, DNA damage
Aop:381	Event:2379	KeyEvent	Altered, Meiotic chromosome dynamics
Aop:381	Event:2380	KeyEvent	Increase, Pollen abnormal
Aop:381	Event:2381	AdverseOutcome	Decrease, Reproduction
Aop:381	Event:2382	AdverseOutcome	Decreased, Population trajectory
Aop:382	Event:2383	MolecularInitiatingEvent	Decreased, ALDH1A (RALDH) enzyme activity
Aop:382	Event:2384	KeyEvent	Decreased, all-trans retinoic acid (atRA) concentration
Aop:382	Event:2385	KeyEvent	Disruption, Progenitor cells of second heart field
Aop:382	Event:2386	KeyEvent	Neural crest cell migration, reduced
Aop:382	Event:2387	AdverseOutcome	transposition of the great arteries
Aop:383	Event:2388	MolecularInitiatingEvent	Inhibition, Mitochondrial Electron Transport Chain Complexes
Aop:383	Event:2389	KeyEvent	Oxidative Stress
Aop:383	Event:2390	KeyEvent	Mitochondrial dysfunction
Aop:383	Event:2391	KeyEvent	Increase, Cytotoxicity (renal tubular cell)
Aop:383	Event:2392	AdverseOutcome	Occurrence, Kidney toxicity
Aop:384	Event:1853	MolecularInitiatingEvent	Hyperactivation of ACE/Ang-II/AT1R axis
Aop:384	Event:1752	KeyEvent	Increased Angiotensin II 
Aop:384	Event:1603	AdverseOutcome	Chronic kidney disease
Aop:384	Event:1852	KeyEvent	Increased Ang II type 1 receptor (AT1R)
Aop:384	Event:1855	KeyEvent	Increased Sodium-sensitive hypertension
Aop:384	Event:1115	KeyEvent	Increase, Reactive oxygen species
Aop:385	Event:2393	MolecularInitiatingEvent	Activation, AhR
Aop:385	Event:2394	KeyEvent	Increase, Inflammation
Aop:385	Event:2395	KeyEvent	Apoptosis
Aop:385	Event:2396	KeyEvent	Increased, Motility
Aop:385	Event:2397	KeyEvent	Increased, Migration (Endothelial Cells)
Aop:385	Event:2398	KeyEvent	Increased, Invasion
Aop:385	Event:2399	KeyEvent	Increase, angiogenesis
Aop:385	Event:2400	KeyEvent	Increased, tumor growth
Aop:385	Event:2401	AdverseOutcome	metastatic breast cancer
Aop:386	Event:2402	MolecularInitiatingEvent	Suppression, Estrogen receptor (ER) activity
Aop:386	Event:2403	KeyEvent	Increased, secretion of GnRH from hypothalamus
Aop:386	Event:2404	KeyEvent	Increased, secretion of LH from anterior pituitary
Aop:386	Event:2405	KeyEvent	Increased, Steroidogenic acute regulatory protein (StAR)
Aop:386	Event:2406	KeyEvent	Increased, estrogens
Aop:386	Event:2407	KeyEvent	Increased, circulating estrogen levels
Aop:386	Event:2408	KeyEvent	Hyperplasia, ovarian epithelium
Aop:386	Event:2409	AdverseOutcome	Promotion, ovarian adenomas
Aop:386	Event:2410	AdverseOutcome	Promotion, Ovarian Cancer
Aop:387	Event:2411	MolecularInitiatingEvent	Deposition of Energy
Aop:387	Event:2412	KeyEvent	Increase, DNA damage
Aop:387	Event:2413	KeyEvent	Activation of Tumor Protein 53
Aop:387	Event:2414	KeyEvent	Premature cell differentiation
Aop:387	Event:2415	KeyEvent	Apoptosis
Aop:387	Event:2416	KeyEvent	decline, neural progenitor cells
Aop:387	Event:2417	AdverseOutcome	Increase risk, microcephaly
Aop:388	Event:2418	MolecularInitiatingEvent	Binding to voltage-gated sodium channel
Aop:388	Event:2419	KeyEvent	Disruption of sodium channel gating kinetics
Aop:388	Event:2420	KeyEvent	Disruption, action potential generation
Aop:388	Event:2421	KeyEvent	Altered neurotransmission in development
Aop:388	Event:2422	KeyEvent	Hippocampal anatomy, Altered
Aop:388	Event:2423	KeyEvent	Hippocampal Physiology, Altered
Aop:388	Event:2424	AdverseOutcome	Cognitive function, decreased
Aop:389	Event:2425	MolecularInitiatingEvent	Increased, DNA damage and mutation
Aop:389	Event:2426	KeyEvent	Inadequate DNA repair
Aop:389	Event:2427	KeyEvent	Increase, Mutations
Aop:389	Event:2428	KeyEvent	Increase Chromosomal Aberrations
Aop:389	Event:2429	KeyEvent	Increased microRNA expression
Aop:389	Event:2430	KeyEvent	Decreased SIRT1 expression
Aop:389	Event:2431	KeyEvent	Increased activation, Nuclear factor kappa B (NF-kB)
Aop:389	Event:2432	KeyEvent	Antagonism, Estrogen receptor
Aop:389	Event:2433	KeyEvent	Epithelial Mesenchymal Transition
Aop:389	Event:2434	AdverseOutcome	metastatic breast cancer
Aop:390	Event:2435	MolecularInitiatingEvent	Deposition of Energy
Aop:390	Event:2436	MolecularInitiatingEvent	Increase in reactive oxygen and nitrogen species (RONS)
Aop:390	Event:2437	MolecularInitiatingEvent	Increase, DNA damage
Aop:390	Event:2438	KeyEvent	Oxidative Stress
Aop:390	Event:2439	KeyEvent	Increase, Apoptosis
Aop:390	Event:2440	KeyEvent	Decreased spermatogenesis
Aop:390	Event:2441	KeyEvent	Decrease, Fecundity
Aop:390	Event:2442	KeyEvent	Decrease, Reproduction
Aop:390	Event:2443	AdverseOutcome	Decrease, Population growth rate
Aop:391	Event:2444	MolecularInitiatingEvent	Activation, estrogen receptor alpha
Aop:391	Event:2445	KeyEvent	Increased, Kisspeptin signalling
Aop:391	Event:2446	KeyEvent	Decreased, Gonadotropins
Aop:391	Event:2447	KeyEvent	Decreased, Androgen and Progestin
Aop:391	Event:2448	KeyEvent	Decreased, Maturation Inducing Steroid Surge by Granulosa cells
Aop:391	Event:2449	KeyEvent	Impaired, Oocyte maturation and ovulation
Aop:391	Event:2450	KeyEvent	Increased, Oocyte Atresia
Aop:391	Event:2451	AdverseOutcome	Impaired, Reproduction
Aop:392	Event:1866	MolecularInitiatingEvent	Fibrinolysis, decreased
Aop:392	Event:1867	MolecularInitiatingEvent	Bradykinin system, hyperactivated
Aop:392	Event:1496	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:392	Event:1497	KeyEvent	Increased, recruitment of inflammatory cells
Aop:392	Event:1868	AdverseOutcome	Hyperinflammation
Aop:393	Event:2452	KeyEvent	Inhibition, Mitochondrial Electron Transport Chain Complexes
Aop:393	Event:2453	KeyEvent	Decrease, Mitochondrial membrane potential
Aop:393	Event:2454	KeyEvent	Mitochondrial dysfunction
Aop:393	Event:2455	KeyEvent	Altered gene expression, NRF2 dependent antioxidant pathway
Aop:393	Event:2456	KeyEvent	Inhibition, Nuclear factor kappa B (NF-kB)
Aop:393	Event:2457	KeyEvent	Activation of ER stress
Aop:393	Event:2458	KeyEvent	Oxidative Stress
Aop:393	Event:2459	KeyEvent	Increase, Apoptosis
Aop:393	Event:2460	KeyEvent	Increase in inflammation
Aop:393	Event:2461	KeyEvent	Occurrence, renal proximal tubular necrosis
Aop:393	Event:2462	KeyEvent	Occurrence, Kidney toxicity
Aop:393	Event:2463	AdverseOutcome	Increased, Kidney Failure
Aop:394	Event:1739	MolecularInitiatingEvent	Binding to ACE2
Aop:394	Event:1738	KeyEvent	SARS-CoV-2 cell entry 
Aop:394	Event:1870	KeyEvent	Sustentacular cells, decrease 
Aop:394	Event:1871	KeyEvent	olfactory sensory neurons, decrease 
Aop:394	Event:1872	KeyEvent	Olfactory epithelium degeneration
Aop:394	Event:1873	AdverseOutcome	impaired olfactory function (anosmia) 
Aop:394	Event:1847	KeyEvent	Increased SARS-CoV-2 production
Aop:395	Event:2464	MolecularInitiatingEvent	Inhibition of Ceramide Synthase
Aop:395	Event:2465	KeyEvent	Reduced complex sphingolipids
Aop:395	Event:2466	KeyEvent	Affected folate transporter
Aop:395	Event:2467	KeyEvent	decreased folate uptake
Aop:395	Event:2468	KeyEvent	Increased sphingolipid-1-phosphate
Aop:395	Event:2469	KeyEvent	Histone deacetylase inhibition
Aop:395	Event:2470	AdverseOutcome	Neural tube defects
Aop:396	Event:2471	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:396	Event:2472	KeyEvent	Activation of Cyp2E1
Aop:396	Event:2473	KeyEvent	Oxidative Stress
Aop:396	Event:2474	KeyEvent	N/A, Neurodegeneration
Aop:396	Event:2475	KeyEvent	Decreased, Neuronal network function in adult brain
Aop:396	Event:2476	AdverseOutcome	Sensory axonal peripheral neuropathy
Aop:396	Event:2477	AdverseOutcome	Increased Mortality
Aop:397	Event:2478	MolecularInitiatingEvent	Substance interaction with the lung resident cell membrane components
Aop:397	Event:2479	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:397	Event:2480	KeyEvent	Increased, recruitment of inflammatory cells
Aop:397	Event:2481	KeyEvent	Increase, Cytotoxicity (epithelial cells)
Aop:397	Event:2482	KeyEvent	Increase, Reactive oxygen species
Aop:397	Event:2483	KeyEvent	Secondary genotoxicity
Aop:397	Event:2484	KeyEvent	Increased, DNA damage and mutation
Aop:397	Event:2485	KeyEvent	Increase, Cell Proliferation
Aop:397	Event:2486	AdverseOutcome	Lung cancer
Aop:398	Event:2487	MolecularInitiatingEvent	Non-coding RNA expression profile alteration
Aop:398	Event:2488	KeyEvent	Activation of inflammation pathway
Aop:398	Event:2489	KeyEvent	Oxidative Stress
Aop:398	Event:2490	KeyEvent	Epithelial Mesenchymal Transition
Aop:398	Event:2491	KeyEvent	Fibroblast proliferation and differentiation
Aop:398	Event:2492	KeyEvent	Apoptosis
Aop:398	Event:2493	KeyEvent	Dysfunctional Autophagy
Aop:398	Event:2494	KeyEvent	Pulmonary inflammation
Aop:398	Event:2495	KeyEvent	Emphysema
Aop:398	Event:2496	KeyEvent	Airway remodeling
Aop:398	Event:2497	AdverseOutcome	Chronic obstructive pulmonary disease
Aop:399	Event:1884	MolecularInitiatingEvent	Inhibition of Fyna
Aop:399	Event:1885	KeyEvent	Inhibition of Plxna2
Aop:399	Event:1886	KeyEvent	Overexpression of rasl11b
Aop:399	Event:1821	KeyEvent	Decrease, Cell proliferation
Aop:399	Event:1878	KeyEvent	Decreased, Eye size
Aop:399	Event:351	AdverseOutcome	Increased Mortality
Aop:399	Event:360	AdverseOutcome	Decrease, Population growth rate
Aop:399	Event:1643	KeyEvent	Altered, Visual function
Aop:400	Event:2498	KeyEvent	Endoplasmic reticulum stress
Aop:400	Event:2499	KeyEvent	Insulin resistance, increased
Aop:400	Event:2500	KeyEvent	Non-alcoholic fatty liver disease
Aop:400	Event:2501	KeyEvent	Inhibition, Fatty acid oxidation
Aop:401	Event:2502	MolecularInitiatingEvent	Activation, AhR
Aop:401	Event:2503	KeyEvent	dimerization, AHR/ARNT
Aop:401	Event:2504	KeyEvent	Increase, slincR expression
Aop:401	Event:2505	KeyEvent	Decrease, sox9 expression
Aop:401	Event:2506	AdverseOutcome	Increase, Early Life Stage Mortality
Aop:401	Event:2507	AdverseOutcome	Facial cartilage structures are reduced in size and morphologically distorted
Aop:402	Event:2508	MolecularInitiatingEvent	Activation, AhR
Aop:402	Event:2509	KeyEvent	dimerization, AHR/ARNT
Aop:402	Event:2510	KeyEvent	Increase, slincR expression
Aop:402	Event:2511	KeyEvent	Decrease, sox9 expression
Aop:402	Event:2512	KeyEvent	Altered, Cardiovascular development/function
Aop:402	Event:2513	AdverseOutcome	Increase, Early Life Stage Mortality
Aop:403	Event:2514	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:403	Event:2515	KeyEvent	Superoxide generation, increased
Aop:403	Event:2516	KeyEvent	Oxidative Stress
Aop:403	Event:2517	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:403	Event:2518	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:403	Event:2519	AdverseOutcome	Insulin resistance, increased
Aop:404	Event:2520	MolecularInitiatingEvent	Activation, AhR
Aop:404	Event:2521	KeyEvent	Induction, Upregulation of glucuronyltransferase activity
Aop:404	Event:2522	KeyEvent	Increased, Clearance of thyroxine from serum
Aop:404	Event:2523	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:404	Event:2524	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:404	Event:2525	KeyEvent	Hippocampal gene expression, Altered
Aop:404	Event:2526	KeyEvent	Hippocampal Physiology, Altered
Aop:404	Event:2527	AdverseOutcome	Cognitive function, decreased
Aop:405	Event:2528	MolecularInitiatingEvent	Activation, AhR
Aop:405	Event:2529	KeyEvent	Induction, CYP1A2/CYP1A5
Aop:405	Event:2530	KeyEvent	Oxidative Stress
Aop:405	Event:2531	KeyEvent	Thyroid hormone synthesis, Decreased
Aop:405	Event:2532	KeyEvent	Thyroxine (T4) in serum, Decreased
Aop:405	Event:2533	KeyEvent	Thyroxine (T4) in neuronal tissue, Decreased
Aop:405	Event:2534	KeyEvent	Hippocampal gene expression, Altered
Aop:405	Event:2535	KeyEvent	Hippocampal Physiology, Altered
Aop:405	Event:2536	AdverseOutcome	Cognitive function, decreased
Aop:406	Event:2537	MolecularInitiatingEvent	Antagonism, Smoothened receptor
Aop:406	Event:2538	KeyEvent	Decrease, Smoothend relocation and activation
Aop:406	Event:2539	KeyEvent	Decrease, GLI1/2 translocation to nucleus
Aop:406	Event:2540	KeyEvent	Decrease, GLI1/2 target gene expression
Aop:406	Event:2541	KeyEvent	Apoptosis
Aop:406	Event:2542	KeyEvent	Decrease, Sonic Hedgehog second messenger production
Aop:406	Event:2543	KeyEvent	Decrease, Cell proliferation
Aop:406	Event:2544	KeyEvent	Decrease, facial prominence outgrowth
Aop:406	Event:2545	AdverseOutcome	Increase, Orofacial clefting
Aop:407	Event:1739	MolecularInitiatingEvent	Binding to ACE2
Aop:407	Event:1738	KeyEvent	SARS-CoV-2 cell entry 
Aop:407	Event:1847	KeyEvent	Increased SARS-CoV-2 production
Aop:407	Event:1869	KeyEvent	Diminished protective oxidative stress response
Aop:407	Event:1895	KeyEvent	NLRP3 inflammasome activity, increased
Aop:407	Event:1967	AdverseOutcome	Pyroptosis
Aop:408	Event:2546	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:408	Event:2547	KeyEvent	Oxidative Stress
Aop:408	Event:2548	KeyEvent	Increase, Endothelial Dysfunction
Aop:408	Event:2549	KeyEvent	Infiltration, Inflammatory cells
Aop:408	Event:2550	KeyEvent	Activation, Macrophages
Aop:408	Event:2551	KeyEvent	Increased, LDL uptake
Aop:408	Event:2552	KeyEvent	Foam cell formation
Aop:409	Event:2553	KeyEvent	liver dysfunction
Aop:410	Event:2554	MolecularInitiatingEvent	Activation of metabotropic glutamate receptor
Aop:410	Event:2555	MolecularInitiatingEvent	Inositol triphosphate receptor activation
Aop:410	Event:2556	MolecularInitiatingEvent	Overactivation, NMDARs
Aop:410	Event:2557	MolecularInitiatingEvent	Inhibition GABAA receptor
Aop:410	Event:2558	MolecularInitiatingEvent	Opening, voltage-gated calcium channels
Aop:410	Event:2559	KeyEvent	Increase, Cell membrane depolarization
Aop:410	Event:2560	KeyEvent	Increased, Intracellular Calcium overload
Aop:410	Event:2561	KeyEvent	Activation of calpain signalling
Aop:410	Event:2562	KeyEvent	Endoplasmic reticulum stress
Aop:410	Event:2563	KeyEvent	Unfolded Protein Response
Aop:410	Event:2564	KeyEvent	Mitochondrial dysfunction
Aop:410	Event:2565	KeyEvent	Proteasomal dysfunction
Aop:410	Event:2566	KeyEvent	Accumulation of misfolded proteins
Aop:410	Event:2567	KeyEvent	Oxidative Stress
Aop:410	Event:2568	KeyEvent	Mitochondrial Injury
Aop:410	Event:2569	KeyEvent	Increase, Cytochrome c release
Aop:410	Event:2570	KeyEvent	Activation, caspases
Aop:410	Event:2571	KeyEvent	Increase, Cell death
Aop:410	Event:2572	AdverseOutcome	Parkinsonian motor deficits
Aop:411	Event:2573	MolecularInitiatingEvent	Increase, Alcohol dehydrogenase
Aop:411	Event:2574	KeyEvent	Increased, Estrogen receptor (ER) activity
Aop:411	Event:2575	KeyEvent	Increase, Vitellogenin mRNA
Aop:411	Event:2576	KeyEvent	Delay, Ovarian maturation
Aop:411	Event:2577	KeyEvent	Increase, Body volume of female adults
Aop:411	Event:2578	KeyEvent	Increase, sex ratio (F/M)
Aop:411	Event:2579	KeyEvent	Increase, developmental abnormalities
Aop:411	Event:2580	KeyEvent	Increase, Mortality
Aop:412	Event:2581	MolecularInitiatingEvent	Decrease, Tyrosine
Aop:412	Event:2582	KeyEvent	Decrease, dopa decarboxylase
Aop:412	Event:2583	KeyEvent	Increase, Defects in tanning of new cuticle
Aop:412	Event:2584	KeyEvent	Increase, impairment of cuticle sclerotization
Aop:412	Event:2585	KeyEvent	Increase, pigmentation
Aop:412	Event:2586	KeyEvent	Increase, Incomplete ecdysis
Aop:412	Event:2587	KeyEvent	Increase, delay in oviposition
Aop:412	Event:2588	KeyEvent	Increase, Mortality
Aop:412	Event:2589	KeyEvent	Decrease, hatching of egg
Aop:413	Event:2590	MolecularInitiatingEvent	Decrease, 20-hydroxyecdysone
Aop:413	Event:2591	KeyEvent	Decrease, knickkopf gene
Aop:413	Event:2592	KeyEvent	Decrease, Chitin laminar organization
Aop:413	Event:2593	KeyEvent	Decrease, Prevent chitin degradation by chitinases
Aop:413	Event:2594	KeyEvent	Weak, Procuticle protection
Aop:413	Event:2595	KeyEvent	Decrease, New cuticle secretion
Aop:413	Event:2596	KeyEvent	Increase, Incomplete ecdysis
Aop:413	Event:2597	KeyEvent	Increase, developmental abnormalities
Aop:413	Event:2598	KeyEvent	Increase, Mortality
Aop:414	Event:2599	MolecularInitiatingEvent	Binding to ACE2
Aop:414	Event:2600	KeyEvent	SARS-CoV-2 cell entry
Aop:414	Event:2601	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:414	Event:2602	KeyEvent	Increased SARS-CoV-2 production
Aop:414	Event:2603	KeyEvent	Increase, Cell death
Aop:414	Event:2604	KeyEvent	Increased, secretion of proinflammatory mediators
Aop:414	Event:2605	KeyEvent	Increased, recruitment of inflammatory cells
Aop:414	Event:2606	AdverseOutcome	Hyperinflammation
Aop:415	Event:18	MolecularInitiatingEvent	Activation, AhR
Aop:415	Event:1921	KeyEvent	Altered gene expression, NF-kB dependent Interleukin-6 pathway
Aop:415	Event:1457	KeyEvent	Epithelial Mesenchymal Transition
Aop:415	Event:1501	KeyEvent	Increased, extracellular matrix deposition
Aop:415	Event:1276	AdverseOutcome	Lung fibrosis
Aop:416	Event:2607	MolecularInitiatingEvent	Deposition of Energy
Aop:416	Event:2608	KeyEvent	Oxidative Stress
Aop:416	Event:2609	KeyEvent	Increase, DNA strand breaks
Aop:416	Event:2610	KeyEvent	Increased Pro-inflammatory mediators
Aop:416	Event:2611	KeyEvent	Altered Stress Response Signaling
Aop:416	Event:2612	KeyEvent	Altered, Nitric Oxide Levels
Aop:416	Event:2613	KeyEvent	Increase, Endothelial Dysfunction
Aop:416	Event:2614	AdverseOutcome	Occurrence, Abnormal Vascular Remodeling
Aop:417	Event:2615	MolecularInitiatingEvent	Increase, CNS Neural cell death
Aop:417	Event:2616	KeyEvent	N/A, Neurodegeneration
Aop:417	Event:2617	KeyEvent	Loss of drebrin
Aop:417	Event:2618	KeyEvent	Neurological disorder
Aop:417	Event:2619	KeyEvent	Decrease, elavl3
Aop:417	Event:2620	KeyEvent	Decrease, sox10
Aop:417	Event:2621	KeyEvent	Decrease, mbp
Aop:417	Event:2622	KeyEvent	Neuroinflammation
Aop:417	Event:2623	KeyEvent	Oxidative Stress
Aop:417	Event:2624	KeyEvent	Decreased, Neuronal network function in adult brain
Aop:417	Event:2625	KeyEvent	Acetylcholine accumulation in synapses
Aop:417	Event:2626	KeyEvent	Acetylcholinesterase (AchE) Inhibition
Aop:417	Event:2627	KeyEvent	Impaired axonial transport
Aop:417	Event:2628	KeyEvent	Sensory axonal peripheral neuropathy
Aop:417	Event:2629	KeyEvent	Overactivation, NMDARs
Aop:417	Event:2630	KeyEvent	Neuronal dysfunction
Aop:417	Event:2631	KeyEvent	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:417	Event:2632	KeyEvent	Synaptic dysfunction
Aop:417	Event:2633	KeyEvent	Disruption, neurotransmitter release
Aop:417	Event:2634	KeyEvent	Activation, Glutamate-gated chloride channels
Aop:417	Event:2635	KeyEvent	Activated, presynaptic neuron 1
Aop:417	Event:2636	KeyEvent	Decreased, Ionotropic GABA receptor chloride channel conductance
Aop:417	Event:2637	KeyEvent	Increased, Inhibitory postsynaptic potential
Aop:417	Event:2638	KeyEvent	Induction, Somatic muscle paralysis
Aop:417	Event:2639	KeyEvent	Increased, Neuronal synaptic inhibition
Aop:417	Event:2640	AdverseOutcome	impaired, Learning and memory
Aop:417	Event:2641	AdverseOutcome	Encephalitis
Aop:417	Event:2642	AdverseOutcome	Parkinsonian motor deficits
Aop:417	Event:2643	AdverseOutcome	Increase, seizure
Aop:417	Event:2644	AdverseOutcome	Increased, epilepsy
Aop:417	Event:2645	AdverseOutcome	Increase, Mortality
Aop:417	Event:2646	AdverseOutcome	Inhibition, Feeding
Aop:418	Event:18	KeyEvent	Activation, AhR
Aop:418	Event:17	KeyEvent	Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway
Aop:418	Event:1115	KeyEvent	Increase, Reactive oxygen species
Aop:418	Event:1825	KeyEvent	Increase, Cell death
Aop:418	Event:1250	KeyEvent	Decrease, Lung function
Aop:419	Event:2647	MolecularInitiatingEvent	Deposition of Energy
Aop:419	Event:2648	KeyEvent	Increase in reactive oxygen and nitrogen species (RONS)
Aop:419	Event:2649	KeyEvent	increase oxidation of the di-copper moiety of the hemocyanin active site
Aop:419	Event:2650	KeyEvent	Decreased, oxygen binding capacity by hemocyanin
Aop:419	Event:2651	KeyEvent	Cognitive, sensed as hypoxic/low oxygen environment
Aop:419	Event:2652	KeyEvent	Increase, hemocyanin mRNA
Aop:419	Event:2653	KeyEvent	Increase, pulmonate breathing
Aop:419	Event:2654	AdverseOutcome	Decrease, Growth
Aop:419	Event:2655	AdverseOutcome	Decreased, Reproductive Success
Aop:420	Event:2656	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:420	Event:2657	KeyEvent	Succinate Accumulation
Aop:420	Event:2658	KeyEvent	Increase, DNA methyltransferase inhibition
Aop:420	Event:2659	KeyEvent	Epithelial Mesenchymal Transition
Aop:420	Event:2660	AdverseOutcome	Increase, Cancer
Aop:421	Event:2661	MolecularInitiatingEvent	Binding of agonist, Ionotropic glutamate receptors
Aop:421	Event:2662	KeyEvent	Overactivation, NMDARs
Aop:421	Event:2663	KeyEvent	Increased, Intracellular Calcium overload
Aop:421	Event:2664	KeyEvent	Loss of drebrin
Aop:421	Event:2665	KeyEvent	Abnormality, dendritic spine morphology
Aop:421	Event:2666	KeyEvent	Synaptic dysfunction
Aop:421	Event:2667	KeyEvent	Decrease of neuronal network function
Aop:421	Event:2668	AdverseOutcome	Impairment, Learning and memory
Aop:422	Event:2669	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:422	Event:2670	MolecularInitiatingEvent	Disruption, Estrogen receptor
Aop:422	Event:2671	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:422	Event:2672	KeyEvent	Oxidative Stress
Aop:422	Event:2673	KeyEvent	Increase, DNA damage
Aop:422	Event:2674	KeyEvent	Mitochondrial dysfunction
Aop:422	Event:2675	KeyEvent	Increased, glycolipid levels
Aop:422	Event:2676	KeyEvent	Apoptosis
Aop:422	Event:2677	KeyEvent	Depletion, Ectoplasmic specialization (ES)
Aop:422	Event:2678	KeyEvent	Impaired, blood testis barrier
Aop:422	Event:2679	KeyEvent	Increased apoptosis, decreased fetal/adult Leydig Cells
Aop:422	Event:2680	KeyEvent	Reduction, fetal/adult testosterone
Aop:422	Event:2681	AdverseOutcome	Decreased sperm quantity or quality in the adult, Decreased fertility
Aop:422	Event:2682	AdverseOutcome	anogenital distance (AGD), decreased
Aop:422	Event:2683	AdverseOutcome	Malformation, cryptorchidism - maldescended testis
Aop:422	Event:2684	AdverseOutcome	Decrease, Reproduction
Aop:423	Event:2685	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:423	Event:2686	KeyEvent	Decrease, androgen receptor activation
Aop:423	Event:2687	AdverseOutcome	Hypospadias, increased
Aop:424	Event:2688	MolecularInitiatingEvent	Deposition of Energy
Aop:424	Event:2689	KeyEvent	Increased Modified Proteins
Aop:424	Event:2690	KeyEvent	Increase, Oxidative DNA damage
Aop:424	Event:2691	KeyEvent	Increase, DNA strand breaks
Aop:424	Event:2692	KeyEvent	Inadequate DNA repair
Aop:424	Event:2693	KeyEvent	Increase, Mutations
Aop:424	Event:2694	KeyEvent	Increase, Chromosomal aberrations
Aop:424	Event:2695	KeyEvent	Increase, Cell Proliferation
Aop:424	Event:2696	KeyEvent	Oxidative Stress
Aop:424	Event:2697	AdverseOutcome	Occurrence of Cataracts
Aop:425	Event:2698	MolecularInitiatingEvent	Inhibition, Mitochondrial Electron Transport Chain Complexes
Aop:425	Event:2699	KeyEvent	Mitochondrial dysfunction
Aop:425	Event:2700	KeyEvent	Oxidative Stress
Aop:425	Event:2701	KeyEvent	Increase, Cell injury/death
Aop:425	Event:2702	KeyEvent	Increase, Cardiac remodelling
Aop:425	Event:2703	KeyEvent	Decrease, Cardiac contractility
Aop:425	Event:2704	AdverseOutcome	Decrease Left Ventricular function
Aop:426	Event:2705	MolecularInitiatingEvent	Inhibition, Mitochondrial Electron Transport Chain Complexes
Aop:426	Event:2706	KeyEvent	Mitochondrial dysfunction
Aop:426	Event:2707	KeyEvent	Decrease, Mitochondrial ATP production
Aop:426	Event:2708	KeyEvent	Decrease, Cardiac contractility
Aop:426	Event:2709	AdverseOutcome	Decrease Left Ventricular function
Aop:427	Event:2710	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:427	Event:2711	KeyEvent	Oxidative Stress
Aop:427	Event:2712	KeyEvent	Mitochondrial dysfunction
Aop:427	Event:2713	KeyEvent	Airway epithelial injury
Aop:427	Event:2714	KeyEvent	Activation, Macrophages
Aop:427	Event:2715	KeyEvent	Pulmonary epithelial injury
Aop:427	Event:2716	KeyEvent	Activation, Fibroblasts
Aop:427	Event:2717	KeyEvent	Airway inflammation
Aop:427	Event:2718	KeyEvent	Pulmonary inflammation
Aop:427	Event:2719	KeyEvent	Pulmonary fibrosis
Aop:427	Event:2720	AdverseOutcome	Increased incidence of respiratory disease
Aop:427	Event:2721	AdverseOutcome	Dysfunction of respiratory system
Aop:428	Event:2722	MolecularInitiatingEvent	Deposition of Energy
Aop:428	Event:2723	KeyEvent	Oxidative Stress
Aop:428	Event:2724	KeyEvent	Altered Cell Differentiation Signaling
Aop:428	Event:2725	KeyEvent	Increase, Cell death
Aop:428	Event:2726	KeyEvent	Altered Bone Cell Homeostasis
Aop:428	Event:2727	KeyEvent	Increase, Bone Remodeling
Aop:428	Event:2728	AdverseOutcome	Occurrence, Bone Loss
Aop:429	Event:2729	MolecularInitiatingEvent	Deposition of Energy
Aop:429	Event:2730	KeyEvent	Oxidative Stress
Aop:429	Event:2731	KeyEvent	Altered Stress Response Signaling
Aop:429	Event:2732	KeyEvent	Tissue resident cell activation
Aop:429	Event:2733	KeyEvent	Increase, Pro-Inflammatory Mediators
Aop:429	Event:2734	KeyEvent	Increase, Abnormal Neural Remodeling
Aop:429	Event:2735	KeyEvent	Increase, DNA strand breaks
Aop:429	Event:2736	AdverseOutcome	Impairment, Learning and memory
Aop:430	Event:1739	MolecularInitiatingEvent	Binding to ACE2
Aop:430	Event:1738	KeyEvent	SARS-CoV-2 cell entry 
Aop:430	Event:1901	KeyEvent	Interferon-I antiviral response, antagonized by SARS-CoV-2
Aop:430	Event:1847	KeyEvent	Increased SARS-CoV-2 production
Aop:430	Event:1939	AdverseOutcome	Viral infection and host-to-host transmission, proliferated
Aop:431	Event:2737	MolecularInitiatingEvent	Antagonism, Thyroid Receptor
Aop:431	Event:2738	KeyEvent	Decreased, thyroid hormone binding to thyroid hormone receptor
Aop:431	Event:2739	KeyEvent	Decreased, myelin basic protein expression in oligodendrocytes
Aop:431	Event:2740	KeyEvent	Impaired, oligodendrocyte maturation
Aop:431	Event:2741	KeyEvent	Hypomyelination
Aop:431	Event:2742	KeyEvent	Altered, white brain matter
Aop:431	Event:2743	AdverseOutcome	Cognitive function, decreased
Aop:432	Event:2744	MolecularInitiatingEvent	Binding, extracellular matrix protein laminin
Aop:432	Event:2745	KeyEvent	Disrupted binding, laminin-beta1-integrin receptors with laminin
Aop:432	Event:2746	KeyEvent	Decreased, neural progenitor cell adhesion to laminin
Aop:432	Event:2747	KeyEvent	Disturbed, radial glia cell alignment and migration
Aop:432	Event:2748	KeyEvent	Decreased, radial glia cell density
Aop:432	Event:2749	KeyEvent	Disturbed, cortical architecture
Aop:432	Event:2750	AdverseOutcome	Cognitive function, decreased
Aop:433	Event:2751	MolecularInitiatingEvent	Unknown, MIE
Aop:433	Event:2752	KeyEvent	Altered, cholesterol metabolism
Aop:433	Event:2753	KeyEvent	Decreased, oligodendrocyte differentiation
Aop:433	Event:2754	KeyEvent	Hypomyelination
Aop:433	Event:2755	KeyEvent	Altered, white brain matter
Aop:433	Event:2756	AdverseOutcome	Cognitive function, decreased
Aop:434	Event:2757	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:434	Event:2758	KeyEvent	Oxidative Stress
Aop:434	Event:2759	KeyEvent	Diminished protective oxidative stress response
Aop:434	Event:2760	KeyEvent	Decreased, oligodendrocyte differentiation
Aop:434	Event:2761	KeyEvent	Hypomyelination
Aop:434	Event:2762	KeyEvent	Altered, white brain matter
Aop:434	Event:2763	AdverseOutcome	Cognitive function, decreased
Aop:435	Event:2764	MolecularInitiatingEvent	Binding to voltage-gated sodium channel
Aop:435	Event:2765	KeyEvent	Disruption of sodium channel gating kinetics
Aop:435	Event:2766	KeyEvent	Decreased, oligodendrocyte differentiation
Aop:435	Event:2767	KeyEvent	Hypomyelination
Aop:435	Event:2768	KeyEvent	Altered, white brain matter
Aop:435	Event:2769	AdverseOutcome	Cognitive function, decreased
Aop:436	Event:2770	MolecularInitiatingEvent	Ryanodine receptor activation
Aop:436	Event:2771	MolecularInitiatingEvent	Inositol triphosphate receptor activation
Aop:436	Event:2772	KeyEvent	Increased, glutamate
Aop:436	Event:2773	KeyEvent	decreased, Bcl-2 expression
Aop:436	Event:2774	KeyEvent	increased, Bax expression
Aop:436	Event:2775	KeyEvent	Activation, Microglia
Aop:436	Event:2776	KeyEvent	Neuroinflammation
Aop:436	Event:2777	KeyEvent	Increase, Cell injury/death
Aop:436	Event:2778	KeyEvent	Hippocampal Physiology, Altered
Aop:436	Event:2779	AdverseOutcome	Impairment, Learning and memory
Aop:436	Event:2780	AdverseOutcome	decreased, Intellectual Quotient
Aop:436	Event:2781	AdverseOutcome	increased, socio-economic burden
Aop:437	Event:2782	MolecularInitiatingEvent	Decrease, GLI1/2 target gene expression
Aop:437	Event:2783	KeyEvent	Decrease, Sonic Hedgehog second messenger production
Aop:437	Event:2784	KeyEvent	Decrease, Cell proliferation
Aop:437	Event:2785	KeyEvent	Decrease, facial prominence outgrowth
Aop:437	Event:2786	KeyEvent	Apoptosis
Aop:437	Event:2787	AdverseOutcome	Increase, Orofacial clefting
Aop:438	Event:2788	MolecularInitiatingEvent	Conjugation, GSH
Aop:438	Event:2789	KeyEvent	Depletion, GSH
Aop:438	Event:2790	KeyEvent	Increase, Reactive oxygen species
Aop:438	Event:2791	KeyEvent	Increase, Lipid peroxidation
Aop:438	Event:2792	AdverseOutcome	decreased, Fertility
Aop:439	Event:2793	MolecularInitiatingEvent	Estrogen receptor alpha inactivation
Aop:439	Event:2794	KeyEvent	Increased, recruitment of inflammatory cells
Aop:439	Event:2795	KeyEvent	Insulin resistance, increased
Aop:439	Event:2796	KeyEvent	Increased adipocyte size
Aop:439	Event:2797	KeyEvent	Increased adipocyte numbers
Aop:439	Event:2798	KeyEvent	Increased fat mass
Aop:439	Event:2799	KeyEvent	increased lipid accumulation
Aop:439	Event:2800	KeyEvent	Increased pro-inflammatory cytokine expression
Aop:439	Event:2801	KeyEvent	Increase in inflammation
Aop:439	Event:2802	AdverseOutcome	Metabolically unhealthy Obesity
Aop:440	Event:2803	MolecularInitiatingEvent	Activation, AhR
Aop:440	Event:2804	KeyEvent	Increased, Liver Steatosis
Aop:440	Event:2805	KeyEvent	Increase, Cell injury/death
Aop:440	Event:2806	KeyEvent	Activation, Stellate cells
Aop:440	Event:2807	KeyEvent	Increased, extracellular matrix deposition
Aop:440	Event:2808	AdverseOutcome	N/A, Liver fibrosis
Aop:441	Event:2809	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:441	Event:2810	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:441	Event:2811	KeyEvent	Increase, Androgen receptor protein expression/abundance
Aop:441	Event:2812	KeyEvent	Decreased, Apoptosis (Epithelial Cells)
Aop:441	Event:2813	KeyEvent	Inflamatory events in light-exposed tissues
Aop:441	Event:2814	KeyEvent	Alterations, Cellular proliferation / hyperplasia
Aop:441	Event:2815	KeyEvent	Increased, Invasion
Aop:441	Event:2816	KeyEvent	prostatic intraepithelial neoplasia
Aop:441	Event:2817	AdverseOutcome	Prostate cancer
Aop:442	Event:2818	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:442	Event:2819	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:442	Event:2820	KeyEvent	Increase, Gonadotropins concentration in plasma
Aop:442	Event:2821	KeyEvent	Decrease, circulating testosterone levels
Aop:442	Event:2822	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:442	Event:2823	KeyEvent	Reduction, the ratio of 17beta-estradiol/11-Keto Testosterone in plasma
Aop:442	Event:2824	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:442	Event:2825	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:442	Event:2826	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:442	Event:2827	AdverseOutcome	Decreased, Population trajectory
Aop:443	Event:2828	MolecularInitiatingEvent	Estrogen receptor alpha inactivation
Aop:443	Event:2829	KeyEvent	Decrease, Fatty acid beta-oxidation
Aop:443	Event:2830	KeyEvent	Increase, Reactive oxygen species
Aop:443	Event:2831	KeyEvent	Mitochondrial dysfunction
Aop:443	Event:2832	KeyEvent	Oxidative Stress
Aop:443	Event:2833	KeyEvent	Impaired insulin signaling
Aop:443	Event:2834	AdverseOutcome	Insulin resistance, increased
Aop:443	Event:2835	AdverseOutcome	Metabolic syndrome
Aop:444	Event:2836	MolecularInitiatingEvent	Increased LCN2/iron complex binds to SLC22A17 receptor in neuron
Aop:444	Event:2837	KeyEvent	Increased intracelluar Iron accumulation
Aop:444	Event:2838	KeyEvent	Neuronal dysfunction
Aop:444	Event:2839	AdverseOutcome	Neurological disorder
Aop:445	Event:2840	MolecularInitiatingEvent	Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2
Aop:445	Event:2841	KeyEvent	Increase, intracellular calcium
Aop:445	Event:2842	KeyEvent	Disruption, neurotransmitter release
Aop:445	Event:2843	AdverseOutcome	Impairment, Learning and memory
Aop:446	Event:2844	MolecularInitiatingEvent	Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2
Aop:446	Event:2845	KeyEvent	Increase, intracellular calcium
Aop:446	Event:2846	KeyEvent	Mitochondrial dysfunction
Aop:446	Event:2847	KeyEvent	Increase, Reactive oxygen species
Aop:446	Event:2848	KeyEvent	Apoptosis
Aop:446	Event:2849	KeyEvent	N/A, Neurodegeneration
Aop:446	Event:2850	AdverseOutcome	Impairment, Learning and memory
Aop:447	Event:2851	MolecularInitiatingEvent	Increased intracelluar Iron accumulation
Aop:447	Event:2852	KeyEvent	Oxidative Stress
Aop:447	Event:2853	KeyEvent	Decrease of neuronal network function
Aop:447	Event:2854	AdverseOutcome	Neurological disorder
Aop:448	Event:2855	KeyEvent	Decrease, facial prominence outgrowth
Aop:448	Event:2856	KeyEvent	Decrease, Cell proliferation
Aop:448	Event:2857	KeyEvent	Decrease, Sonic Hedgehog second messenger production
Aop:448	Event:2858	KeyEvent	Apoptosis
Aop:448	Event:2859	KeyEvent	Decrease, GLI1/2 target gene expression
Aop:448	Event:2860	KeyEvent	Decrease, GLI1/2 translocation to nucleus
Aop:448	Event:2861	AdverseOutcome	Increase, Orofacial clefting
Aop:449	Event:2862	MolecularInitiatingEvent	Activation, estrogen receptor alpha
Aop:449	Event:2863	KeyEvent	Epigenetic modification process
Aop:449	Event:2864	KeyEvent	Expression of factors ruling proliferation, modified
Aop:449	Event:2865	KeyEvent	Increase, Hyperplasia (glandular epithelial cells of endometrium)
Aop:449	Event:2866	KeyEvent	Genomic instability
Aop:449	Event:2867	AdverseOutcome	Uterine adenocarcinoma (endometrioid adenocarcinoma Type I)
Aop:450	Event:2868	MolecularInitiatingEvent	Inhibition of Sulfotransferase E1 (SULT1E1)
Aop:450	Event:2869	KeyEvent	Estradiol availability, increased
Aop:450	Event:2870	AdverseOutcome	Activation, estrogen receptor alpha
Aop:451	Event:2871	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:451	Event:2872	KeyEvent	Oxidative Stress
Aop:451	Event:2873	KeyEvent	Increase, Inflammation
Aop:451	Event:2874	KeyEvent	General Apoptosis
Aop:451	Event:2875	AdverseOutcome	Increase, Cancer
Aop:452	Event:2876	MolecularInitiatingEvent	Influenza A Virus (IAV) binds sialic acid glycan receptor
Aop:452	Event:2877	KeyEvent	Influenza A virus (IAV) cell entry
Aop:452	Event:2878	KeyEvent	Influenza A Virus production increased
Aop:452	Event:2879	KeyEvent	Immune mechanisms antagonized by viral proteins
Aop:452	Event:2880	KeyEvent	Influenza A Virus (IAV) budding
Aop:452	Event:2881	AdverseOutcome	Influenza A Virus (IAV) shedding and transmission
Aop:453	Event:2882	MolecularInitiatingEvent	NFE2/Nrf2 repression
Aop:453	Event:2883	KeyEvent	Oxidative Stress
Aop:453	Event:2884	KeyEvent	Activation of inflammation pathway
Aop:453	Event:2885	KeyEvent	increased，Vascular endothelial dysfunction
Aop:453	Event:2886	KeyEvent	Angiogenesis dysfunction
Aop:453	Event:2887	AdverseOutcome	Increase, Vascular disrupting effects
Aop:454	Event:2888	MolecularInitiatingEvent	NFE2/Nrf2 repression
Aop:454	Event:2889	KeyEvent	Activation, HIF1α
Aop:454	Event:2890	KeyEvent	Activation Sema6A
Aop:454	Event:2891	KeyEvent	Activation, Dll4-Notch pathway
Aop:454	Event:2892	KeyEvent	increased，Vascular endothelial dysfunction
Aop:454	Event:2893	KeyEvent	Angiogenesis dysfunction
Aop:454	Event:2894	AdverseOutcome	Increase, Vascular disrupting effects
Aop:455	Event:2895	MolecularInitiatingEvent	NFE2/Nrf2 repression
Aop:455	Event:2896	KeyEvent	Oxidative Stress
Aop:455	Event:2897	KeyEvent	Increase, Apoptosis
Aop:455	Event:2898	KeyEvent	Mitochondrial dysfunction
Aop:455	Event:2899	KeyEvent	increased，Vascular endothelial dysfunction
Aop:455	Event:2900	KeyEvent	Angiogenesis dysfunction
Aop:455	Event:2901	AdverseOutcome	Increase, Vascular disrupting effects
Aop:456	Event:2902	MolecularInitiatingEvent	peroxisome proliferator activated receptor promoter demethylation
Aop:456	Event:2903	KeyEvent	Activation of PPAR
Aop:456	Event:2904	KeyEvent	Oxidative Stress
Aop:456	Event:2905	KeyEvent	Abnormal expression of NO
Aop:456	Event:2906	KeyEvent	Activation of MMP-2 MMP-9
Aop:456	Event:2907	KeyEvent	Activation of angiopoietin like protein 4
Aop:456	Event:2908	KeyEvent	Activation of Angiogenic cytokines
Aop:456	Event:2909	KeyEvent	increased，Vascular endothelial dysfunction
Aop:456	Event:2910	KeyEvent	Angiogenesis dysfunction
Aop:456	Event:2911	AdverseOutcome	Increase, Vascular disrupting effects
Aop:457	Event:2912	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:457	Event:2913	KeyEvent	Oxidative Stress
Aop:457	Event:2914	KeyEvent	Activation of inflammation pathway
Aop:457	Event:2915	KeyEvent	Activated ANG/Tie2 pathway
Aop:457	Event:2916	KeyEvent	Activation, Dll4-Notch pathway
Aop:457	Event:2917	KeyEvent	Activated BMP/TGF-beta pathway
Aop:457	Event:2918	KeyEvent	Activated Wnt/Frizzled pathway
Aop:457	Event:2919	KeyEvent	KE4 : Uncoupling, eNOS
Aop:457	Event:2920	KeyEvent	Activated AKT/ERK/PI3K pathway
Aop:457	Event:2921	KeyEvent	Inhibition VEGF/VEGFR pathway
Aop:457	Event:2922	KeyEvent	Mitochondrial dysfunction
Aop:457	Event:2923	KeyEvent	Vascular barrier disruption
Aop:457	Event:2924	KeyEvent	Impaired Platelet Aggregation
Aop:457	Event:2925	KeyEvent	increased，Vascular endothelial dysfunction
Aop:457	Event:2926	KeyEvent	Angiogenesis dysfunction
Aop:457	Event:2927	AdverseOutcome	Increase, Vascular disrupting effects
Aop:458	Event:2928	KeyEvent	Decreased, LH Surge
Aop:459	Event:2929	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:459	Event:2930	KeyEvent	Decreased, PPAR-gamma activation
Aop:459	Event:2931	KeyEvent	Alteration, lipid metabolism
Aop:459	Event:2932	KeyEvent	General Apoptosis
Aop:459	Event:2933	AdverseOutcome	Increase, Cancer
Aop:460	Event:2027	MolecularInitiatingEvent	Antagonism, Smoothened receptor
Aop:460	Event:2028	KeyEvent	Decrease, GLI1/2 translocation to nucleus 
Aop:460	Event:2040	KeyEvent	Decrease, GLI1/2 target gene expression
Aop:460	Event:1821	KeyEvent	Decrease, Cell proliferation
Aop:460	Event:2041	KeyEvent	Decrease, facial prominence outgrowth
Aop:460	Event:2042	AdverseOutcome	Increase, Orofacial clefting
Aop:460	Event:2043	KeyEvent	Decrease, Sonic Hedgehog second messenger production
Aop:460	Event:2044	KeyEvent	Decrease, Smoothend relocation and activation 
Aop:460	Event:1262	KeyEvent	Apoptosis
Aop:462	Event:2934	MolecularInitiatingEvent	Decreased Na/K ATPase activity
Aop:462	Event:2935	AdverseOutcome	Hypertension
Aop:463	Event:2936	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:463	Event:2937	KeyEvent	Up Regulation, CD36
Aop:463	Event:2938	KeyEvent	Increase, FA Influx
Aop:463	Event:2939	KeyEvent	Accumulation, Triglyceride
Aop:463	Event:2940	AdverseOutcome	Increased, Liver Steatosis
Aop:464	Event:2941	MolecularInitiatingEvent	Activation, LXR
Aop:464	Event:2942	KeyEvent	Increased, Expression of LXR activated genes
Aop:464	Event:2943	KeyEvent	Synthesis, De Novo Fatty Acid (FA)
Aop:464	Event:2944	KeyEvent	Accumulation, Triglyceride
Aop:464	Event:2945	AdverseOutcome	Increased, Liver Steatosis
Aop:465	Event:2946	MolecularInitiatingEvent	Cardiac ion channels blockade
Aop:465	Event:2947	KeyEvent	Prolongation of Action Potential Duration
Aop:465	Event:2948	KeyEvent	Increased the early premature depolarizations during repolarization
Aop:465	Event:2949	AdverseOutcome	Increased incidence of cardiovascular morbidity and mortality in the general population
Aop:466	Event:2950	MolecularInitiatingEvent	Agonism, Retinoic acid receptor
Aop:466	Event:2951	KeyEvent	Altered expression of cell cycle genes
Aop:466	Event:2952	KeyEvent	Decreased proliferation of cortical neural progenitor cells
Aop:466	Event:2953	KeyEvent	Altered brain morphology
Aop:466	Event:2954	AdverseOutcome	Impairment, Learning and memory
Aop:467	Event:2955	MolecularInitiatingEvent	Increased, essential element imbalance
Aop:467	Event:2956	KeyEvent	Increase, Reactive oxygen species
Aop:467	Event:2957	KeyEvent	Oxidative Stress
Aop:467	Event:2958	KeyEvent	Increase, Lipid peroxidation
Aop:467	Event:2959	KeyEvent	Increased, histomorphological alteration of testis
Aop:467	Event:2960	KeyEvent	Impaired, Spermatogenesis
Aop:467	Event:2961	AdverseOutcome	Decreased, Viable Offspring
Aop:468	Event:2962	MolecularInitiatingEvent	Antagonism, Estrogen receptor
Aop:468	Event:2963	KeyEvent	inhibition, EKR1/2 signaling pathway
Aop:468	Event:2964	KeyEvent	Inhibition, NMDARs
Aop:468	Event:2965	KeyEvent	Aberrant, synaptic formation and plasticity
Aop:468	Event:2966	KeyEvent	Decrease of neuronal network function
Aop:468	Event:2967	AdverseOutcome	autism-like behavior
Aop:469	Event:2968	MolecularInitiatingEvent	Agonism, Retinoic acid receptor
Aop:469	Event:2969	KeyEvent	Altered expression of cell cycle genes
Aop:469	Event:2970	KeyEvent	Decreased proliferation of cortical neural progenitor cells
Aop:469	Event:2971	KeyEvent	Reduced cortical thickness
Aop:469	Event:2972	AdverseOutcome	Increase risk, microcephaly
Aop:470	Event:2973	MolecularInitiatingEvent	Human leukocyte antigen DQ2/8-gluten complexes, formation
Aop:470	Event:2974	MolecularInitiatingEvent	Gluten-reactive T cell receptors, generation
Aop:470	Event:2975	MolecularInitiatingEvent	Gluten-reactive and transglutaminase 2 reactive B cell receptors, generation
Aop:470	Event:2976	KeyEvent	Gluten reactive adaptive T-cells with antigen presenting cells, co-localization
Aop:470	Event:2977	KeyEvent	Innate immune response, activation
Aop:470	Event:2978	KeyEvent	Gluten-reactive CD4+ T cells, activation
Aop:470	Event:2979	KeyEvent	Gluten-reactive B cells and transglutaminase 2-reactive B cells, activation
Aop:470	Event:2980	KeyEvent	Intestinal barrier, disruption
Aop:470	Event:2981	AdverseOutcome	Celiac disease
Aop:471	Event:2982	MolecularInitiatingEvent	Binding of antagonist to thyroid hormone receptor
Aop:471	Event:2983	MolecularInitiatingEvent	Binding of antagonist to glucocorticoid hormone receptor
Aop:471	Event:2984	MolecularInitiatingEvent	Binding of (ant)agonist to liver X receptor
Aop:471	Event:2985	MolecularInitiatingEvent	Binding of (ant)agonist to peroxisome proliferator–activated receptor alpha
Aop:471	Event:2986	KeyEvent	Antagonism, Thyroid Receptor
Aop:471	Event:2987	KeyEvent	Antagonism, Glucocorticoid hormone receptor
Aop:471	Event:2988	KeyEvent	Altered Liver X receptor activity
Aop:471	Event:2989	KeyEvent	Altered peroxisome proliferator–activated receptor alpha activity
Aop:471	Event:2990	KeyEvent	Altered, cholesterol metabolism
Aop:471	Event:2991	KeyEvent	Reduced number of oligodendrocytes
Aop:471	Event:2992	KeyEvent	Hypomyelination
Aop:471	Event:2993	KeyEvent	Altered, white brain matter
Aop:471	Event:2994	AdverseOutcome	Impairment, Learning and memory
Aop:472	Event:2995	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:472	Event:2996	KeyEvent	Decreased, steroidogenic protein expression
Aop:472	Event:2997	KeyEvent	Decrease, circulating testosterone levels
Aop:472	Event:2998	KeyEvent	Epididymal agenesis
Aop:472	Event:2999	AdverseOutcome	Impaired, Spermatogenesis
Aop:473	Event:3000	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:473	Event:3001	KeyEvent	Decreased, steroidogenic protein expression
Aop:473	Event:3002	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:473	Event:3003	KeyEvent	Impaired, urethral tube closure
Aop:473	Event:3004	AdverseOutcome	Hypospadias, increased
Aop:474	Event:3005	KeyEvent	Decreased, Insulin-like peptide 3 (INSL3)
Aop:474	Event:3006	KeyEvent	Impaired inguinoscrotal testicular descent phase
Aop:474	Event:3007	AdverseOutcome	Malformation, cryptorchidism - maldescended testis
Aop:475	Event:3008	MolecularInitiatingEvent	Stressor binding PPAR isoforms
Aop:475	Event:3009	KeyEvent	Disrupted PPAR isoform nuclear signaling
Aop:475	Event:3010	KeyEvent	Dysregulation of transcriptional expression within PPAR signaling network
Aop:475	Event:3011	KeyEvent	Decrease, Fatty acid beta-oxidation
Aop:475	Event:3012	KeyEvent	Disrupted Lipid Storage
Aop:475	Event:3013	KeyEvent	Accumulation, Fatty acid
Aop:475	Event:3014	KeyEvent	Accumulation, Triglyceride
Aop:475	Event:3015	AdverseOutcome	Increased, Liver Steatosis
Aop:476	Event:3016	MolecularInitiatingEvent	Endocytotic lysosomal uptake
Aop:476	Event:3017	KeyEvent	Disruption, Lysosome
Aop:476	Event:3018	KeyEvent	Mitochondrial dysfunction
Aop:476	Event:3019	KeyEvent	Increase, Cell injury/death
Aop:476	Event:3020	AdverseOutcome	Intestinal barrier, disruption
Aop:477	Event:2082	AdverseOutcome	Hypospadias, increased
Aop:477	Event:26	MolecularInitiatingEvent	Antagonism, Androgen receptor
Aop:477	Event:1614	KeyEvent	Decrease, androgen receptor activation
Aop:478	Event:3021	MolecularInitiatingEvent	Agonism, Retinoic acid receptor
Aop:478	Event:3022	KeyEvent	Cerebellar gene expression. Altered
Aop:478	Event:3023	KeyEvent	Cerebellar neuronal differentiation. Decreased
Aop:478	Event:3024	KeyEvent	Cerebellar hypoplasia
Aop:478	Event:3025	AdverseOutcome	Locomotor function. Impaired
Aop:479	Event:3026	MolecularInitiatingEvent	Antagonism, Retinoic acid receptors
Aop:479	Event:3027	KeyEvent	Altered, Gene Expression
Aop:479	Event:3028	KeyEvent	Decrease of GABAergic interneurons
Aop:479	Event:3029	KeyEvent	Decrease of synaptogenesis
Aop:479	Event:3030	KeyEvent	Decrease of neuronal network function
Aop:479	Event:3031	AdverseOutcome	Impairment, Learning and memory
Aop:480	Event:3032	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:480	Event:3033	KeyEvent	Decrease, Coupling of oxidative phosphorylation
Aop:480	Event:3034	KeyEvent	Increase, Reactive oxygen species
Aop:480	Event:3035	KeyEvent	Oxidative Stress
Aop:480	Event:3036	KeyEvent	Increase mutations
Aop:480	Event:3037	AdverseOutcome	Increase, Cancer
Aop:481	Event:3038	MolecularInitiatingEvent	protein-coupled estrogen receptor 1 (GPER) activation
Aop:481	Event:3039	KeyEvent	Increased, Intracellular Calcium overload
Aop:481	Event:3040	KeyEvent	Decreased, ERαβ heterodimers
Aop:481	Event:3041	KeyEvent	Oxidative Stress
Aop:481	Event:3042	KeyEvent	Apoptosis
Aop:481	Event:3043	KeyEvent	Aberrant, synaptic formation and plasticity
Aop:481	Event:3044	KeyEvent	Disruption, neurotransmitter release
Aop:481	Event:3045	KeyEvent	Neuroinflammation
Aop:481	Event:3046	AdverseOutcome	Impairment, Learning and memory
Aop:482	Event:3047	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:482	Event:3048	KeyEvent	Increase, Vitellogenin synthesis in liver
Aop:482	Event:3049	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:482	Event:3050	KeyEvent	Increase, Renal pathology due to VTG deposition
Aop:482	Event:3051	KeyEvent	Increased Mortality
Aop:482	Event:3052	KeyEvent	Decrease, Population growth rate
Aop:483	Event:3053	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:483	Event:3054	KeyEvent	Increase, Vitellogenin synthesis in liver
Aop:483	Event:3055	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:483	Event:3056	KeyEvent	Impaired development of, Reproductive organs
Aop:483	Event:3057	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:484	Event:3058	KeyEvent	Oxidative Stress
Aop:484	Event:3059	KeyEvent	The NO synthase pathway activation
Aop:484	Event:3060	KeyEvent	increased，Vascular endothelial dysfunction
Aop:484	Event:3061	KeyEvent	Ferroptosis related pathways activation
Aop:484	Event:3062	AdverseOutcome	Increase, Vascular disrupting effects
Aop:485	Event:3063	MolecularInitiatingEvent	Decreased Na/K ATPase activity
Aop:485	Event:3064	KeyEvent	Decreased, Sodium uptake in gills
Aop:485	Event:3065	KeyEvent	Decreased, Plasma sodium concentrations
Aop:485	Event:3066	KeyEvent	Decreased, blood plasma volume
Aop:485	Event:3067	KeyEvent	Increased, Blood viscosity
Aop:485	Event:3068	KeyEvent	Increased, Cardiac stress
Aop:485	Event:3069	AdverseOutcome	Heart failure
Aop:486	Event:3070	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:486	Event:3071	KeyEvent	Oxidative Stress
Aop:486	Event:3072	KeyEvent	Apoptosis
Aop:486	Event:3073	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:486	Event:3074	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:486	Event:3075	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:486	Event:3076	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:486	Event:3077	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:486	Event:3078	AdverseOutcome	Decrease, Population growth rate
Aop:487	Event:1114	MolecularInitiatingEvent	Unknown, MIE
Aop:487	Event:2115	KeyEvent	Altered, cholesterol metabolism
Aop:487	Event:2116	KeyEvent	Decreased, oligodendrocyte differentiation
Aop:487	Event:2107	KeyEvent	Hypomyelination
Aop:487	Event:2108	KeyEvent	Altered, white brain matter
Aop:487	Event:402	AdverseOutcome	Cognitive function, decreased 
Aop:488	Event:3079	MolecularInitiatingEvent	Neuropathy target esterase, inhibited
Aop:488	Event:3080	KeyEvent	Lysolecithin, increased
Aop:488	Event:3081	KeyEvent	Lysolecithin cell membrane integration, increased
Aop:488	Event:3082	KeyEvent	Oligodendrocyte death, increased
Aop:488	Event:3083	KeyEvent	Demyelination, increased
Aop:488	Event:3084	AdverseOutcome	Delayed neuropathy, increased
Aop:489	Event:3085	MolecularInitiatingEvent	Neuropathy target esterase, inhibited
Aop:489	Event:3086	KeyEvent	Lysolecithin, increased
Aop:489	Event:3087	KeyEvent	Increase, Inflammation
Aop:489	Event:3088	KeyEvent	Oligodendrocyte death, increased
Aop:489	Event:3089	KeyEvent	Demyelination, increased
Aop:489	Event:3090	AdverseOutcome	Delayed neuropathy, increased
Aop:490	Event:3091	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:490	Event:3092	KeyEvent	Decreased, insulin-induced gene 1 (INSIG1) protein activity
Aop:490	Event:3093	KeyEvent	Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression
Aop:490	Event:3094	KeyEvent	Increased, cholesterol synthesis enzymes
Aop:490	Event:3095	AdverseOutcome	Increased, plasma low-density lipoprotein (LDL) cholesterol
Aop:491	Event:3096	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:491	Event:3097	KeyEvent	Succinate Accumulation
Aop:491	Event:3098	KeyEvent	Inhibition, Prolyl hydroxylases
Aop:491	Event:3099	KeyEvent	N/A, hypoxia
Aop:491	Event:3100	AdverseOutcome	Increase, Cancer
Aop:492	Event:3101	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:492	Event:3102	KeyEvent	Androgen receptor activation, increased
Aop:492	Event:3103	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:493	Event:3104	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:493	Event:3105	KeyEvent	Decreased, insulin-induced gene 1 (INSIG1) protein activity
Aop:493	Event:3106	KeyEvent	Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression
Aop:493	Event:3107	KeyEvent	Increased, protein expression of proprotein convertase subtilisin/kexin type 9 (PCSK9)
Aop:493	Event:3108	AdverseOutcome	Increased, plasma low-density lipoprotein (LDL) cholesterol
Aop:494	Event:3109	MolecularInitiatingEvent	Inhibition, Aromatase
Aop:494	Event:3110	KeyEvent	Inhibition, aromatase activity in plasma
Aop:494	Event:3111	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:494	Event:3112	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:494	Event:3113	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:494	Event:3114	AdverseOutcome	Growth, reduction
Aop:494	Event:3115	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:494	Event:3116	AdverseOutcome	Decreased, Population trajectory
Aop:495	Event:3117	MolecularInitiatingEvent	Increased LMNA Mutation
Aop:495	Event:3118	KeyEvent	Structural changes in lamin A/C
Aop:495	Event:3119	KeyEvent	Altered Signaling Pathways
Aop:495	Event:3120	KeyEvent	Increased，Cardiac fibrosis
Aop:495	Event:3121	AdverseOutcome	Heart failure
Aop:496	Event:3122	MolecularInitiatingEvent	Increased Muscarinic Acetylcholine Receptors
Aop:496	Event:3123	KeyEvent	Increased, blood potassium concentration
Aop:496	Event:3124	KeyEvent	Disruption, action potential generation
Aop:496	Event:3125	KeyEvent	Increased delay in heart electrical conduction
Aop:496	Event:3126	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:497	Event:3127	MolecularInitiatingEvent	Blockade, L-Type Calcium Channels
Aop:497	Event:3128	KeyEvent	Altered, Action Potential
Aop:497	Event:3129	KeyEvent	Prolongation of QT interval
Aop:497	Event:3130	KeyEvent	Torsades de Pointes
Aop:497	Event:3131	KeyEvent	Increased uncoordinated cardiac contraction
Aop:497	Event:3132	AdverseOutcome	Heart failure
Aop:498	Event:3133	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:498	Event:3134	KeyEvent	Altered, Action Potential
Aop:498	Event:3135	KeyEvent	Decrease, Cardiac contractility
Aop:498	Event:3136	AdverseOutcome	Heart failure
Aop:499	Event:3137	MolecularInitiatingEvent	Activation, beta-2 adrenergic receptor
Aop:499	Event:3138	KeyEvent	Increased Intracellular cAMP Levels
Aop:499	Event:3139	KeyEvent	Increased the delayed and early afterdepolarizations
Aop:499	Event:3140	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:500	Event:3141	MolecularInitiatingEvent	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel
Aop:500	Event:3142	KeyEvent	Prolongation of Action Potential Duration
Aop:500	Event:3143	KeyEvent	Prolongation of QT interval
Aop:500	Event:3144	KeyEvent	Increased the early premature depolarizations during repolarization
Aop:500	Event:3145	AdverseOutcome	Heart failure
Aop:501	Event:3146	MolecularInitiatingEvent	Decreased Na/K ATPase activity
Aop:501	Event:3147	KeyEvent	Increased, intracellular sodium (Na+)
Aop:501	Event:3148	KeyEvent	Impaired Sodium-Calcium Exchange
Aop:501	Event:3149	KeyEvent	Increased, Intracellular Calcium overload
Aop:501	Event:3150	KeyEvent	Decrease, Cardiac contractility
Aop:501	Event:3151	AdverseOutcome	Heart failure
Aop:502	Event:3152	MolecularInitiatingEvent	Increased activity, beta-2 adrenergic receptor
Aop:502	Event:3153	AdverseOutcome	Abnormal Cardiac Structure and Function
Aop:503	Event:3154	MolecularInitiatingEvent	Phosphodiesterase inhibition
Aop:503	Event:3155	KeyEvent	Increased, cyclic adenosine monophosphate
Aop:503	Event:3156	KeyEvent	Hyperphosphorylation of ryanodine receptor (RyR2)
Aop:503	Event:3157	KeyEvent	Increased, Intracellular Calcium overload
Aop:503	Event:3158	KeyEvent	Decrease, Cardiac contractility
Aop:503	Event:3159	AdverseOutcome	Heart failure
Aop:504	Event:3160	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:504	Event:3161	KeyEvent	Increased Muscarinic Acetylcholine Receptors
Aop:504	Event:3162	KeyEvent	Altered, Action Potential
Aop:504	Event:3163	KeyEvent	Increased delay in heart electrical conduction
Aop:504	Event:3164	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:505	Event:3165	MolecularInitiatingEvent	Inhibition of Funny current (If)
Aop:505	Event:3166	KeyEvent	Slowed Heart Rate
Aop:505	Event:3167	KeyEvent	Altered Cardiac Electrical Conduction
Aop:505	Event:3168	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:506	Event:3169	MolecularInitiatingEvent	Aromatase, induction
Aop:506	Event:3170	KeyEvent	Increased, circulating estrogen levels
Aop:506	Event:3171	KeyEvent	Plasma estradiol, increased
Aop:506	Event:3172	KeyEvent	Estradiol availability, increased
Aop:506	Event:3173	AdverseOutcome	Activation, estrogen receptor alpha
Aop:507	Event:3174	MolecularInitiatingEvent	HCN Channel Inhibition
Aop:507	Event:3175	KeyEvent	Reduced Pacemaker Activity in SA Node
Aop:507	Event:3176	KeyEvent	Slowed Heart Rate
Aop:507	Event:3177	KeyEvent	Altered Cardiac Electrical Conduction
Aop:507	Event:3178	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:508	Event:3179	MolecularInitiatingEvent	Activation, AhR
Aop:508	Event:3180	KeyEvent	dimerization, AHR/ARNT
Aop:508	Event:3181	KeyEvent	increased, Bax expression
Aop:508	Event:3182	KeyEvent	Apoptosis
Aop:508	Event:3183	KeyEvent	Decreased, size of the ovarian reserve
Aop:508	Event:3184	AdverseOutcome	Premature ovarian Insufficiency
Aop:509	Event:3185	MolecularInitiatingEvent	Mitochondrial Complex I inhibition
Aop:509	Event:3186	KeyEvent	Altered, Redox Homeostasis
Aop:509	Event:3187	KeyEvent	Disruption, Mitochondrial electron transport chain
Aop:509	Event:3188	KeyEvent	Decrease, Mitochondrial ATP production
Aop:509	Event:3189	KeyEvent	Disruption, Glucolipid metabolism
Aop:509	Event:3190	KeyEvent	Disruption, neurotransmitter release
Aop:509	Event:3191	KeyEvent	Abnormal, Behavior
Aop:509	Event:3192	AdverseOutcome	impaired, Larval development
Aop:509	Event:3193	AdverseOutcome	Increase, Malformations
Aop:509	Event:3194	AdverseOutcome	Increased Mortality
Aop:509	Event:3195	AdverseOutcome	Decrease, Population growth rate
Aop:510	Event:3196	MolecularInitiatingEvent	17β-Hydroxysteroid dehydrogenase 2, inhibition
Aop:510	Event:3197	KeyEvent	Estradiol availability, increased
Aop:510	Event:3198	KeyEvent	Activation, estrogen receptor alpha
Aop:511	Event:3199	KeyEvent	Decreased, GnRH pulsatility/release
Aop:511	Event:3200	KeyEvent	Decreased, LH Surge
Aop:511	Event:3201	KeyEvent	Impaired ovulation
Aop:511	Event:3202	KeyEvent	Increased plasma estradiol to progesterone ratio (estrogen dominance/unopposed estrogen)
Aop:511	Event:3203	KeyEvent	Estradiol availability, increased
Aop:511	Event:3204	AdverseOutcome	Persistent vaginal cornification
Aop:512	Event:3205	MolecularInitiatingEvent	Binding of plastoquinone B
Aop:512	Event:3206	KeyEvent	Decrease, Photosystem II efficiency
Aop:512	Event:3207	KeyEvent	Decrease, Photosynthesis
Aop:512	Event:3208	KeyEvent	Decrease in mitochondrial oxidative phosphorylation
Aop:512	Event:3209	KeyEvent	Decrease, ATP production
Aop:512	Event:3210	AdverseOutcome	Decrease, Population growth rate
Aop:513	Event:3211	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:513	Event:3212	KeyEvent	Increased, extracellular serotonin
Aop:513	Event:3213	KeyEvent	Increased, stimulation of brain serotonin 5-HT1a, 5-HT2c receptors
Aop:513	Event:3214	AdverseOutcome	Inhibition, Feeding
Aop:514	Event:3215	MolecularInitiatingEvent	Decreased DNA methylation of FAM50B/PTCHD3
Aop:514	Event:3216	KeyEvent	Elevated gene expression of FAM50B/PTCHD3
Aop:514	Event:3217	KeyEvent	Inhibition of PI3K-Akt pathway
Aop:514	Event:3218	KeyEvent	Increase, Reactive oxygen species
Aop:514	Event:3219	KeyEvent	Increase, CNS Neural cell death
Aop:514	Event:3220	AdverseOutcome	decreased, Intellectual Quotient
Aop:515	Event:3221	KeyEvent	Decrease, intratesticular testosterone levels
Aop:515	Event:3222	KeyEvent	Decrease, circulating testosterone levels
Aop:515	Event:3223	KeyEvent	Decrease, androgen receptor activation
Aop:515	Event:3224	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:515	Event:3225	AdverseOutcome	Hypospadias, increased
Aop:516	Event:3226	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:516	Event:3227	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:516	Event:3228	KeyEvent	Decrease, androgen receptor activation
Aop:516	Event:3229	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:516	Event:3230	AdverseOutcome	Hypospadias, increased
Aop:517	Event:239	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:517	Event:54	KeyEvent	Up Regulation, CD36
Aop:517	Event:115	KeyEvent	Increase, FA Influx
Aop:517	Event:291	KeyEvent	Accumulation, Triglyceride
Aop:517	Event:459	AdverseOutcome	Increased, Liver Steatosis
Aop:518	Event:3231	MolecularInitiatingEvent	Inhibition, cytochrome oxidase
Aop:518	Event:3232	KeyEvent	Increase, Cell death
Aop:518	Event:3233	AdverseOutcome	Increased, pulmonary edema
Aop:519	Event:3234	MolecularInitiatingEvent	Inhibition, cytochrome oxidase
Aop:519	Event:3235	KeyEvent	Increase, Cell death
Aop:519	Event:3236	AdverseOutcome	Loss of olfactory function
Aop:520	Event:3237	KeyEvent	Decrease, intratesticular testosterone levels
Aop:520	Event:3238	KeyEvent	Decrease, circulating testosterone levels
Aop:520	Event:3239	KeyEvent	Decrease, androgen receptor activation
Aop:520	Event:3240	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:520	Event:3241	AdverseOutcome	Nipple retention (NR), increased
Aop:521	Event:3242	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:521	Event:3243	KeyEvent	Decrease, dihydrotestosterone (DHT) levels
Aop:521	Event:3244	KeyEvent	Decrease, androgen receptor activation
Aop:521	Event:3245	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:521	Event:3246	AdverseOutcome	Nipple retention (NR), increased
Aop:522	Event:112	MolecularInitiatingEvent	Antagonism, Estrogen receptor
Aop:522	Event:2207	KeyEvent	inhibition, EKR1/2 signaling pathway
Aop:522	Event:195	KeyEvent	Inhibition, NMDARs
Aop:522	Event:2208	KeyEvent	Aberrant, synaptic formation and plasticity
Aop:522	Event:386	KeyEvent	Decrease of neuronal network function
Aop:522	Event:2209	AdverseOutcome	autism-like behavior
Aop:523	Event:3247	MolecularInitiatingEvent	Activation, AhR
Aop:523	Event:3248	KeyEvent	Over-expression of PD-L1 in cancer cells
Aop:523	Event:3249	KeyEvent	Dysregulation of Treg/Th17 cell ratio
Aop:523	Event:3250	KeyEvent	Lymphocytes T CD8+ cytotoxicity
Aop:523	Event:3251	AdverseOutcome	Increased, tumor growth
Aop:524	Event:2252	MolecularInitiatingEvent	Human leukocyte antigen DQ2/8-gluten complexes, formation
Aop:524	Event:2253	MolecularInitiatingEvent	Gluten-reactive T cell receptors, generation
Aop:524	Event:2254	MolecularInitiatingEvent	Gluten-reactive and transglutaminase 2 reactive B cell receptors, generation
Aop:524	Event:2255	KeyEvent	Innate immune response, activation
Aop:524	Event:2256	KeyEvent	Gluten-reactive B cells and transglutaminase 2-reactive B cells, activation
Aop:524	Event:1931	KeyEvent	Intestinal barrier, disruption
Aop:524	Event:2257	AdverseOutcome	Celiac disease
Aop:524	Event:2260	KeyEvent	Gluten-reactive CD4+ T cells, activation
Aop:524	Event:2275	KeyEvent	Gluten reactive adaptive T-cells with antigen presenting cells, co-localization
Aop:525	Event:3252	MolecularInitiatingEvent	Activation, Mineralocorticoid Receptor
Aop:525	Event:3253	KeyEvent	Accumulation, Triglyceride
Aop:525	Event:3254	KeyEvent	Increase, Lipid droplet
Aop:525	Event:3255	KeyEvent	Increase, Fat mass
Aop:525	Event:3256	KeyEvent	Increase, DGAT1
Aop:525	Event:3257	KeyEvent	Increase, SREBF1
Aop:525	Event:3258	KeyEvent	Increase, perilipin-2
Aop:525	Event:3259	AdverseOutcome	Increase, body mass index
Aop:526	Event:3260	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:526	Event:3261	KeyEvent	Altered expression of cell cycle genes
Aop:526	Event:3262	KeyEvent	Decreased proliferation of cortical neural progenitor cells
Aop:526	Event:3263	KeyEvent	Microcephaly
Aop:526	Event:3264	AdverseOutcome	Cognitive function, decreased
Aop:527	Event:656	KeyEvent	Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII)
Aop:527	Event:647	KeyEvent	Decreased, steroidogenic protein expression
Aop:527	Event:1613	KeyEvent	Decrease, dihydrotestosterone (DHT) level
Aop:527	Event:2213	KeyEvent	Impaired, urethral tube closure 
Aop:527	Event:2082	AdverseOutcome	Hypospadias, increased
Aop:528	Event:2214	KeyEvent	Decreased, Insulin-like peptide 3 (INSL3)
Aop:528	Event:1615	KeyEvent	Impaired inguinoscrotal testicular descent phase
Aop:528	Event:1616	AdverseOutcome	Malformation, cryptorchidism - maldescended testis
Aop:529	Event:327	KeyEvent	Accumulation, Fatty acid
Aop:529	Event:459	AdverseOutcome	Increased, Liver Steatosis
Aop:529	Event:179	KeyEvent	Decrease, Fatty acid beta-oxidation
Aop:529	Event:291	KeyEvent	Accumulation, Triglyceride
Aop:529	Event:2224	KeyEvent	Dysregulation of transcriptional expression within PPAR signaling network
Aop:529	Event:2225	KeyEvent	Disrupted Lipid Storage
Aop:529	Event:2226	MolecularInitiatingEvent	Stressor binding PPAR isoforms 
Aop:529	Event:2227	KeyEvent	Disrupted PPAR isoform nuclear signaling
Aop:530	Event:1539	MolecularInitiatingEvent	Endocytotic lysosomal uptake
Aop:530	Event:177	KeyEvent	Mitochondrial dysfunction
Aop:530	Event:55	KeyEvent	Increase, Cell injury/death
Aop:530	Event:1931	AdverseOutcome	Intestinal barrier, disruption
Aop:530	Event:898	KeyEvent	Disruption, Lysosome
Aop:532	Event:3265	MolecularInitiatingEvent	Inhibition, cytochrome bc1 complex (complex III)
Aop:532	Event:3266	KeyEvent	Mitochondrial dysfunction
Aop:532	Event:3267	KeyEvent	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:532	Event:3268	AdverseOutcome	Parkinsonian motor deficits
Aop:533	Event:3269	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:533	Event:3270	KeyEvent	Mitochondrial dysfunction
Aop:533	Event:3271	KeyEvent	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:533	Event:3272	AdverseOutcome	Parkinsonian motor deficits
Aop:534	Event:3273	MolecularInitiatingEvent	Mitochondrial Complex IV inhibition
Aop:534	Event:3274	KeyEvent	Mitochondrial dysfunction
Aop:534	Event:3275	KeyEvent	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:534	Event:3276	AdverseOutcome	Parkinsonian motor deficits
Aop:535	Event:3277	MolecularInitiatingEvent	Increase of intracellular copper
Aop:535	Event:3278	KeyEvent	Oligomerisation of dihydrolipoamide acetyltransferase (DLAT)
Aop:535	Event:3279	KeyEvent	Loss of iron-sulfur clusters
Aop:535	Event:3280	KeyEvent	Impaired, Proteostasis
Aop:535	Event:3281	KeyEvent	Disruption of tricarboxylic acid (TCA) cycle
Aop:535	Event:3282	KeyEvent	Decrease, Oxidative phosphorylation
Aop:535	Event:3283	KeyEvent	Decrease, Mitochondrial ATP production
Aop:535	Event:3284	AdverseOutcome	Cell death, Cuproptosis
Aop:536	Event:111	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:536	Event:307	KeyEvent	Increase, Vitellogenin synthesis in liver
Aop:536	Event:220	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:536	Event:252	KeyEvent	Increase, Renal pathology due to VTG deposition
Aop:536	Event:351	KeyEvent	Increased Mortality
Aop:536	Event:360	KeyEvent	Decrease, Population growth rate
Aop:537	Event:111	MolecularInitiatingEvent	Agonism, Estrogen receptor
Aop:537	Event:307	KeyEvent	Increase, Vitellogenin synthesis in liver
Aop:537	Event:220	KeyEvent	Increase, Plasma vitellogenin concentrations
Aop:537	Event:364	KeyEvent	Impaired development of, Reproductive organs
Aop:537	Event:78	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:538	Event:1392	KeyEvent	Oxidative Stress 
Aop:538	Event:2240	KeyEvent	The NO synthase pathway activation
Aop:538	Event:1928	KeyEvent	increased，Vascular endothelial dysfunction
Aop:538	Event:2161	AdverseOutcome	Increase, Vascular disrupting effects
Aop:538	Event:2241	KeyEvent	Ferroptosis related pathways activation
Aop:539	Event:1562	MolecularInitiatingEvent	Decreased Na/K ATPase activity
Aop:539	Event:2236	KeyEvent	Decreased, Sodium uptake in gills
Aop:539	Event:2237	KeyEvent	Decreased, Plasma sodium concentrations
Aop:539	Event:2238	KeyEvent	Increased, Blood viscosity
Aop:539	Event:2239	KeyEvent	Increased, Cardiac stress
Aop:539	Event:1535	AdverseOutcome	Heart failure 
Aop:539	Event:2261	KeyEvent	Decreased, blood plasma volume
Aop:540	Event:1115	MolecularInitiatingEvent	Increase, Reactive oxygen species
Aop:540	Event:1392	KeyEvent	Oxidative Stress 
Aop:540	Event:1262	KeyEvent	Apoptosis
Aop:540	Event:3	KeyEvent	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
Aop:540	Event:285	KeyEvent	Reduction, Vitellogenin synthesis in liver
Aop:540	Event:221	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:540	Event:309	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:540	Event:78	KeyEvent	Reduction, Cumulative fecundity and spawning
Aop:540	Event:360	AdverseOutcome	Decrease, Population growth rate
Aop:543	Event:2262	MolecularInitiatingEvent	 Neuropathy target esterase, inhibited
Aop:543	Event:2263	KeyEvent	 Lysolecithin, increased
Aop:543	Event:2264	KeyEvent	 Lysolecithin cell membrane integration, increased
Aop:543	Event:2265	KeyEvent	 Oligodendrocyte death, increased
Aop:543	Event:2266	KeyEvent	Demyelination, increased
Aop:543	Event:2267	AdverseOutcome	Delayed neuropathy, increased
Aop:544	Event:2262	MolecularInitiatingEvent	 Neuropathy target esterase, inhibited
Aop:544	Event:2263	KeyEvent	 Lysolecithin, increased
Aop:544	Event:149	KeyEvent	Increase, Inflammation
Aop:544	Event:2265	KeyEvent	 Oligodendrocyte death, increased
Aop:544	Event:2266	KeyEvent	Demyelination, increased
Aop:544	Event:2267	AdverseOutcome	Delayed neuropathy, increased
Aop:545	Event:239	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:545	Event:2268	KeyEvent	Decreased, insulin-induced gene 1 (INSIG1) protein activity
Aop:545	Event:2269	KeyEvent	Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression 
Aop:545	Event:2270	KeyEvent	Increased, cholesterol synthesis enzymes 
Aop:545	Event:2271	AdverseOutcome	Increased, plasma low-density lipoprotein (LDL) cholesterol 
Aop:546	Event:2118	MolecularInitiatingEvent	Succinate dehydrogenase, inhibited
Aop:546	Event:2243	KeyEvent	Succinate Accumulation
Aop:546	Event:798	KeyEvent	Inhibition, Prolyl hydroxylases
Aop:546	Event:590	KeyEvent	N/A, hypoxia
Aop:546	Event:885	AdverseOutcome	Increase, Cancer
Aop:547	Event:2274	KeyEvent	Androgen receptor activation, increased
Aop:547	Event:25	MolecularInitiatingEvent	Agonism, Androgen receptor
Aop:547	Event:286	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:548	Event:239	MolecularInitiatingEvent	Activation, Pregnane-X receptor, NR1l2
Aop:548	Event:2268	KeyEvent	Decreased, insulin-induced gene 1 (INSIG1) protein activity
Aop:548	Event:2269	KeyEvent	Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression 
Aop:548	Event:2276	KeyEvent	Increased, protein expression of proprotein convertase subtilisin/kexin type 9 (PCSK9)
Aop:548	Event:2271	AdverseOutcome	Increased, plasma low-density lipoprotein (LDL) cholesterol 
Aop:549	Event:36	MolecularInitiatingEvent	Inhibition, Aromatase
Aop:549	Event:219	KeyEvent	Reduction, Plasma 17beta-estradiol concentrations
Aop:549	Event:221	KeyEvent	Reduction, Plasma vitellogenin concentrations
Aop:549	Event:2277	KeyEvent	Inhibition, aromatase activity in plasma
Aop:549	Event:309	KeyEvent	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
Aop:549	Event:78	AdverseOutcome	Reduction, Cumulative fecundity and spawning
Aop:549	Event:442	AdverseOutcome	Decreased, Population trajectory
Aop:549	Event:1467	AdverseOutcome	Growth, reduction
Aop:550	Event:2278	MolecularInitiatingEvent	Increased LMNA Mutation
Aop:550	Event:2279	KeyEvent	Structural changes in lamin A/C
Aop:550	Event:2066	KeyEvent	Altered Signaling Pathways
Aop:550	Event:1924	KeyEvent	Increased，Cardiac fibrosis
Aop:550	Event:1535	AdverseOutcome	Heart failure 
Aop:551	Event:1106	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:551	Event:1602	MolecularInitiatingEvent	Increased Muscarinic Acetylcholine Receptors
Aop:551	Event:1098	KeyEvent	Increased, blood potassium concentration
Aop:551	Event:1983	KeyEvent	Disruption, action potential generation
Aop:551	Event:2280	KeyEvent	Increased delay in heart electrical conduction
Aop:552	Event:1529	MolecularInitiatingEvent	Blockade, L-Type Calcium Channels 
Aop:552	Event:698	KeyEvent	Altered, Action Potential
Aop:552	Event:1962	KeyEvent	Prolongation of QT interval
Aop:552	Event:1963	KeyEvent	Torsades de Pointes
Aop:552	Event:2281	KeyEvent	Increased uncoordinated cardiac contraction
Aop:552	Event:1535	AdverseOutcome	Heart failure 
Aop:553	Event:584	MolecularInitiatingEvent	Inhibition, sodium channel
Aop:553	Event:698	KeyEvent	Altered, Action Potential
Aop:553	Event:1532	KeyEvent	Decrease, Cardiac contractility 
Aop:553	Event:1535	AdverseOutcome	Heart failure 
Aop:554	Event:1038	MolecularInitiatingEvent	Activation, beta-2 adrenergic receptor
Aop:554	Event:2284	KeyEvent	 Increased Intracellular cAMP Levels
Aop:554	Event:2285	KeyEvent	Increased the delayed and early afterdepolarizations
Aop:554	Event:1106	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:555	Event:593	MolecularInitiatingEvent	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel 
Aop:555	Event:1961	KeyEvent	Prolongation of Action Potential Duration
Aop:555	Event:1962	KeyEvent	Prolongation of QT interval
Aop:555	Event:2283	KeyEvent	Increased the early premature depolarizations during repolarization
Aop:555	Event:1535	AdverseOutcome	Heart failure 
Aop:556	Event:1535	AdverseOutcome	Heart failure 
Aop:556	Event:1321	KeyEvent	Increased, intracellular sodium (Na+)
Aop:556	Event:2287	KeyEvent	Impaired Sodium-Calcium Exchange
Aop:556	Event:389	KeyEvent	Increased, Intracellular Calcium overload
Aop:556	Event:1532	KeyEvent	Decrease, Cardiac contractility 
Aop:556	Event:1562	MolecularInitiatingEvent	Decreased Na/K ATPase activity
Aop:557	Event:1039	MolecularInitiatingEvent	Increased activity, beta-2 adrenergic receptor
Aop:557	Event:2157	AdverseOutcome	 Abnormal Cardiac Structure and Function
Aop:558	Event:2288	MolecularInitiatingEvent	Phosphodiesterase inhibition
Aop:558	Event:2289	KeyEvent	Hyperphosphorylation of ryanodine receptor (RyR2)
Aop:558	Event:389	KeyEvent	Increased, Intracellular Calcium overload
Aop:558	Event:1532	KeyEvent	Decrease, Cardiac contractility 
Aop:558	Event:1535	AdverseOutcome	Heart failure 
Aop:558	Event:693	KeyEvent	Increased, cyclic adenosine monophosphate
Aop:559	Event:12	MolecularInitiatingEvent	Acetylcholinesterase (AchE) Inhibition
Aop:559	Event:1602	KeyEvent	Increased Muscarinic Acetylcholine Receptors
Aop:559	Event:698	KeyEvent	Altered, Action Potential
Aop:559	Event:2280	KeyEvent	Increased delay in heart electrical conduction
Aop:559	Event:1106	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:560	Event:2290	MolecularInitiatingEvent	Inhibition of Funny current (If)
Aop:560	Event:2291	KeyEvent	Slowed Heart Rate 
Aop:560	Event:2292	KeyEvent	Altered Cardiac Electrical Conduction
Aop:560	Event:1106	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:561	Event:2293	MolecularInitiatingEvent	Aromatase, induction
Aop:561	Event:1076	KeyEvent	Increased, circulating estrogen levels
Aop:561	Event:2251	KeyEvent	Estradiol availability, increased
Aop:561	Event:1065	AdverseOutcome	Activation, estrogen receptor alpha
Aop:561	Event:2294	KeyEvent	Plasma estradiol, increased
Aop:562	Event:2295	MolecularInitiatingEvent	HCN Channel Inhibition
Aop:562	Event:2296	KeyEvent	Reduced Pacemaker Activity in SA Node
Aop:562	Event:2291	KeyEvent	Slowed Heart Rate 
Aop:562	Event:2292	KeyEvent	Altered Cardiac Electrical Conduction
Aop:562	Event:1106	AdverseOutcome	Occurrence, cardiac arrhythmia
Aop:563	Event:18	MolecularInitiatingEvent	Activation, AhR
Aop:563	Event:944	KeyEvent	dimerization, AHR/ARNT
Aop:563	Event:2124	KeyEvent	increased, Bax expression
Aop:563	Event:1262	KeyEvent	Apoptosis
Aop:563	Event:1883	KeyEvent	Decreased, size of the ovarian reserve
Aop:563	Event:2305	AdverseOutcome	Premature ovarian Insufficiency
Aop:564	Event:1541	MolecularInitiatingEvent	Mitochondrial Complex I inhibition
Aop:564	Event:2299	KeyEvent	Altered, Redox Homeostasis
Aop:564	Event:178	KeyEvent	Disruption, Mitochondrial electron transport chain
Aop:564	Event:40	KeyEvent	Decrease, Mitochondrial ATP production
Aop:564	Event:2300	KeyEvent	Disruption, Glucolipid metabolism
Aop:564	Event:2151	KeyEvent	Disruption, neurotransmitter release
Aop:564	Event:2301	KeyEvent	Abnormal, Behavior
Aop:564	Event:566	AdverseOutcome	impaired, Larval development
Aop:564	Event:2302	AdverseOutcome	Increase, Malformations
Aop:564	Event:351	AdverseOutcome	Increased Mortality
Aop:564	Event:360	AdverseOutcome	Decrease, Population growth rate
Aop:565	Event:2250	MolecularInitiatingEvent	17β-Hydroxysteroid dehydrogenase 2, inhibition
Aop:565	Event:2251	KeyEvent	Estradiol availability, increased
Aop:565	Event:1065	KeyEvent	Activation, estrogen receptor alpha
Aop:566	Event:530	KeyEvent	Decreased, GnRH pulsatility/release
Aop:566	Event:531	KeyEvent	Decreased, LH Surge
Aop:566	Event:1695	KeyEvent	Impaired ovulation
Aop:566	Event:2303	KeyEvent	Increased plasma estradiol to progesterone ratio (estrogen dominance/unopposed estrogen)
Aop:566	Event:2251	KeyEvent	Estradiol availability, increased
Aop:566	Event:2306	AdverseOutcome	Persistent vaginal cornification
Aop:568	Event:619	MolecularInitiatingEvent	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)
Aop:568	Event:1320	KeyEvent	Increased, extracellular serotonin
Aop:568	Event:2308	KeyEvent	Increased, stimulation of brain serotonin 5-HT1a, 5-HT2c receptors
Aop:568	Event:1016	AdverseOutcome	Inhibition, Feeding
Aop:569	Event:2309	MolecularInitiatingEvent	Decreased DNA methylation of FAM50B/PTCHD3
Aop:569	Event:2310	KeyEvent	Elevated gene expression of FAM50B/PTCHD3
Aop:569	Event:2311	KeyEvent	Inhibition of PI3K-Akt pathway
Aop:569	Event:2195	KeyEvent	Increase, CNS Neural cell death
Aop:569	Event:2121	AdverseOutcome	decreased, Intellectual Quotient
Aop:569	Event:1115	KeyEvent	Increase, Reactive oxygen species
Aop:570	Event:2298	KeyEvent	Decrease, intratesticular testosterone levels
Aop:570	Event:1690	KeyEvent	Decrease, circulating testosterone levels 
Aop:570	Event:1614	KeyEvent	Decrease, androgen receptor activation
Aop:570	Event:286	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:570	Event:2082	AdverseOutcome	Hypospadias, increased
Aop:571	Event:1617	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:571	Event:1613	KeyEvent	Decrease, dihydrotestosterone (DHT) level
Aop:571	Event:1614	KeyEvent	Decrease, androgen receptor activation
Aop:571	Event:286	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:571	Event:2082	AdverseOutcome	Hypospadias, increased
Aop:573	Event:1840	MolecularInitiatingEvent	Inhibition, cytochrome oxidase
Aop:573	Event:1825	KeyEvent	Increase, Cell death
Aop:573	Event:2316	AdverseOutcome	Increased, pulmonary edema
Aop:574	Event:1840	MolecularInitiatingEvent	Inhibition, cytochrome oxidase
Aop:574	Event:1825	KeyEvent	Increase, Cell death
Aop:574	Event:2317	AdverseOutcome	Loss of olfactory function
Aop:575	Event:2298	KeyEvent	Decrease, intratesticular testosterone levels
Aop:575	Event:1690	KeyEvent	Decrease, circulating testosterone levels 
Aop:575	Event:1614	KeyEvent	Decrease, androgen receptor activation
Aop:575	Event:286	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:575	Event:1786	AdverseOutcome	Nipple retention (NR), increased
Aop:576	Event:1617	MolecularInitiatingEvent	Inhibition, 5α-reductase
Aop:576	Event:1613	KeyEvent	Decrease, dihydrotestosterone (DHT) level
Aop:576	Event:1614	KeyEvent	Decrease, androgen receptor activation
Aop:576	Event:286	KeyEvent	Altered, Transcription of genes by the androgen receptor
Aop:576	Event:1786	AdverseOutcome	Nipple retention (NR), increased
Aop:578	Event:18	MolecularInitiatingEvent	Activation, AhR
Aop:578	Event:2323	KeyEvent	Over-expression of PD-L1 in cancer cells
Aop:578	Event:2324	KeyEvent	Dysregulation of Treg/Th17 cell ratio
Aop:578	Event:2326	KeyEvent	Lymphocytes T CD8+ cytotoxicity
Aop:578	Event:1971	AdverseOutcome	Increased, tumor growth
Aop:581	Event:122	MolecularInitiatingEvent	Activation, Glucocorticoid Receptor
Aop:581	Event:2202	KeyEvent	Altered expression of cell cycle genes
Aop:581	Event:2203	KeyEvent	Decreased proliferation of cortical neural progenitor cells
Aop:581	Event:2211	KeyEvent	Microcephaly
Aop:581	Event:402	AdverseOutcome	Cognitive function, decreased 
